













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 

















Motor Neuron Degeneration and 
Compensatory Sprouting in Mouse 
Models of Spinal Muscular Atrophy 
 
 




A thesis submitted for the degree of PhD  







I declare that the work presented in this thesis is entirely my own, unless 
otherwise stated in the text, and has not been submitted for any other degree 











There are many people that I’d like to acknowledge, for their help and 
support throughout my PhD. 
 
Firstly, and most importantly, my supervisor Lyndsay Murray. I will never be 
able to find the words that appropriately describe how thankful I am for all of 
your help, support, guidance and time. Your encouragement has been 
invaluable and I thank you for being so patient and understanding. It is 
thanks to you that I continued in science and have genuinely enjoyed this 
PhD journey. You are an incredible teacher and a true role model. 
 
Thank you also to my thesis committee; Tom Gillingwater and Mandy 
Jackson. Your help, advice and guidance over the course of my PhD has 
been very much appreciated.  
 
Thank you to all of the past and present Murray lab members. Notably, 
Rachel Kline, Alannah Mole, Roxanna Munir and Ali Thomson. Thank you to 
you all for supporting and encouraging me, both professionally and 
personally. Specifically, thanks to Alannah for your help with the work on 
motor neuron pathology and to Roxanna for your help with the work on motor 
neuron sprouting. Thank you also to Shilpa Purushotham, for your help with 
looking at the effect of YFP on motor neuron pathology.  
 
Thank you to all of the members of the Gillingwater and Paxton Labs, both 
past and present. Notably, thanks to Ewout Groen and Hannah Shorrock; 
you both played a huge part in my time at the University of Edinburgh and 
supported me from day one. 
 
Thank you also to Yvonne Clarkson for your support, mentoring and advice. 
You really have kept me sane! 
 iv	  
Thank you also to Viv Allison and Louise Dunn in the Histology Department 
of the Hugh Robson Building (HRB), Anisha of the Impact facility and the 
stores department of the HRB. In addition, thanks to the BRR facilities at 
both the HRB and Western General Hospital (WGH). Especially, John and 
Vicky, who helped me immensely with the P53 colony. 
 
Of course, none of this would have been possible without the studentship 
provided by the Euan MacDonald Centre for Motor Neurone Disease 
Research. This is an incredible organisation that I am proud to be a part of 
and will always do my best to represent in such a way that it deserves.  
 
Last but not at all least, thank you to all of my friends and family.  
 
Thank you to my flatmate, Catriona MacLean, for helping me through the 
hard times but also for helping me celebrate the good times. 
 
Thank you to Rachael Reid. I sometimes wonder how I ended up in the 
position I am now, but then I remember that it was you that told me of an 
opportunity at the University of Edinburgh that I might be interested in – so 
really, for all of this, I have to you to thank.  
 
Thank you to my Mum and Dad, and to my brother Ross. I am so grateful to 
have such a loving family around me. Mum and Dad, you have given me the 
opportunity to fulfil my dreams and you have supported me every step of the 
way. I honestly cannot ever thank you enough.  
 
Hamish, thank you for proof reading this thesis, for reminding me that I can 
do it, for making me dinner and for being unbelievably patient. I really do feel 




Spinal muscular atrophy (SMA) is a childhood onset form of motor neuron 
disease. It is characterised by the degeneration and loss of lower motor 
neurons with subsequent muscle weakness and atrophy. It has long been 
assumed that these motor neurons degenerate in a distal to proximal 
manner, with the neuromuscular junction (NMJ) being an early pathological 
target. However, it is unknown how the onset of pathology at the distal 
portion of the motor neuron (the NMJ) relates to the onset of pathology at the 
proximal portion of the motor neuron (motor neuron cell body (MNCB)). 
Therefore, the timing of the onset of NMJ and MNCB pathology, in the 
Smn2B/- mouse model of SMA, is addressed within this thesis. The results 
show that NMJ pathology begins between P5 and P7 in Smn2B/- mice and 
MNCB morphology is altered in Smn2B/- mice between P10 and P15. 
Furthermore, the up-regulation of transcripts involved in the P53 signaling 
pathway is shown to coincide with the onset of NMJ pathology. Therefore 
whether NMJ pathology is the cause or a consequence P53 activation is 
subsequently investigated. By using an inducible P53 knock down Smn2B/- 
mouse model, it is shown that reducing P53 in Smn2B/- mice can decrease 
denervation.   
 
In this thesis, the possibility that the degeneration of motor neurons induces 
remaining motor neurons to sprout and whether it is this compensatory 
sprouting that allows certain muscles and mice to remain apparently 
‘resistant’ to reduced Smn levels is also addressed. In mouse models and 
patients of SMA, some muscles are relatively spared, with lower levels of 
denervation even at late stages of disease. It is hypothesised that these 
‘resistant’ muscles have increased motor neuron sprouting that compensates 
for ongoing denervation. To address this, degeneration and regeneration was 
quantified in resistant and vulnerable muscles in Smn2B/- mice as well as 
mouse models that have reduced Smn but are asymptomatic. The pathology 
of individual motor units was also assessed to determine whether there are 
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compensatory populations of motor units. Furthermore, degeneration and 
regeneration in mouse models that have reduced Smn but are asymptomatic 
was quantified. In both of these cases, it was found that sprouting is not 
compensating for denervation in these ‘resistant’ muscles and mice, 
suggesting that these NMJs remain stable. 
 
Overall, these results provide an important insight into the pattern of motor 
neuron degeneration and remodeling in SMA and therefore provide 




Motor neurons are long cells that connect the spinal cord to muscles and 
instruct muscles to contract. They have a cell body that lies within the spinal 
cord, a long axon that stretches from the spinal cord to the muscles and a 
neuromuscular junction (NMJ), which is where the motor neuron connects 
with the muscle. In motor neuron diseases, like spinal muscular atrophy 
(SMA), motor neurons breakdown, or degenerate. This means that there is a 
loss of the connections between motor neurons and muscles and as a result, 
muscles are no longer able to contract as efficiently. Patients experience 
muscle weakness and ultimately paralysis. It has long been assumed that, in 
SMA, motor neurons degenerate by withdrawing away from the muscle, as 
the NMJ is thought to be the first part of the motor neuron to breakdown. 
However, the relationship between the degeneration of the NMJ and the 
degeneration of the cell body is actually unknown. Therefore, in this thesis, 
degeneration at both the cell body and the NMJ is investigated, in a mouse 
model of SMA, to try and determine where exactly degeneration begins. In 
addition, work is performed to try and determine the relationship between 
motor neuron degeneration and the turning on of a ‘switch’ that is known to 
cause cells to die. 
 
Further to this, not all muscles in SMA are equally affected by the 
degeneration and withdrawal of motor neurons. While some ‘vulnerable’ 
muscles are severely affected, others are ‘resistant’ and appear to be 
relatively unaffected. In this thesis, it is suggested that in ‘resistant’ muscles 
motor neurons that have not broken down grow new branches to make up for 
the motor neurons that have been lost. This process of growing new 
branches is called compensatory sprouting. Therefore whether 
compensatory sprouting is occurring in resistant muscles in a mouse model 
of SMA is investigated. 
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List of Abbreviations 
 
𝜇m     Micrometer 
AAL    Abductor Auris Longus 
AAV    Adeno-associated virus 
AChR    Acetylcholine Receptor 
ALS    Amyotrophic Lateral Sclerosis 
AS    Auricularis Superior 
ASO    Antisense Oligonucleotide 
BSA    Bovine Serum Albumin 
BTX    Bungarotoxin 
ChAT    Choline Acetyltransferase 
CNS    Central nervous system 
CSF    Cerebrospinal fluid 
EO    External Oblique 
ESE    Exon Splicing Enhancer 
g    Grams 
(p)H2AX   (phosphorylated) H2A histone family member X 
LAL(c/r)   Levator Auris Longus (caudal/rostral bands) 
mg    Milligram 
mM    Microgram 
MNCB   Motor neuron cell body 
MND    Motor Neuron Disease 
mRBP    mRNA binding proteins 
mRNA   messenger RNA 
NF(A)    Neurofilament (Accumulation) 
NMJ    Neuromuscular Junction 
P    Postnatal (i.e. Postnatal Day 5 = P5) 
PBS    Phosphate Buffered Saline 
PCR    Polymerase Chain Reaction 
PFA    Paraformaldehyde  
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PLS    Primary Lateral Sclerosis 
qPCR Quantitative Reverse Transcription Polymerase 
Chain Reaction 
RA Rectus Abdominis 
SMA    Spinal Muscular Atrophy 
SMARD   Spinal Muscular Atrophy with Respiratory Distress  
SMN/ Smn   Survival Motor Neuron gene (italisised) 
(HUMAN/ Murine) 
SMN/ Smn  Survival Motor Neuron protein (HUMAN/ Murine) 
snRNPs   small nuclear ribonuclear proteins 
TA    Turn Around (test) 
TMX    Tamoxifen  
TS    Triangularis Sterni 
TtR    Time to right (test) 
TVA    Transverse Abdominis 
WT    Wild Type 
YFP    Yellow Fluorescent Protein  
 III	  





1.1 Upper and lower motor neurons are responsible for initiating muscle 
contraction. 
1.2 SMN2 is alternatively spliced resulting in a reduction in the amount 





2.1 PCR and gel electrophoresis determines the Smn genotype of a 
mouse. 
2.2 PCR and gel electrophoresis reveals the presence or absence of 
Cre. 
2.3 PCR and gel electrophoresis reveals the presence or absence of 
the P53fl allele. 
2.4 PCR and gel electrophoresis separates mice positive and negative 
for YFP-H. 
2.5 Cranial musculature was dissected for subsequent NMJ analysis. 
2.6 Abdominal musculature was dissected for subsequent NMJ 
analysis. 
2.7 The thoracic TS muscle was dissected for subsequent NMJ 
analysis. 








3.1 Phenotypic analysis of the Smn2B/- mouse model of SMA shows that 
it becomes significantly different from control littermates around P9 to 
P10. 
3.2 Representative images of NMJs in the TVA muscle of Smn2B/- and 
Smn2B/+ mice displaying features of NMJ pathology. 
3.3 There is significant pathology in the TVA muscle in Smn2B/- mice from 
P10. 
3.4 At P7, there is significantly more pre-synaptic swelling at the NMJs in 
the TVA muscle of Smn2B/- mice compared to Smn2B/+ mice. 
3.5 Analysis of NMJs in the Rectus Abdominis (RA) muscle of Smn2B/- 
mice confirms that there is no pre-synaptic pathology observed at P5. 
3.6 There is a loss of MNCBs in Smn2B/- mice between P10 and P15.  
3.7 There is a significant difference in the area of MNCBs in Smn2B/- mice 
compared to controls at P15. 
3.8 There is an increase in the percentage of activated caspase-3 
positive cells in the ventral horn of the thoracic spinal cord of Smn2B/- 
mice at P15. 
3.9 There is a significant increase in the expression of transcripts 
involved in the P53 signalling pathway in the spinal cords of Smn2B/- 
mice compared to controls at P7. 
3.10 Derivation process to obtain experimental Smn2B/-;P53fl/fl;Cre+ mice 
and control littermates. 
3.11 Copy number genotyping separates P53fl/+ mice and the desired 
P53fl/fl mice. 
3.12 Reduction of P53 was confirmed using qPCR on spinal cord cDNA. 
3.13 Reducing P53 does not improve the phenotype of Smn2B/- mice. 
3.14 A reduction in P53 reduces denervation in the TVA of Smn2B/- mice. 
3.15 A reduction in P53 in control Smn2B/+ mice does not alter NMJ 
morphology. 
3.16 Reducing P53 in Smn2B/- and Smn2B/+ mice does not alter the 
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morphology of MNCBs in the ventral horn of their spinal cord. 
3.17 Reducing P53 does not alter the number or size of MNCBs in the 
ventral horn of the thoracic spinal cord. 
3.18 Reducing P53 does not alter the overall regulation of transcripts that 




4.1 Motor neurons sprouting can take to form of either terminal or nodal 
sprouting. 
4.2 There are different suggestions for how compensatory sprouting of 
motor neurons could occur following denervation in MNDs. 
4.3 The YFP-H transgene was crossed onto mouse models that express 
various levels of Smn protein. 
4.4 A high number of YFP expressing axons entering a muscle means 
individual axonal inputs are untraceable. 
4.5 Carrying the YFP-H transgene does not affect the severity of NFA in 
the Smn2B/- mouse model of SMA at P18. 
4.6 Expressing YFP does not have an adverse effect on the NMJ, in 
terms of NFA, in Smn2B/- mice at P18. 
4.7 Expressing YFP does increase the levels of pH2AX in motor neurons 
from Smn2B/- mice at P18. 
4.8 The TS muscle of Smn2B/- mice exhibits significant denervation and 
pre-synaptic swelling when compared to Smn2B/+ controls. 
4.9 The LALr muscle of Smn2B/- mice exhibits increased pre-synaptic 
swelling but shows no significant denervation compared to controls 
4.10 The TS muscle displays significantly more pathology than the LALr 
muscle in P18 Smn2B/- mice 
4.11 There is no significant difference in sprouting between the TS and 
LALr muscles in P18 Smn2B/- mice 
4.12 YFP allows individual motor neurons to be traced. 
4.13 Features of denervation were visible using YFP expression in motor 
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neurons 
4.14 Denervation was visible in 50% of LALr motor units analysed in 
Smn2B/-;YFP-H mice. 
4.15 Pre-synaptic swelling can be observed in motor neurons expressing 
YFP. 
4.16 Pre-synaptic swelling severity is not synchronous within motor units 
of Smn2B/-;YFP-H mice. 
4.17 The area of post-synaptic endplates varies throughout a motor units 
of Smn2B/-;YFP-H mice. 
4.18 Endplate maturation varies within motor units of Smn2B/-;YFP-H mice. 
4.19 Sprouting can be observed in motor neurons expressing YFP. 





5.1 There is no significant difference in the number of MNCBs in Smn+/- 
mice compared to Smn+/+ mice at 1 year old. 
5.2 There is no significant degenerative or regenerative NMJ phenotype 
observed in Smn+/- mice at 1 year old. 
5.3 YFP positive NMJs of Smn+/- mice were examined for morphological 
alterations. 
5.4 There is no significant degenerative or regenerative phenotype in the 
LALr muscle of Smn+/- mice at 1 year old compared to age matched 
Smn+/+ controls. 
5.5 There is no significant difference in the number of MNCBs in 
Smn2B/2B mice compared to Smn+/+ mice at 3 months old. 
5.6 There is no significant degenerative or regenerative NMJ phenotype 
observed in Smn2B/2B mice. 
5.7 There is no significant degenerative or regenerative phenotype in the 
LALr muscle of Smn2B/2B mice at 3 months old compared to age 
matched Smn+/+ controls. 
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5.8 There is no significant degenerative or regenerative phenotype in the 
TS muscle of Smn2B/2B mice at 3 months old compared to age 
matched Smn+/+ controls. 
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2.1 PCR temperature cycling for Smn2B genotyping protocol. 
2.2 PCR temperature cycling for mSmn genotyping protocol. 
2.3 PCR temperature cycling for Cre genotyping protocol. 
2.4 PCR temperature cycling for P53fl genotyping protocol. 
2.5 PCR temperature cycling for YFP-H genotyping protocol. 
2.6 Primer sequences used in genotyping protocols. 
2.7 Antibodies, and their associated information, used in the 
immunofluorescent staining of spinal cord sections. 
2.8 The criteria used to determine endplate occupancy of post-synaptic 
endplates. 
2.9 The criteria used to determine the level of pre-synaptic swelling in 
NMJ analysis. 
2.10 The criteria used to determine the stage of endplate maturation in 
NMJ analysis. 








	   	  





Motor neuron disease (MND) is an umbrella term that incorporates a variety 
of different disorders, all of which are caused by the degeneration of motor 
neurons within the brain and spinal cord. Upper motor neurons carry signals 
from the motor cortex to the brainstem or ventral horn of the spinal cord and 
lower motor neurons receive these signals from the upper motor neurons and 
carry them to the muscle where they elicit a contraction (Figure 1.1). The 
most common MND is Amyotrophic Lateral Sclerosis (ALS) (James & Talbot 
2006). The terms ALS and MND are often used interchangeably, however, 
there are other types of MND, including Primary Lateral Sclerosis (PLS) and 
Spinal Muscular Atrophy (SMA). One of the differences between these three 
MNDs is the type of motor neuron degeneration they present with; while 
patients with ALS experience degeneration of both the upper and lower 
motor neurons, PLS patients experience purely upper motor neuron 
degeneration and SMA patients experience purely lower motor neuron 
degeneration (Talbot 2002).  
 
In addition, the cause of the different MNDs varies; both ALS and PLS most 
commonly occur sporadically while SMA has a heritable genetic origin 
(James & Talbot 2006; Statland et al. 2015). Unlike sporadic diseases, where 
their cause is unknown, genetic diseases are often easier to study, mainly 
due to the ability to create animal models of these diseases (Fisher et al. 
2009). The genetic cause of SMA is well documented and as a result various 
models have been developed to study this disease. By studying SMA, we will 
not only increase our knowledge of SMA but may also be able to provide an 
understanding of motor neuron degeneration that could be transferable 
amongst the other MNDs, to help in the search for therapeutic options for 
these devastating disorders (Bowerman et al. 2018). 
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1.1 Overview of SMA 
 
Spinal muscular atrophy (SMA) is the leading genetic cause of infant 
mortality (Monani 2005). The commonly reported incidence is 1 in 6,000 - 
10,000 live births however, recent data has found that the incidence is now 1 
in ~12,000 live births (Lunn & Wang 2008; Verhaart et al. 2017). It is 
characterised by the loss of lower alpha motor neurons from the ventral horn 
Figure 1.1: Upper and lower motor neurons are responsible for initiating 
muscle contraction. (A) Upper motor neurons carry signals from the brain to the 
spinal cord. These synapse onto lower motor neurons that carry the signal from the 
spinal cord to muscles. (B) The schematic shows the anatomy of the lower motor 
neuron. The motor neuron cell body (MNCB) is located within the ventral horn of the 
spinal cord and receives signals from the upper motor neurons. These signals are 
transmitted along the axon of the lower motor neuron where they reach the 
neuromuscular junction (NMJ). The NMJ consists of the pre-synaptic terminal of the 
motor neuron and the post-synaptic endplate of the muscle. Together, the motor 
neuron and all of the muscle fibres it innervates are called the motor unit.    
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of the spinal cord that results in progressive muscle weakness and atrophy 
with subsequent paralysis.  
 
As an autosomal recessive disorder, SMA is caused by mutations and 
deletions in the survival motor neuron 1 (SMN1) gene, which leads to a 
reduction in the ubiquitously expressed survival motor neuron (SMN) protein 
(Lefebvre 1995). Due to the presence of a second partially functionally copy 
of the SMN gene (SMN2; refer to section 1.3), SMN protein levels vary 
amongst patients, with lower levels of SMN protein resulting in severe SMA 
phenotypes and higher levels SMN protein resulting in more mild 
phenotypes. SMA is therefore separated into four different types based upon 
the severity of the phenotype patients exhibit (Munsat & Davies 1992; Taylor 
et al. 1998; Mailman et al. 2002).  
1.2 Types of SMA 
 
The severity and onset of SMA can vary considerably, with some patients 
being diagnosed early in infancy and others not diagnosed until adulthood. 
As a result, SMA was categorised into different types by the International 
SMA Consortium in 1992 (Munsat & Davies 1992). These types ranged from 
type I to type IV based on phenotypic severity and the milestones that were 
reached by SMA patients. A brief description of each is detailed below. 
 
SMA type I is normally diagnosed within the first 6 months of life and, without 
treatment or respiratory support, most patients will not live past their second 
birthday (Wirth et al. 2006). Type I infants are unable to sit or hold their body 
weight, and from their appearance it is clear why SMA can also be referred to 
as ‘floppy baby syndrome’ (Wirth et al. 2006). Type I was the first type of 
SMA to be described in the literature when Guido Werdnig reported patients 
with SMA type I symptoms in 1891. John Hoffmann subsequently reviewed 
and added to these reports and as a result, SMA type I is also known as 
Werdnig-Hoffmann’s disease (Dubowitz 2009). With 60% of SMA patients 
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presenting with type 1, this is the most common of the various types of SMA 
(Ogino & Wilson 2004; Verhaart et al. 2017b). 
 
Type II SMA is an intermediate form of the disease where infants are 
diagnosed after 6 months of age and live past 2 years of age. It is defined as 
having the ability to sit but not to stand and walk however, its manifestation 
has a large degree of variably (Wirth et al. 2006; Dubowitz 2009). 
 
Type III is a milder form of SMA. Patients are not diagnosed until after 18 
months of age, have the ability to sit and walk and do not have a shortened 
life expectancy. Type III SMA can be subcategorised into type IIIa and type 
IIIb based on age at diagnosis; with diagnosis between 18 months and 3 
years of age defined as type IIIa SMA and diagnosis after 3 years defined as 
type IIIb SMA (Zerres & Rudnik-Schöneborn 1995; Wirth et al. 2006). Type III 
SMA was comprehensively described by Kugelberg and Welander in 1956 
and as a result is also known as Kugelberg-Welander disease (Dubowitz 
2009).   
 
Type IV SMA is adult onset and patients are diagnosed around 30 years old. 
Although patients experience muscle weakness that results in mild disability 
later in life, patients do not experience a reduction in overall life span (Pearn 
1978; Wirth et al. 2006). 
 
These types of SMA described above (types I-IV) are all caused by 
mutations or deletions in the SMN1 gene, leading to a reduction in SMN 
protein levels. However, the term spinal muscular atrophy is also sometimes 
used to refer to other disorders that are caused by different genetic 
mutations. These different types are also characterised by the loss of lower 
motor neurons and as a result, exhibit similar symptoms to types I-IV SMA. 
For example, SMA with respiratory distress (SMARD) is an autosomal 
recessive disorder caused by mutations in the IGHMBP2 gene. It is first 
noticeable through breathing difficulties due to the paralysis of the diaphragm 
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from the degeneration of motor neurons supplying this muscle (Baumbach-
Reardon et al. 2012). In addition, X-linked SMA is caused by mutations in the 
UBA1 gene and due to the X-linked recessive nature of this disorder it 
primarily affects males (Baumbach-Reardon et al. 2012). Both SMARD and 
X-linked SMA are severe forms of this motor neuron disease with patients 
affected very early in infancy. They are also are much rarer than SMA type I-
IV. In the context of this thesis, when SMA is used it will refer exclusively to 
types I-IV SMA, which are caused by mutations and deletions in the SMN1 
gene. 
1.3 The genetics of SMA  
 
In 1990, the gene responsible for SMA was mapped, using linkage analysis, 
to the 5q13 chromosome region (Figure 1.2A)(Brzustowicz et al. 1990; 
Gilliam et al. 1990; Melki et al. 1990; Verhaart et al. 2017). In 1995, it was 
reported that the SMN1 gene was the disease determining gene in SMA after 
it was shown that this gene was either deleted, interrupted or mutated in all 
229 SMA patients examined (Lefebvre 1995). Moreover, this study also 
showed that an almost identical gene, SMN2, was responsible for modifying 
the SMA phenotype in these patients (Lefebvre 1995). 
 
Within chromosome 5q13, a portion of the genetic sequence is duplicated 
and inverted; while SMN1 lies in the telomeric region, SMN2 lies within the 
inverted centromeric copy (Figure 1.2A) (Lunn & Wang 2008). SMN1 and 
SMN2 are similar as both contain 9 exons separated by 8 introns, with only 5 
nucleotide changes in SMN2 when compared with SMN1 (Figure 1.2B) 
(Bürglen et al. 1996). It is the C to T transition within exon 7 that is 
responsible for the disease modifying properties of SMN2 (Lefebvre 1995; 
Lorson et al. 1999; Singh et al. 2017). While this transition is a silent mutation 
that would not result in an amino acid alteration, it does result in a G-U 
transition within SMN2 pre-mRNA that is responsible for disrupting the exon 
splicing enhancer (ESE) site or creating a exon splicing silencer (ESS) in 
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exon 7 (Singh et al. 2017). This results in the alternative splicing and 
skipping of exon 7 in the SMN2 pre-mRNA (Lorson et al. 1999). The 
exclusion of exon 7 does not alter the half-life and stability of the mRNA but 
does create a truncated, short-lived and non-functional protein known as 
SMNΔ7 (Lefebvre 1995; Lorson et al. 1999; Monani et al. 1999). As exon 7 
can be randomly included in some SMN2 mRNA, approximately 10-15% of 
SMN2 protein product is full-length, functional SMN protein (Figure 1.2C). 
This small production of SMN means that life, to some extent, can be 
sustained when there is a loss of SMN1. 
 
This small production of SMN from the SMN2 gene means that in those 
individuals with no functional SMN1 gene, SMN2 copy number is important in 
determining the severity of SMA phenotype; those with a greater copy 
number of SMN2 often have an increased production of SMN protein (Taylor 
et al. 1998; Mailman et al. 2002). The number of copies of SMN2 that an 
individual carries can vary. Within the general population, 14.4% have no 
copies of SMN2, 33% have one copy of SMN2 while 50% have three copies 
of SMN2 (Mailman et al. 2002; Oskoui et al. 2017). SMA patients with severe 
type I SMA tend to have only one or two copies of SMN2 while type II-III 
patients tend to have ≥3 copies of SMN2 (Harada et al. 2002; Calucho et al. 
2018). This demonstrates a dose dependent effect of SMN2 copy number.  
 
However, it should be noted that although SMN2 copy number is the 
predominant phenotypic modifier in SMA, it is not the only modifier of disease 
severity. Patients have previously presented with disease phenotypes that 
are milder than would be expected based on their SMN2 copy number and 
this was shown to be caused by mutations within SMN2 itself (Prior et al. 
2009). In addition, in a case where two siblings were shown to have the 
same SMN genetics but one was symptomatic while the other was 
asymptomatic, it was the expression of Plastin 3, an actin-binding protein, 
that was found to be the modifying factor (Oprea et al. 2008). As a result, 
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although SMA is ultimately caused by mutations and deletions in SMN1, 
there are clearly other genetic factors that impact upon this disease.	  
Figure 1.2: SMN2 is alternatively spliced resulting in a reduction in the amount 
of functional SMN protein translated from this gene. (A) SMN genes are located 
on chromosome 5q13 with SMN1 in the telomeric region and SMN2 in the 
centeromeric region. Note that the centeromeric region is inverted when compared 
to the telomeric region of chromosome 5q13. (B) Both SMN genes have 8 exons 
separated by 9 introns. SMN1 sequences are shown on top and the altered SMN2 
sequence on the bottom, this includes the C to T transition that is important in 
splicing. (C) The C to T substitution in exon 7 of SMN2 causes a C to U alteration in 
pre-mRNA. This results in the alternative splicing of this gene. While all SMN1 pre-
mRNA is spliced to include exon 7, only 10% of SMN2 pre-mRNA is spliced to 
include exon 7. Therefore, only 10% of functional SMN protein is obtained from the 
SMN2 gene. The majority of SMN2 protein product is a short-lived and non-
functional SMNΔ7 protein. Figure based on Lung & Wang, 2008; Codey & Lorson, 
2011; Butchbach, 2016.  
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1.4 SMN protein  
 
SMN protein contains 294 amino acids and has a predicted molecular weight 
of 32kDa, although subsequent western blotting has shown a molecular 
weight of ~38kDa (Lefebvre 1995; Giavazzi et al. 2006). This alteration is 
possibly as a result of post-translational modifications. The levels of SMN 
protein expressed can vary with age and between tissues, with a higher level 
of Smn in the CNS tissues observed in control mice (Coovert 1997; Groen et 
al. 2018a). At the cellular level, SMN is located in both the cytoplasm and the 
nucleus. In the nucleus, SMN is concentrated in “gems” (or Gemini of Cajal 
bodies) (Gubitz et al. 2004). As the name suggests these gems are often 
associated with Cajal bodies and are similar in size and number (Gubitz et al. 
2004). The exact function of these gems remains unknown however due to 
their composition, it is thought that gems play a role in RNA processing 
(Gubitz et al., 2004; Q. Liu & Dreyfuss, 1996; Pellizzoni et al., 1998). 
 
The best characterised role for SMN is in pre-mRNA splicing (reviewed by 
(Burghes & Beattie 2009)). Pre-mRNA splicing is the process whereby non-
coding introns are removed from pre-mRNA and the remaining coding exons 
are rejoined to allow translation to progress. This process is facilitated by 
protein complexes known as spliceosomes and, from work in HeLa cells, it is 
known that SMN is involved in their assembly (Pellizzoni et al., 1998; 
Burghes & Beattie 2009). Specifically, SMN is involved in the assembly of 
snRNPs (small nuclear ribonuclear proteins), which are a major component 
of the spliceosome (Burghes & Beattie 2009). In its role in snRNP assembly, 
SMN exists as a complex, comprising of SMN and several Gemin proteins, 
specifically Gemins 2-8 and Unrip (Burghes & Beattie 2009). This SMN 
complex binds Sm proteins and snRNAs (small nuclear RNAs) that combine 
to create snRNPs (Burghes & Beattie 2009). Therefore, a lack of SMN will 
result in preventing snRNP assembly and subsequent insufficient production 
of spliceosomes (Burghes & Beattie 2009). 
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Although pre-mRNA splicing is the best-characterised role of SMN, it is not 
the only suggested role of this protein. In fact, due to the finding that splicing 
defects increased over disease progression it is thought that perhaps 
defective splicing is a secondary cause of the disease (Bäumer et al. 2009). 
It has been suggested that SMN can also function in the assembly of mRNPs 
(messenger ribonucleoproteins) from mRNA and mRNA binding proteins 
(mRBPs) (Fallini et al. 2012). It is in this form that mRNAs are transported 
within cells for their local translation within specific compartments of the cell. 
In neurons, local translation of mRNAs appears to be important as many of 
the proteins that are involved in synapse formation appear to be locally 
translated (Cajigas et al., 2012; Khalil et al., 2018). In motor neurons 
specifically, this transportation of mRNAs for local translation may be more 
important due to the substantial length of their axons (Czaplinski, 2014; 
Donlin-Asp et al., 2017; Fallini et al., 2016; Khalil et al., 2018). It is also 
postulated that SMN acts as an mRNA chaperone, supported by the finding 
that SMN is transported in both the anterograde and retrograde direction 
along the axon of motor neurons (Zhang et al. 2003).  
 
In addition, a lack of SMN leads to impairment of the cytoskeleton and this 
has been shown to contribute to SMA pathogenesis. Levels of RhoA, a 
regulator of actin dynamics, is increased in an SMA mouse model and the 
inhibition of ROCK, a downstream effector of RhoA, using Y-27632 or 
Fasudil, has been shown to improve the phenotype of this mouse model 
(Bowerman et al. 2010; Bowerman et al. 2012b). As the cytoskeleton is 
important for the transport of mRNAs within motor neurons, it may be 
possible that this impairment of the cytoskeleton adversely impacts on local 
translation of mRNAs at the synapse.   
 
It has also been suggested that SMN functions in DNA repair (Fayzullina & 
Martin 2014), stress granule formation (Hua & Zhou 2004), ubiquitin 
homeostasis (Groen & Gillingwater 2015) and synaptic vesicle release (Kong 
et al. 2009). However, despite the large number of suggested roles of SMN, 
Chapter 1 10	  
the disease-causing function of SMN ultimately remains unknown. It also 
remains unclear as to why a reduction in a ubiquitously expressed protein 
leads specifically to a motor neuron disease phenotype.  
1.5 Selective and differential vulnerability of motor neurons 
in SMA 
 
SMA is characterised by the selective degeneration of lower alpha-motor 
neurons. However, as SMN is a ubiquitously expressed protein, it is unclear 
why these motor neurons are selectively vulnerable. Defects in SMNs role in 
splicing are disputed as the causative factor of SMA due to splicing being a 
universal process that is not exclusive to motor neurons. However, one 
theory is that motor neurons have a greater requirement for transcripts that 
are spliced by the minor spliceosome (Gabanella et al. 2007). It is known that 
there are two types of spliceosome, major and minor, and these differ in their 
composition of snRNAs. Minor spliceosomes are responsible for splicing only 
1% of transcripts but are thought to be more affected by a reduction in SMN 
(Gabanella et al. 2007). Therefore, it is suggested that motor neurons may 
require transcripts that are spliced by the minor spliceosome and as a result 
are more affected by a reduction in SMN protein than other tissue types.  
 
It is also suggested that disruption in the transportation and local translation 
of mRNAs impacts on motor neurons to a greater extent than other tissues. 
This is due to motor neurons having extremely long axons, and as a result, 
having an increased requirement for local translation at their synapses 
(Czaplinski 2014; Fallini et al. 2016; Donlin-Asp et al. 2017; Khalil et al. 
2018). By impairing the process of local translation, motor neurons are no 
longer able to translate proteins required at the synapse. 
 
Another theory is that there is a threshold requirement for SMN, meaning that 
some tissues have a greater requirement for SMN than others (Sleigh et al. 
2011). It would suggest that motor neurons require large amounts of SMN 
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compared to other tissues. This is supported by the recent report that 
neuronal tissues have a higher level of Smn in control mice compared to 
other tissue types (Groen et al. 2018a). In addition, heart defects have been 
seen in patients of severe type I SMA, where SMN levels are very low, but 
not in patients of type II-III SMA, where SMN levels are higher (Shababi et al. 
2014; Deguise et al. 2016). Thus, suggesting that when SMN levels drop 
below a certain threshold for the heart it can no longer sustain normal 
function.  
 
However, motor neurons are not only selectively vulnerable to degeneration, 
they are also differentially vulnerable. This means that not all motor neurons 
are equally affected by a decrease in SMN and while some motor neurons 
degenerate, others do not, even at a late stage in the disease. This is a 
phenomenon that is observed in SMA mouse models and in patients with 
SMA. In patients, the upper limbs are less affected that the lower limbs and 
distal musculature is less affected than proximal musculature (Dubowitz 
1999). While the intercostal muscles are always affected, the diaphragm and 
facial muscles are comparatively spared (Dubowitz 1999). In mouse models, 
differential vulnerability of muscles varies between the different mouse 
models in the field. For example, in the Smn2B/- mouse model abdominal 
musculature displays vast denervation and pathology while cranial 
musculature shows less denervation (Murray et al. 2015). However, in the 
more severe mouse models of SMA, the vulnerability status of the muscle 
varies even between the four cranial muscles (Murray et al., 2008; Thomson 
et al., 2012). The reasons for this differential vulnerability remain unknown. 
Recent transcriptional analysis of the motor neurons supplying these 
differentially vulnerable muscle groups has highlighted pathways that are 
altered between the subpopulations of motor neurons (Murray et al. 2015). 
This revealed an up-regulation of transcripts involved in DNA repair in less 
vulnerable motor neurons providing one theory as to how protection against 
severe degeneration is obtained (Murray et al. 2015).  
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Ultimately, the reasons for this selective and differential vulnerability of motor 
neurons in SMA remains unclear and whether there is one particular reason 
for this or rather a multitude of different genetic disruptions between 
subpopulations has yet to be determined. However, investigation into these 
differences between motor neurons and in fact between motor neurons of 
different types of MND may highlight particular modifiers of motor neuron 
health that can be exploited as therapeutic targets (Murray et al. 2015; Kline 
et al. 2017).  
1.6 Animal models of SMA 
 
The discovery of the causative gene of SMA started the hunt for appropriate 
models of the disease. As SMN2 is unique to humans, SMA is a disease that 
only affects the human species (Rochette et al. 2001). Genetic modification 
of various other species, including Drosophila melanogaster (Chan et al. 
2003; Chang et al. 2008), Dario renia (zebrafish) (McWhorter et al. 2003; 
Boon et al. 2009) and Mus musculus (mouse) (Monani et al. 2000; Hsieh-Li 
et al. 2000; Le et al. 2005; Bowerman et al. 2012a), has been performed in 
order to create models of SMA. Each animal model has their strengths, and 
each provide different opportunities in SMA research. For example, 
Drosophila provides a quick screening tool for modifiers of the disease or for 
genetic mapping. However, it should be remembered that conclusions 
regarding the human disease cannot be drawn solely from findings within this 
relatively basic model (Schmid & DiDonato 2007; Burghes & Beattie 2009). A 
prime example of this is restoration of Smn in muscle; in Drosophila models 
of SMA, restoration of Smn in muscle provides a significant rescue of the 
disease whereas restoration of Smn in the muscles of mouse models has 
little effect on disease phenotype (Chan et al. 2003; Gavrilina et al. 2008; 
Burghes & Beattie 2009).  
 
Moreover, zebrafish are popular in the research of neurodegeneration due to 
their highly conserved genome, their rapid development and transparent 
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morphology, which makes imaging very accessible (Babin et al. 2014). 
Again, as they only have a single Smn gene, modification is required to 
create an SMA-like phenotype. In zebrafish, knocking out Smn reduces 
survival to a mean of 12 day post-fertilization (Boon et al. 2009). This is in 
contrast to mice where Smn knockout is embryonically lethal (Schrank et al. 
1997). In zebrafish, the increased survival of Smn knockout animals is 
thought to be caused by a higher dose of maternal Smn that is available in 
the early gestation period of zebrafish compared to mice (Boon et al. 2009). 
To further extend the survival of this zebrafish model of SMA, the transgenic 
expression of human SMN2 was introduced. This SMN2 expression on a null 
Smn background extended survival to 15 days post-fertilization (Hao et al. 
2011). 
 
An alternative method of reducing Smn expression in zebrafish is through the 
administration of modified antisense oligonucleotides, termed morpholinos, 
into embryos, rather than modifying the genome. This method targets protein 
production by inhibiting the translation of target mRNA. Injecting this 
morpholino into embryos resulted in a 61% reduction in Smn and abnormal 
axonal morphology (McWhorter et al. 2003). 
 
With regards to mouse models of SMA, many different mouse models have 
been created through a variety of genetic modifications. The initial creation of 
the first mouse model of SMA began when exon 2 in the murine Smn gene 
was disrupted. However, it was found that disruption of both copies of this 
gene, resulting in a completely null background and a complete lack of Smn, 
was embryonically lethal (Schrank et al. 1997). Transgenic expression of 
human SMN2 on this null background provided a small production of Smn 
protein that resulted in a mouse model with a phenotype that resembled that 
of SMA (Monani et al. 2000). With only one or two copies of SMN2 mice 
display a very severe phenotype and have a short life span; with two copies 
of SMN2 this mouse model will not survive past 6 days (Monani et al. 2000). 
However, with eight or more copies of SMN2 mice are phenotypically normal, 
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demonstrating the dose dependent requirement of Smn (Monani et al. 2000). 
Due to the severe phenotype of those mice with only two copies of SMN2, 
this mouse model is known colloquially as the ‘severe’ mouse model of SMA. 
 
The ‘Taiwanese’ mouse model of SMA is genetically similar to the ‘severe’ 
model. It also expresses SMN2 on a null background, however in the 
‘Taiwanese’ mouse model this null background is created through the 
disruption of exon 7 within the murine Smn gene, rather than exon 2 (Hsieh-
Li et al. 2000). With the expression of two copies of SMN2, this mouse model 
has an expected survival of 8-10 days and with the expression of four copies 
mice have a normal lifespan (Hsieh-Li et al. 2000). 
 
Approximately 5 years later, the SMNΔ7 transgene, developed from human 
SMN cDNA that excluded exon 7, was introduced into the ‘severe’ mouse 
model of SMA (Le et al. 2005). This addition was originally developed to 
determine whether the non-functional SMNΔ7 protein that is produced by 
SMN2 contributes to the SMA phenotype. However, it was found that 
incorporation of SMNΔ7 in fact moderately reduced the severity of the SMA-
like phenotype and extended life span to between 12 and 17 days (Le et al. 
2005). As a result, this ‘SmnΔ7’ mouse model of SMA is still used in SMA 
research.  
 
A mouse model in which the Smn deletion was exclusive to motor neurons, 
achieved using the Cre-Lox system, was used to determine the effect of Smn 
reduction on motor neurons specifically (Cifuentes-Diaz 2002). However, 
since Smn is reduced ubiquitously in SMA, this mouse model is less 
representative of the disease than other mouse models. Despite this, it did 
provide some of the first reports of pathological features of the NMJ that have 
since been shown in other, perhaps more representative, mouse models of 
SMA (Cifuentes-Diaz 2002; Murray et al. 2008).  
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The Smn2B/- mouse model of SMA is created through the genetic modification 
of the murine Smn gene (Bowerman et al. 2012a). One of the Smn alleles in 
this mouse model is non-functional due to the disruption of exon 2 (Schrank 
et al. 1997). The other allele is known as the ‘Smn2B’ allele and contains a 
three base pair substitution within exon 7 which causes it to mimic the effects 
of human SMN2 (DiDonato et al. 2001; Hammond et al. 2010). It expresses 
approximately 15% of full-length SMN but, as in SMN2, its main protein 
product is SMNΔ7. This mouse model is often referred to as an ‘intermediate’ 
mouse model of SMA due to its extended life span, of approximately 28 
days, compared to previously reported mouse models. It is also because of 
the lack of symptoms observed in the model until approximately 10 days old 
(Bowerman et al. 2012a). 
 
Mice that have reduced Smn levels but have a normal life span, and remain 
asymptomatic throughout, have also been created and characterised 
(Bowerman et al. 2012a; Jablonka et al. 2000). The Smn2B/2B mouse model 
carries two copies of the Smn2B allele and, as one copy of this allele is 
responsible for producing ~15% of normal Smn levels, the Smn2B/2B mouse 
expresses ~30% of normal Smn protein (Bowerman et al. 2012a). Analysis of 
specific tissue has shown that expression does vary between tissues with 
~36% in the spinal cord and ~25% in the brain (Bowerman et al. 2012a). 
Despite the reduction in Smn protein, this mouse model was shown to have 
no overt phenotype, with no significant difference in motor performance, NMJ 
morphology and motor neuron cell body (MNCB) number at both 6 months 
and 1 year of age (Bowerman et al. 2012a).  
 
Furthermore, the Smn+/- mouse model has only one functional murine Smn 
gene and therefore expresses approximately 50% of normal SMN levels 
(Jablonka et al. 2000).  This mouse model has been shown to have a loss of 
MNCBs in the ventral horn of the spinal cord, although the degree of loss 
appears to vary considerably within the published literature (Jablonka et al. 
2000; Simon et al. 2010; Bowerman et al. 2014; Udina et al. 2017). While it 
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was initially reported that there was a 54% loss of MNCBs from the 
lumbosacral region of the spinal cord, subsequent reports saw a 40% and a 
19% loss of MNCBs (Jablonka et al. 2000; Simon et al. 2010; Udina et al. 
2017). One report also shows no loss of MNCBs from the lumbar region of 
the spinal cord in the Smn+/- mouse model (Bowerman et al. 2014). Those 
that have found a loss of motor neurons within this mouse model report that 
axonal sprouting is responsible for masking the loss and the resulting motor 
phenotype (Simon et al. 2010; Udina et al. 2017). 
 
Having a variety of different models within SMA research provides an 
opportunity for us to strengthen findings regarding the pathogenesis of SMA 
and the reliability of therapeutic targets. Being able to replicate results in 
mouse models of different severities makes findings more promising. It also 
provides an opportunity to observe how alterations in genetics may influence 
outcomes, just as can occur in humans.  
1.7 Motor neuron pathology in SMA  
 
Motor neuron pathology has been investigated in both patients and mouse 
models of SMA. Motor neurons are extremely long cells that can be 
separated into distinct compartments; the cell body, located within the spinal 
cord, the axon, which extends from the spinal cord into the periphery, and the 
neuromuscular junction (NMJ), the point at which the pre-synaptic terminal of 
the motor neuron meets the post-synaptic endplate of the muscle (Figure 
1.1). Defects have been reported in each of these compartments and some 
of these defects are detailed below. 
 
A reduction in MNCB area and number has been documented in both 
patients and mouse models of the disease (Simic et al. 2000; Soler-Botija et 
al. 2002; d’Errico et al. 2013; Powis & Gillingwater 2016; Pérez-García et al. 
2017). Analysis on fetuses from terminated pregnancies has shown that SMA 
fetuses have a reduced number of MNCBs in their spinal cords from as early 
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as 12 weeks of gestation, when compared to age matched control fetuses 
(Soler-Botija et al. 2002). While there are many studies that report a loss of 
MNCB in post-mortem tissue for patients of SMA, very few provide 
quantification in support of this. One study however, carried out by Soler-
Botija et. al., reported a 50-60% loss of MNCBs in the spinal cord of patients 
with SMA type I during post-mortem analysis (Soler-Botija et al. 2002). In 
mouse models of SMA, the loss of MNCBs appears to vary between the 
different models. While the Taiwanese mouse model showed a 20% loss of 
MNCBs compared to controls, the SmnΔ7 and the Smn2B/- mouse models 
had a 40% and a 50% loss of MNCBs, respectively (Bowerman et al. 2012a; 
d’Errico et al. 2013; Powis & Gillingwater, 2016). In addition, there are 
reports of reduced excitatory inputs as well as abnormal morphology of 
mitochondria at the cell body of motor neurons (Neve et al. 2016).  
 
The axon of the motor neuron extends from the spinal cord within the ventral 
root. By examining the ventral roots of SMA type I patients, it has been 
shown that they experience a reduction in the number of myelinated axons 
(Pérez-García et al. 2017). This loss of myelinated axons was also shown in 
sural nerve of SMA type I patients (Carpenter et al. 1978). In a mouse model 
of SMA, there was a 78% loss of axons from the ventral root showing that 
this degeneration of axons is conserved in both patients and mouse models 
(Cifuentes-Diaz 2002).  
 
The NMJ has many well-reported defects that have become hallmarks of 
SMA pathology. Denervation has been shown to occur in a die-back manner 
in which the pre-synaptic terminal withdraws away from the muscle (Murray 
et al. 2008). Post-synaptic endplates become progressively denervated, as 
evidenced by the presence of partially occupied and vacant clusters of 
acetylcholine receptors (AChRs) (Murray et al. 2008; Murray et al. 2015). 
 
Furthermore, NMJs also exhibit an abnormal accumulation of neurofilament 
(or neurofilament accumulation/ NFA), a component of the cytoskeleton, at 
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their pre-synaptic terminals (Cifuentes-Diaz 2002; Murray et al. 2008; Kariya 
et al. 2008). This is regarded as a pathological hallmark of SMA as it is 
widely observed in both patients and mouse models of SMA (Murray et al. 
2008; Kariya et al. 2008; Kong et al. 2009). As NFs are the intermediate 
filaments of neurons, they are part of the cytoskeletal system (Yuan et al. 
2012). They are predominately located within the axons of neurons, where 
they are important during development and in nerve conduction and axon 
diameter (Yuan et al. 2012). NFs are primarily made within the cell body and 
are transported into and along axons (Miller et al. 2002). Therefore, it has 
been suggested that the accumulation of NFs observed in SMA may be 
caused by impaired axonal transport (Boyd & Gillingwater 2017). However, it 
has been reported that NFA is due to synaptic alterations rather than axonal 
transport defects and therefore, the causes of NFA in SMA remain unknown 
(Dale et al. 2011).  
 
In fact, NFA occurs in other neurodegenerative diseases such as ALS, 
Alzheimer’s disease and Parkinson’s disease in which the cause and 
resulting consequences of this NFA are yet to be determined (Yuan et al. 
2012). However, in these diseases NFA occurs within the cell body and 
axon, therefore it appears that pre-synaptic NFA is unique to SMA (Kong et 
al. 2009; Cifuentes-Diaz 2002). Interestingly, mice that have been genetically 
modified to overexpress NFs exhibit motor neuron degeneration suggesting 
perhaps that NFA can be a causative factor of motor neuron degeneration 
(Côté et al. 1993). Despite this, it remains unclear how the onset of NFA 
relates to the degeneration of the NMJ in SMA (Cifuentes-Diaz 2002; Boyd & 
Gillingwater 2017).   
 
The post-synaptic endplate is formed by acetylcholine receptors (AChRs) on 
muscle fibers. In development, AChRs reorder and perforate, altering their 
morphology from immature plaque-like to mature pretzel-like structures 
(Sanes & Lichtman 2001). They also develop molecularly with a shift in the 
expression of the fetal γ-subunit to the adult subunit during the first two 
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weeks of postnatal development (Mishina et al. 1986).  In SMA, immature 
endplates persist. In the SmnΔ7 mouse model of SMA, 50% of endplates 
were morphologically immature at P14 while only 10% of endplates in 
controls appeared immature at the same age (Kariya et al. 2008). In addition, 
there was also an increase in the endplates that expressed the fetal γ-
subunit of AChRs in this mouse model (Kariya et al. 2008). This pathological 
feature is conserved in humans, as patients of SMA exhibit a decrease in 
endplates with mature morphology and increase in endplates expressing the 
immature fetal AChR γ-subunit (Harding et al. 2015). 
 
Although these hallmarks of SMA motor neuron pathology are relatively well 
documented in the literature, how they are related is unknown. Despite 
speculation that motor neurons degenerate in a distal to proximal manner, 
due to the NMJ being an early pathological target in SMA (Murray et al. 
2008), there is no literature that explicitly explores this idea. 
 
In addition, since the NMJ is an early target in SMA, it has been proposed 
that degeneration of the NMJ is what causes the motor neuron to die. 
However, two recent studies have shown that transcripts involved in the P53 
signaling pathway are up-regulated prior to symptom onset in vulnerable 
motor neurons of three different SMA mouse models (Murray et al. 2015; 
Simon et al. 2017). As the P53 signaling pathway is important in DNA repair 
and apoptosis and is activated upon excessive DNA damage (Williams & 
Schumacher 2016), it suggests that motor neuron death could be initiated 
prior to visible motor neuron pathology. 
 
In order to determine when and where degeneration of the motor neuron 
begins, a coherent study that looks at the hallmark features of pathology in 
SMA over a time course would be required in order to draw conclusions on 
the relationship of motor neuron pathology in SMA.  
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1.8 Non-neuronal defects in SMA  
 
SMA is characterised by the degeneration of motor neurons, which are 
reportedly selectively vulnerable to a reduction in SMN. However, there are 
now many reports of defects in other tissues, from both patients and mouse 
models of SMA, suggesting that SMN plays a role within non-neuronal 
tissues. Below, a few of the non-neuronal defects that have been reported to 
occur within SMA mouse models and/or patients are briefly detailed. 
 
Skeletal muscle in SMA experiences atrophy and this is, at least in part, due 
to the loss of innervation following motor neuron degeneration. However, it 
has also been shown that Smn reduction causes intrinsic defects of sketal 
muscle. For example, Smn reduction in myoblast cell lines results in 
defective myotubule formation and reduced myoblast proliferation (Shafey et 
al. 2005). Furthermore, proteomic analysis of skeletal muscle has been 
carried out at a pre-symptomatic time point, when there is a lack of 
denervation, and this revealed that there are molecular changes in muscle 
from SMA mice compared to controls (Mutsaers et al. 2011). Specifically, 
there were abnormalities in the regulation of proteins involved in muscle 
function and pathology (Mutsaers et al. 2011). 
 
Moreover, skeletal muscle has been shown to have an immature phenotype 
in both mouse models and patients of SMA, when compared with that of age-
matched controls (Kariya et al. 2008; Kong et al. 2009; Lee et al. 2011; Boyer 
et al. 2014). Not only has it been shown that there is delayed maturation of 
the post-synaptic endplates of the muscle, but also the persistence of the 
immature form of the myosin heavy chain in the skeletal muscle of the 
SmnΔ7 mouse model (Kariya et al. 2008; Kong et al. 2009; Lee et al. 2011). 
This is important to consider as it Is belived that delayed maturation of the 
motor unit can be detrimental for its survival (Hausmanowa-Petrusewicz & 
Vrbová 2005). 
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Bone defects have been reported in both patients and mouse models of 
SMA. The Taiwanese mouse model displayed significantly thinner and more 
porous cortical bone in their vertebrae than control mice (Shanmugarajan et 
al. 2009). Similarly, SMA patients have been shown to have a low bone 
mineral density, with high rates of osteopenia. In fact, SMA patients 
presented with the lowest average bone mineral density when compared to 
patients of other neuromuscular disorders, such as Duchene Muscular 
Dystrophy (DMD) (Khatri et al. 2008).  
 
Furthermore, the density of vasculature in the Taiwanese mouse model is 
significantly reduced compared to controls, in a variety of different muscles 
(Somers et al. 2016). This finding was also observed in muscle biopsies from 
SMA patients (Somers et al. 2016). In the spinal cord, the density of capillary 
bed was decreased in both the Taiwanese and SmnΔ7 mouse models of 
SMA and this was reported to cause hypoxia of motor neurons at a pre-
symptomatic time point (Somers et al. 2016). Therefore, the authors suggest 
that SMN plays a role in the development of vasculature and that hypoxia of 
motor neurons may be contributing to their death (Somers et al. 2016).  
 
Additionally, the density of capillaries within cardiac muscle is decreased and 
cardiac defects have been reported in both patients and mouse models of 
SMA (Shababi et al. 2014; Deguise et al. 2016; Maxwell et al. 2018). Both 
the intraventricular septum and the ventricular wall were thinner in the 
severe, SmnΔ7 and Taiwanese mouse models of SMA, when compared to 
controls (Shababi et al. 2014; Maxwell et al. 2018). Patients with severe SMA 
have an increased risk of developing congenital heart defects, including atrial 
and ventricular septal defects, suggesting a role for SMN in cardiac tissue 
(Rudnik-Schoneborn et al. 2008).  
 
Moreover, the spleen has been shown to be significantly smaller in size with 
abnormal morphology in various mouse models of SMA (Deguise et al. 2017; 
Thomson et al. 2017; Khairallah et al. 2017). Preliminary observations of 
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spleens from those with SMA type I/II suggest that splenic defects may also 
be a symptom of SMA in patients (Thomson et al. 2017). SMN expression 
within the spleen is high in wild type mice, suggesting a greater requirement 
for this protein (Deguise et al. 2017). It has also been shown that introducing 
one copy of SMN2 into the Smn2B/- mouse model of SMA rescued the splenic 
defects observed in this mouse model (Deguise et al. 2017). Therefore, it is 
thought that SMN plays an important role within this tissue. 
 
An abnormal morphology of the thymus has also been reported in mouse 
models of SMA and since both the thymus and the spleen are involved in 
immunity, it is suggested that a lack of SMN may be detrimental to the 
immune system (Deguise & Kothary 2017). However, this idea remains 
relatively unexplored and warrants further investigation to determine whether 
SMA patients have a greater susceptibility to infections due to impairment of 
their immune system (Deguise & Kothary 2017).  
 
Analysis of the liver from the Taiwanese mouse model of SMA revealed this 
tissue fails to develop normally, with an immature morphology persisting 
(Szunyogova et al. 2016). It also displayed abnormal accumulation of iron, 
which is consistent with previous reports that found that deletion of SMN from 
the liver exclusively, leads to embryonic death as a result of iron 
accumulation (Vitte et al. 2004; Szunyogova et al. 2016). 
 
Furthermore, gastrointestinal problems are also reported in patients of SMA, 
with symptoms including reflux, bloating and constipation (Wang et al. 2007). 
Diarrhea was reported in the Taiwanese mouse model of SMA, which also 
had a decreased number of villi, that had an abnormal appearance compared 
to controls, within their small intestine (Schreml et al. 2013). 
 
The pancreas has been assessed in patients of SMA and in the Smn2B/- 
mouse model (Bowerman et al. 2012c). This revealed that in both cases, the 
pancreas has an abnormal cellular composition, with an increase in the 
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percentage of alpha cells, that produce glucagon, and a decrease in 
percentage of beta cells, that produce insulin  (Bowerman et al. 2012c). This 
observation is consistent with reports of metabolic abnormalities in SMA 
patients including abnormal fatty acid metabolism and hypoglycemia (Bruce 
et al. 1995; Crawford et al. 1999). Further investigation into the pancreas in 
Smn+/- mice, which, in this case, was found to have no overt phenotype, 
showed that even with SMN levels that appear sufficient to sustain survival, 
there were metabolic differences in these mice when they were placed under 
stressed conditions (Bowerman et al. 2014). Therefore, highlighting the 
importance of SMN in regulating metabolism, even when SMN levels are 
sufficient to sustain survival of motor neurons. 
 
From this brief overview of some of the defects that have been reported in 
non-neuronal tissues, in both patients and mouse models of SMA, it is clear 
that when levels of SMN are severely low SMA is no longer exclusively a 
neuromuscular disorder. This is important to consider when looking at 
therapeutic options, as correction of all pathologies would be required in 
order to benefit patients of SMA. 
1.9 Therapeutics in SMA 
 
SMA has now been at the forefront of therapeutic research for a number of 
years. Since the discovery of SMN, the disease-causing gene, the main line 
of therapeutic research has looked to restore the production of SMN protein. 
This has been attempted by replacing the faulty SMN1 gene, using gene 
therapy techniques, or by altering the aberrant splicing of SMN2 pre-mRNA, 
using an antisense oligonucleotide (ASO) or splice-altering, small molecules. 
Thanks to this research, the SMA field reached a major milestone when the 
first SMA treatment, Spinraza, was approved initially in the USA in December 
2016 and since in the European Union in May 2017. Spinraza (Nursinersen, 
Biogen/Ionis) is an ASO based therapy. ASOs are short, single stranded, 
synthetic oligodeoxynucleotides that bind to the pre-mRNA of SMN2 to 
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enhance the inclusion of exon 7 during splicing. This results in an increase in 
the amount of full-length SMN protein synthesised from the SMN2 gene 
(Shorrock et al. 2018). In clinical trials (ENDEAR and CHERISH) of Spinraza, 
patients with type I, II and III SMA showed a significant increase in motor 
performance and in patients with type I SMA, there was a significant increase 
in lifespan. In fact, these trials were so successful that they were both closed 
and all patients were enrolled onto an open-label trial, SHINE, that now looks 
at the long-term effects of Spinraza (Mercuri et al. 2017; Finkel et al. 2017).  
 
Spinraza itself has not been associated with many adverse side effects but 
rather the delivery method is what appears to cause the majority of the side 
effects reported during clinical trials (Finkel et al. 2016). Spinraza is 
administered intrathecally, into the cerebrospinal fluid (CSF) of patients via a 
lumbar puncture, as ASOs cannot cross the blood brain barrier (Wood et al. 
2017). This ensures that a large dose of the ASO is delivered to the CNS, 
and importantly, the motor neurons (Shorrock et al. 2018). Although, as CSF 
is reabsorbed into systemic circulation, Spinraza is also detectable within the 
liver and kidneys, showing delivery is not exclusively to the nervous tissues 
(Finkel et al. 2016). Patients receive a loading period of the drug whereby 3 
treatments are given 14 days apart and the fourth is given 30 days after 
(Finkel et al. 2016). Patients will receive subsequent treatments every 4 
months. Since lumbar punctures are a rather invasive treatment, side effects 
of which include back pain, headaches and post-lumbar puncture syndrome, 
the frequent treatment of Spinraza is less than desirable (Finkel et al. 2016; 
Shorrock et al. 2018). Therefore, despite the efficacy of Spinraza, a 
treatment that requires a less invasive procedure would be more desirable. 
 
Gene therapy is an alternative method of restoring SMN protein that is 
currently in clinical trials (AVXS-101, AveXis). This involves the systemic 
administration of an adeno-associated virus (AAV) vector that contains 
SMN1, replacing the endogenous faulty version of the gene. In mouse 
models, this therapy showed promising results and therefore it was brought 
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into clinical trials that assessed its safety (Foust et al. 2010; Valori et al. 
2010; Dominguez et al. 2011). This initial trial proved encouraging and 
AVXS-101 is now in long-term trials that assess its efficacy and look at long-
term effects of gene therapy treatment (Shorrock et al. 2018). The clear 
advantage of this therapy is its delivery method; it requires only a single, 
intravenous injection, which removes the side effects associated with more 
invasive procedures. 
 
Small molecule therapies target the alternative splicing of SMN2 pre-mRNA. 
There are two small molecule drugs currently in clinical trials; Branaplam 
(LMI070, Novartis) and RG7916 (RO7034067, Roche). Although both of 
these therapeutics can be given orally, which is a much more desirable 
delivery method in the clinic, they have shown only a modest improvement in 
motor function in patients (Shorrock et al. 2018).  
 
Valproic Acid (VPA) is a drug that is currently used to treat a variety of 
neurological disorders, including epilepsy. The mechanism of how it works 
therapeutically is unknown but as a histone deacetylase (HDAC) inhibitor it is 
involved in regulating gene expression. In terms of SMA, it is thought to alter 
splicing of SMN2 and in turn increase SMN levels (Sumner et al. 2003). 
Although a study looking at an alternative HDAC inhibitor, Trichostatin A, 
disputes this claim, reporting that this substance does not increase SMN 
levels (Liu et al. 2014). Interestingly, clinical trials of VPA for SMA, showed 
mixed results among patients (Swoboda et al. 2009). While some patients 
experienced the desired increase in SMN protein levels, others had no 
increase or even decreased SMN levels during the treatment (Garbes et al. 
2013). A subsequent comparison of fibroblasts from those that responded to 
the treatment and from those that did not showed that CD36 RNA levels 
were significantly increased in those that did not responded to VPA treatment 
(Garbes et al. 2013). CD36 is a cell surface membrane protein that is known 
to be involved in the transportation of fatty acids (Garbes et al. 2013). By 
treating cultured cells, that had been transfected with CD36, with VPA the 
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authors were able to show that CD36 had a negative effect on SMN 
production (Garbes et al. 2013). This highlights the genetic differences 
amongst the population that should not be forgetten when considering SMA 
treatments. 
 
One of the key findings from mouse models of SMA is that early restoration 
of SMN is key to the successful treatment of SMA (Lutz et al. 2011; Robbins 
et al. 2014). As this is likely due to the fact that motor neuron death is 
irreversible, it is assumed that this will also be the case in patients. The 
NURTURE trial of Spinraza therefore looks at the effects of administering 
Spinraza to pre-symptomatic patients. Through genetic testing these patients 
have been diagnosed with SMA but have not yet displayed symptoms. After 
one-year of treatment, these patients are showing promising results with all 
attaining normal head control and most being able to sit and crawl (Hwu et al. 
2017). However, only three out of nine were able to stand unaided 
suggesting that although early intervention is beneficial and that Spinraza 
shows promising improvement for patients, it is clearly still not a ‘cure’ for 
SMA (Hwu et al. 2017; Shorrock et al. 2018). The hope is that by finding 
other treatments, that could be given to patients in conjunction with Spinraza, 
it may be possible to enhance the therapeutic effects of this treatment. 
 
Other therapeutics being investigated for SMA are SMN-independent and 
target the motor unit, either through muscle enhancing or neuroprotection, 
rather than SMN expression. These are certainly not as effective as SMN-
dependent therapies but are the focus of research into combinatorial 
therapies. For example, SRK-015 (Scholar Rock) is a myostatin inhibitor. 
Myostatin is involved in the inhibition of muscle growth and differentiation and 
therefore inhibition of this protein results in increased muscle mass. In mouse 
models of SMA, SRK-015 improved muscle function and as a result, Scholar 
Rock have recently begun safety and tolerability trials of SRK-015 in healthy 
adult controls (ScholarRock 2017; Shorrock et al. 2018). Assuming success 
in this trial, a subsequent Phase II trial will look at the effects of SRK-015 in 
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SMA patients that have or have not been treated with Spinraza (ScholarRock 
2017; Shorrock et al. 2018).  
 
Olesoxime (Roche) has been shown to stop excessive permeability of 
mitochondria under stressful conditions and to prevent the release of pro-
apoptotic factors from mitochondria, resulting in neuroprotection within 
mouse models of neurodegenerative diseases (Bordet et al. 2010; Sunyach 
et al. 2012). Therefore, Olesoxime was put into clinical trials for SMA (Bertini 
et al. 2017). However, following poor results, Roche ended these clinical 
trials in June 2018 (Marques Lopes 2018). Despite the poor results with 
Olesoxime, the idea of a neuroprotection drug is one that should perhaps be 
further explored as research into combinational therapies continues.  
 
All research to date has been paramount in the success of SMA therapies. 
However, more research into SMA is still required while the long-term effects 
of Spinraza and other gene therapy treatments are awaited. Continuing to 
look into possible therapeutic modifiers may give rise to other combinational 
therapies. Furthermore, increasing our understanding of SMA pathogenesis, 
through fundamental scientific research, continues to be important as an 
increased knowledge of SMA will give us a better chance of finding further 
ways to improve the lives of SMA patients. It is for this reason that the aims 
of this thesis are presented below.	  
  
Chapter 1 28	  
1.10 Aims 
 
A number of aims that will be addressed in the remainder of this thesis are 
detailed below. These aims have been formulated in order to further our 
knowledge into the pathogenesis of SMA. 
 
Aim 1: Investigate the timing and mechanism of motor neuron 
pathology onset in the Smn2B/- mouse model of SMA 
 
Hypothesis 1A: Motor neuron pathology occurs in a distal to proximal manner  
 
1A Perform a temporal analysis of NMJ and MNCB pathology in 
the Smn2B/- mouse model of SMA 
 
Hypothesis 1B: The activation of the P53 signaling pathway causes NMJ 
degeneration 
 
1B Investigate the effects of a reduction in P53 on pathology at the 
NMJ and the MNCB in the Smn2B/- mouse model of SMA 
 
Aim 2: Investigate whether there are compensatory subpopulations of 
motor neurons in the Smn2B/- mouse model that are responsible for 
masking degeneration in muscles that are less vulnerable to 
degeneration 
 
Hypothesis 2A: Compensatory sprouting is responsible for the lack of 
denervation observed in less vulnerable muscles of the Smn2B/- mouse model 
of SMA 
 
2A Investigate NMJ degeneration in vulnerable and resistant 
muscles of the Smn2B/- mouse model of SMA and determine 
whether sprouting could be responsible for masking 
degeneration in resistant muscles 
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Hypothesis 2B: There are subpopulations of motor neurons that are 
‘healthier’ and compensate for the degeneration of other motor neurons in 
the Smn2B/- mouse model of SMA 
 
2B  Examine pathology of single motor units within Smn2B/- mice to 
determine whether there are divergent populations of motor 
neurons 
 
Aim 3: Investigate motor unit pathology in mouse models that have 
reduced Smn but are asymptomatic  
 
Hypothesis 3: Compensatory sprouting is responsible for the lack of 
denervation observed in mice that have reduced Smn but are asymptomatic 
 
 
3A Investigate MNCB loss as well as degeneration and 
regeneration of the NMJ in the Smn+/- mouse model, which 
expresses only 50% of normal Smn protein levels 
 
3B  Investigate MNCB loss as well as degeneration and 
regeneration of the NMJ in the Smn2B/2B mouse model, which 
expresses only 30% of normal Smn protein levels 
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Chapter 2 
 
Materials and Methods 
2.1 Mouse breeding 
2.1.1 Smn2B/- mice 
 
The Smn2B/- mouse model of SMA, which had been established within our 
laboratory, was maintained at the University of Edinburgh animal facilities 
(Central Campus) in Individually Ventilated Cages (IVCs) on a C57BL/6 
background. Male and female Smn2B/+ mice (mice with the Smn2B allele 
were originally obtained from the Kothary Laboratory, Ottawa) had been 
crossed to produce Smn2B/2B mice, as well as Smn2B/+ and Smn+/+ littermates. 
Subsequently, Smn2B/2B mice were bred with Smn+/- mice (Strain: 10921, 
Jackson Laboratories) to give experimental Smn2B/- mice and control Smn2B/+ 
littermates (Bowerman et al. 2012a).  
 
2.1.2 Smn2B/-;P53fl/fl ;Cre+ mice 
 
Smn2B/-;P53fl/fl ;Cre+ mice were established within our laboratory (for the 
establishment of this colony please refer to Figure 3.10 within Chapter 3). 
They were maintained at the University of Edinburgh animal facilities 
(Western General Hospital Campus) in open caging on a C57BL/6 
background. 
 
To establish this colony, Smn+/+;P53fl/+;Cre- mice were kindly donated to our 
laboratory by Dr Luke Boulter and Dr Kevin Myant (University of Edinburgh). 
These were bred with mice carrying CAG-Cre-ER, a tamoxifen inducible Cre 
that is ubiquitously expressed (strain: 004682, Jackson Laboratories), which 
had been kindly donated by Dr You-Ying Chau (University of Edinburgh). 
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Using Smn2B/2B and Smn+/- from our own colony, the Smn2B/2B;P53fl/fl;Cre- and 
Smn+/-;P53fl/fl;Cre+ mice were derived (Figure 3.10) and were bred to give 
experimental litters containing mice of the following genotypes; 
 
• Smn2B/-;P53fl/fl;Cre+ mice    
• Smn2B/-;P53fl/fl;Cre- mice   
• Smn2B/+;P53fl/fl;Cre+ mice 
• Smn2B/+;P53fl/fl;Cre- mice 
 
2.1.3 Thy-1-YFP-H mice 
 
Thy1-YFP-H mice were purchased from Jackson Laboratories (Strain: 
003782). These mice were wild type for Smn and so had the genotype 
Smn+/+;YFP-H. They were crossed with Smn+/- to produce Smn+/-;YFP-H and 
Smn+/+;YFP-H mice that were aged at Charles River Laboratories, East 
Lothian, in IVCs.  
 
Additionally, Smn+/+;YFP-H mice were bred with Smn2B/2B mice at the 
University of Edinburgh animal facilities (Central Campus) in IVCs. 
Smn2B/+;YFP-H mice were interbred to produce Smn2B/2B;YFP-H mice. By 
crossing these with Smn+/-;YFP-H mice, Smn2B/-;YFP-H mice and control 
Smn2B/+;YFP-H mice were obtained. 
2.2 Genotyping 
2.2.1 DNA Extraction 
	  
DNA was extracted from tail tips or ear clips by digesting the tissue in 500µl 
of Tail Tip Lysis Buffer (TTLB; 0.5M EDTA, 1M Triz-HCl, 1M NaCl, 10% SDS, 
ddH2O) and 2.5µl of Proteinase K (1mg/ml) for 24 hours at 55oC. DNA was 
precipitated in Isopropanol and washed in 70% ethanol. It was re-suspended 
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in 50µl of ddH2O for ear clips and 200µl of ddH2O for tail tips to give a 
concentration of approximately 200ng/µl. 
 
2.2.2 Smn2B/- mice 
Smn2B gene 
	  
To determine what mice carried the Smn2B allele, PCR was carried out 
using the Invitrogen Taq Polymerase kit with a forward and reverse primer 
(please refer to Table 2.6 for primer sequences; sequences originally 
obtained from the Kothary Laboratory). Temperature cycling was as shown in 
Table 2.1. 
 
Gel electrophoresis, using a 1.5% agarose gel that contained 0.01% 
SYBRSafe DNA stain (Invitrogen), separated the DNA strands created by 
this PCR protocol.  An upper 700bp band denoted the Smn2B allele and a 
lower 500bp band denoted the murine Smn (mSmn) allele (Figure 2.1).  
 
As the primers for this protocol bind within exon 7 of the Smn gene and the 
mutation that results in this gene being null is within exon 2 (Schrank et al. 
1997), this protocol does not determine whether the mSmn allele is non-
functional (null) or functional. A non-functioning Smn allele would result in no 
Smn product from this allele, as in the case of Smn2B/- mice. Therefore, to 
separate Smn2B/+ (functioning Smn allele) and Smn2B/- (null Smn allele) mice 
the ‘mSmn gene’ protocol, shown below, must be used. 
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Table 2.1: PCR temperature cycling for Smn2B genotyping protocol 
Step Temperature (oC) Duration 
1 94 3 minutes 
2 94 45 seconds 
3 58 45 seconds 
4 72 45 seconds 
5 Repeat steps 2-4 35 times 
6 72 5 minutes 





To determine whether the mSmn allele Smn2B mice carried was functional 
or non-functional (null), PCR was preformed using the Invitrogen Taq 
Polymerase kit, a common forward primer and two reverse primers, one that 
binds to the wild-type genetic sequence and another that binds to the 
inserted cassette that creates the null allele (Table 2.6; sequences obtained 
from Jackson Laboratories). Table 2.2 displays the temperature cycling 
protocol. 
 
As above, gel electrophoresis separated the DNA strands created from this 
PCR protocol and these are shown in Figure 2.1. An upper 800bp band 
represents the wild-type Smn allele and a lower 500bp band represents the 
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Table 2.2: PCR temperature cycling for mSmn genotyping protocol 
Step Temperature (oC) Duration 
1 94 3 minutes 
2 94 30 seconds 
3 58 1 minute 
4 72 1 minute 
5 Repeat steps 2-4 35 times 
6 72 2 minutes 












Figure 2.1: PCR and gel electrophoresis determines the Smn genotype of a 
mouse (A) Image of a gel showing the results of the Smn2B PCR protocol. The 
Smn2B allele is amplified to give a 700bp band and the mSmn gene is amplified to 
give a 500bp band. (B) To determine whether this mSmn allele was functional or 
non-functional (null), the mSmn PCR protocol was performed. The gel shows a 
500bp band where the mouse carries a null Smn allele. 
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2.2.3 Smn2B/-;P53fl/fl ;Cre+ mice 
 
Throughout the breeding of this colony several genotyping protocols were 
required. Genotyping for the Smn2B and null mSmn alleles followed the 
same protocols noted above under ‘Smn2B/- mice’. In addition to this, 




Mice were bred to only express only one or no copies of Cre and therefore 
genotyping was required to separate those positive or negative for Cre. PCR 
was carried out using the Invitrogen Taq Polymerase kit, and two primer sets; 
one that amplifies a control sequence within interleukin-2 (Primer-BLAST, 
NCBI), to show a successful PCR, and another that amplifies the Cre 
sequence (primer sequences are shown in Table 2.6; sequences obtained 
from Dr Luke Boulter). The temperature cycling for this PCR protocol is 
shown in Table 2.3. 
 
Subsequent gel electrophoresis was preformed and shows the control band, 
denoting a successful PCR, at 300bp and, if positive for Cre, a band is 
displayed at 100bp (Figure 2.2). 
 
 
Table 2.3: PCR temperature cycling for Cre genotyping protocol 
Step Temperature (oC) Duration 
1 94 3 minutes 
2 94 30 seconds 
3 51.7 1 minute 
4 72 1 minute 
5 Repeat steps 2-4 35 times 
6 72 2 minutes 
7 4 Hold 
 




To differentiate between mice that carried a P53-floxed (P53fl) allele and 
those that did not, PCR was carried out using the KAPA2G Robust PCR kit 
with dNTPs (KAPA Biosystems Ltd) and two sets of primers. One set 
amplified a control sequence, within a non-floxed region of the P53 gene, 
and the other amplified a region of the P53fl allele (Table 2.6; sequences 
obtained from Dr Luke Boulter). The temperature cycling programme was as 
shown in Table 2.4. 
 
Again, gel electrophoresis separated the two products giving a lower 100bp 
control band, denoting a successful PCR, and an upper 300bp band if 
positive for P53fl (Figure 2.3). 
 
Homozygosity for the P53fl allele was required to ensure the maximum 
knockdown of P53. In order to separate homozygous and heterozygous 
mice, copy number genotyping, using qPCR, was required. To preform 
qPCR, all DNA samples were diluted to 10ng/ul. SYBR green-based qPCR 
was preformed using Kapa SYBR Fast Universal (Kapa Biosystems) and the 
CFX Connect Real-time PCR Detection system (Biorad). The P53fl primers 
detailed in Table 2.6 were optimised for quantitative use (please refer to 
Figure 3.11 in Chapter 3). The primers that amplified the control sequence 
and the primers that amplified the P53fl sequence were separated and each 
run in technical triplicate in separate wells. The Cq values for each sample 
Figure 2.2: PCR and gel 
electrophoresis reveals the 
presence or absence of 
Cre. The image of a gel 
displays the result of the Cre 
PCR protocol. A control band 
at 300bp denotes a 
successful PCR run and a 
band at 100bp represents 
positivity for Cre. 
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were collated in Microsoft Excel and the mean for each technical triplicate 
calculated. The mean Cq value of the P53fl amplicon was subtracted from 
the internal control amplicon Cq value for each sample. GraphPad Prism was 
used to produce a graph that plotted the difference between the mean Cq 
values of the two primer sets to compare unknown samples to samples that 
were known to be from heterozygous mice. Detailed results for this can be 
found in Chapter 3 (Figure 3.11). 
 
 
Table 2.4: PCR temperature cycling for P53fl genotyping protocol 
Step Temperature (oC) Duration 
1 94 2 minutes 
2 94 20 seconds 
3 65 15 seconds 
4 68 10 seconds 
5 Repeat steps 2-4 10 times 
6 94 15 seconds 
7 60 15 seconds 
8 72 10 seconds 
9 Repeat steps 6-8 28 times 
10 72 10 minutes 




Figure 2.3: PCR and gel 
electrophoresis reveals the 
presence or absence of the 
P53fl allele. The image of a 
gel displays the result of the 
P53fl PCR protocol. A control 
band at 100bp denotes a 
successful PCR run and a 
band at 300bp would mean at 
least one of the P53 alleles is 
P53fl. 
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2.2.4 Thy-1-YFP-H mice 
 
Mice that were bred to express YFP-H were either Smn+/+, Smn+/-, Smn2B/2B, 
Smn2B/+ or Smn2B/-. The genotyping of for these Smn genotypes can be found 




To separate mice positive for YFP and mice negative for YFP the following 
PCR protocol was obtained from Jackson Laboratories. It was optimised 
using the GoTaq Flexi DNA polymerase kit with the four primer sequences 
given in their protocol. A forward and a reverse primer set that amplified the 
transgene itself and a forward and reverse primer set that displays mice 
negative for YFP-H (Table 2.6; sequences obtained from Jackson 
Laboratories). The temperature cycling programme shown in Table 2.5 was 
used. 
 
Gel electrophoresis separated the two DNA sequences giving an upper 
500bp band that represents the YFP-H positive mice and a lower 300bp 
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Table 2.5: PCR temperature cycling for YFP-H genotyping protocol 
Step Temperature (oC) Duration 
1 94 2 minutes 
2 94 20 seconds 
3 65 15 seconds 
4 68 10 seconds 




6 94 15 seconds 
7 60 15 seconds 
8 72 10 seconds 
9 Repeat steps 6-8 28 times 
10 72 10 minutes 
11 4 Hold 
  
Decreasing the temperature of Step 3 by 0.5oC each 
cycle 
Figure 2.4: PCR and gel 
electrophoresis separates 
mice positive and negative 
for YFP-H. The image of a gel 
displays the result of the YFP-
H PCR protocol. A mouse 
positive for YFP-H will show a 
500bp band and a mouse 
negative for YFP-H will show 
a 300bp band. 
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Table 2.6: Primer sequences used in genotyping protocols 
(all from Sigma) 
Protocol Sequence 
Smn2B 
Forward: 5’- AAC TCC GGG TCC TCC TTC CT -3’ 
Reverse: 5’- TTT GGC AGA CTT TAG CAG GGC -3’ 
mSmn 
Forward: 5’- CTC CGG ATA TTG GGA TTG -3’ 
Reverse (for wildtype mSmn): 
5’-TTT CTT CTG GCT GTG CCT TT -3’ 
Reverse (for null mSmn): 
5’- GGT AAC GCC AGG GTT TTC C -3’ 
Cre 
Forward (Control): 
5’-CTA GGC CAC AGA ATT GAA AGA TCT-3’ 
Reverse (Control): 
5’-GTA GGT GGA AAT TCT AGC ATC ATC C-3’ 
Forward (Cre): 
5’-GCG GTC TGG CAG TAA AAA CTA TC-3’ 
Reverse (Cre): 




5’- CTC AGC AGT AAG GAA GAC AAA GTC A-3’ 
Reverse (Control): 
5’- CCA TGA GAC AGG GTC TTG CTA TT-3’ 
Forward (P53-floxed): 
5’-CTG TGC CCT CCG TCC TTT T -3’ 
Reverse (P53-floxed): 
5’-GGC TGC AGA TAA CTT CGT ATA GCA T-3’ 
YFP 
Forward (Control): 
5’- CTA GGC CAC AGA ATT GAA AGA TCT -3’ 
Reverse (Control): 
5’- GTA GGT GGA AAT TCT AGC ATC ATC C -3’ 
Forward (YFP): 
5’- ACA GAC ACA CAC CCA GGA CA -3’ 
Reverse (YFP): 
5’- CGG TGG TGC AGA TGA ACT T -3’ 
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2.3 Tamoxifen dosing 
 
To induce Cre production in Smn2B/-;P53fl/fl;Cre+ and Smn2B/+;P53fl/fl;Cre+ 
mice, experimental litters were treated with a tamoxifen solution. Tamoxifen 
(Sigma-Aldrich) was dissolved in corn oil, to give a 20mg/ml solution, using a 
sonicating water bath. The solution was exposed to the water bath for 45 
minutess at room temperature. Pups in experimental litters were dosed 
75mg/kg of this tamoxifen solution by modified oral gavage at P4 and P5. 
Following dosing, body weights were recorded and motor tests were 
performed as detailed below. 
2.4 Phenotypic analysis 
 
Motor testing of mice involved two tests. The first was the ‘time to right’ test 
that was carried out on mice younger than P11-P12. Mice were placed on 
their back and the time it took for them to right themselves (turn to be on all 
four paws) was noted. The test was stopped when mice had been attempting 
to do this for 30 seconds. This test was repeated 3 times with a two-minute 
rest period between testing. Mice were nested together during rest period to 
reduce the risk of hypothermia.  
 
As all mice aged over 11 days were able to perform this task well, including 
experimental Smn2B/- mice, a second test was created to test motor 
performance in older pups. This second test, which was termed the ‘turn 
around test’, involved placing mice, head down on a gridded cage top that 
was at a 45o angle. The time it took for mice to turn 180o to face up was 
noted. This test was also stopped at 30 seconds. If mice were unable to 
remain on the angled cage top then this was noted as the maximum time of 
30 seconds.  
 
Body weight was also tracked over time and any phenotypic abnormalities 
were recorded.  
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2.5 Euthanasia 
 
Mice housed at the Central Campus facilities were sacrificed by overdose of 
anaesthetic (IsoFlo, Abbott, Quèbec, Canada) and death was confirmed 
using exsanguination of the carotid artery. Mice housed at this campus that 
were under the age of P7 were sacrificed by decapitation following 
anaesthesia (IsoFlo, Abbott, Quèbec, Canada).  
 
Smn2B/-;P53fl/fl ;Cre+ and control mice that were housed at the Western 
General Hospital Campus were sacrificed by overdose of CO2 and death was 
confirmed using exsanguination of the carotid artery. 
 
All procedures were carried out in accordance with the procedures approved 
and licensed by the Home Office, United Kingdom.  
2.6 Immunofluorescence  
	  
2.6.1 Immunofluorescence for NMJ Analysis 
Preparation of muscles 
	  
Several different muscles have been used in various aspects of this thesis, 
including cranial, abdominal and thoracic musculature. This is due to the 
status of differential vulnerability to pathology that these muscles express. 
For example, while the abdominal musculature is vulnerable to the 
degeneration of motor neurons, cranial musculature has significantly less 
degeneration of motor neurons (Figure 4.10; Murray et al. 2012).  
 
Cranial musculature includes the Levator Auris Longus caudal band (LALc), 
Lavator Auris Longus rostral band (LALr), Abductor Auris Longus (AAL) and 
Auricularis Superior (AS) muscles, which are located superficially at the base 
of the skull and are involved in moving the ear. They originate from a 
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tendonous raphae that connects to the midline of the skull and insert onto the 
cartilage of the ear (Murray et al. 2010).  To obtain these muscles, the 
muscles themselves and the tissue that surrounds them were gross 
dissected from the mouse and fixed for 15 minutes in 4% Paraformaldehyde 
(PFA; Electron Microscopy Science) in Phosphate Buffered Saline (PBS). 
Following fixation, muscles were finely dissected out of the surrounding 
tissue and prepared for immunofluorescent staining by removing excess 
fascia (Figure 2.5). 
 
Abdominal musculature forms the abdominal wall of the mouse and includes 
the Rectus Abdomins (RA), External Oblique (EO) and Transverse 
Abdominis (TVA) muscles. The abdominal wall was gross dissected from the 
mouse and fixed in 4% PFA in PBS for 15 minutes. These muscles were 
finely dissected from the abdominal wall and prepared for immunofluorescent 
staining by removing excess fascia (Figure 2.6). 
 
The Triangularis Sterni (TS) is a thoracic muscle that lies deep to the ribs 
and intercostal muscles. Therefore, the ribcage was grossly dissected and 
was fixed in 4% PFA in PBS for 15 minutes. The TS muscle was fine 
dissected by removal of the ribs and intercostal muscles (Figure 2.7).  
 
Staining of Muscles for NMJ Analysis  
	  
Muscles were permeabilised in 2% Triton X-100 in PBS for 30 minutes and 
blocked in 4% Bovine Serum Albumin (BSA), 1% Triton X-100 in PBS for 30 
minutes. They were subsequently incubated in primary antibody 
(Neurofilament (2H3) at 1:50 and SV2 (Synaptic Vesicle 2) at 1:100, 
Developmental Hybridoma Bank) in blocking solution for 72 hours at 4oC on a 
rocking platform. Following three 10-minute PBS washes, muscles were 
immersed in secondary antibody (AlexaFluor-488 rabbit anti-mouse (green) 
at 1:250, Jackson) in PBS for 24 hours at room temperature. Subsequently, 
muscles were incubated in α- bungarotoxin (tetramethylrhodimine conjugate, 
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Life Technologies) in PBS for 2 hours at room temperature to label post-
synaptic acetylcholine receptors. Following another three 10-minute PBS 
washes, muscles were mounted in Mowiol (Sigma).  
 
  
Figure 2.5: Cranial musculature was dissected for subsequent NMJ analysis. 
(A) Image shows gross dissected muscles following fixation. Note the large amount 
of surrounding tissue that obscures a clear view of the muscles of interest. (B) 
Image shows cranial muscles that connect to the skin of the mouse (left) and the 
midline (right in the image) following the fine dissection of tissue seen in A. (C) 
Image is the same as is seen in B with an overlay of the muscles of interest. (D) 
Image shows the muscles that have been removed from the skin of the mouse and 
opened from the midline to lie flat on the surface of the dish. At this point excess 
fascia is removed. (D) This image is the same as that seen in C but with an overlay 
labelling the individual cranial muscles. All scale bars = 25mm. 




Figure 2.6: Abdominal musculature was dissected for subsequent NMJ 
analysis. The process of dissection is laid out from A-G (A) Image shows gross 
dissected abdominal wall following fixation. (B) Red lines indicate where the 
superficial RA and EO will be cut. (C) Image shows the RA muscle (thick vertical 
band of muscle on the far right) and the EO muscle (splayed out on the left from the 
RA muscle) following removal from the abdominal wall. (D) Image shows the 
abdominal wall following removal of the RA and EO muscles. Note the blood vessel 
(orange arrowhead) and the internal oblique (blue arrowhead) that are superficial to 
the TVA and will be removed. (E) By cutting along the red lines shown in the image, 
the TVA muscle and a proportion of the rib cage is removed from the abdominal wall 
as shown in F. (G) The ribs are removed from the TVA muscle and excess fascia is 
removed in preparation for immunostaining. All scale bars = 2.5mm. 
	  
Chapter 2 46	  
 
Figure 2.7: The thoracic TS muscle was dissected for subsequent NMJ 
analysis. The process of dissection is laid out from A-E. The red line in images A-D 
indicates the midline of the ribcage. (A) Image shows half of the gross dissected 
ribcage following fixation. The ribcage has been cut down its midline (red line) and 
the two halves separated (B) Between the ribs, intercostal muscles are cut to 
expose the underlying TS muscle (blue arrowhead). (C) Ribs are cut from the 
sternum and peeled from the underlying TS muscle (blue arrowhead). (D) Once 
exposed, excess fascia is removed from the TS muscle and it is cut from the 
ribcage around its exposed periphery. (E) The TS muscle, as seen in this image, is 
processed for immunostaining. (F) Note that the red line shows the axonal layout 
within this muscle. All scale bars = 1mm. 
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Staining of Muscles for Motor Unit Analysis 
	  
Muscles that should contain YFP were dealt with quickly to avoid fading of 
the YFP. Muscles that had been removed from recently sacrificed mice were 
pinned and fixed for 15 minutes in 4% PFA. Muscles were at room 
temperature and on a rocking platform in the dark. Fine dissection was 
completed immediately after and muscles were incubated in BTX at 1:250 for 
1 hour at room temperature, in the dark and on a rocking platform. Muscles 
were mounted in mowiol (Sigma) on glass slides and stored at 4oC. 
 
2.6.2 Immunofluorescence on spinal cord sections 
	  
Preparation of spinal cords 
	  
Spinal columns were removed from recently sacrificed mice in order to 
retrieve the spinal cord. Spinal cords were ejected from the column by forcing 
PBS from a syringe through a needle placed within the lumbar end of the 
spinal column.  For all mice used in Chapter 3, the left and right sides of the 
spinal cord were separated down the midline as one half was prepared for 
immunofluorescence and the other was frozen on dry ice and stored at -80oC 
for use in qPCR analysis. For mice used in Chapter 4 and 5, whole spinal 
cords were prepared for immunofluorescence. Spinal cords processed for 
immunofluorescence were fixed in 4% PFA in PBS for 4 hours before 
washing in PBS. They were immersed in 30% sucrose for 48 hours prior to 
embedding in 50% OCT; 30% sucrose in PBS mixture.  
 
For mice used in the characterisation of pathology work carried out in 
Chapter 3 (i.e MNCB number and size), spinal cords were trimmed at the 
lumbar enlargement prior to embedding to ensure that those from Smn2B/- 
mice and from Smn2B/+ littermate controls were the same length. The 
embedding method for these spinal cords varied depending on the age of the 
mouse from which the spinal cord was obtained from. P1 and P5 spinal cords 
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were embedded medial side down and so sagittal sections were obtained. 
P10 and P15 spinal cords were embedded first in agar and once set, the 
agar block was embedded so the ventral surface of the spinal cord was 
facing down. This would allow coronal sections of the spinal cord to be cut. 
This was to ensure that the maximum number of motor neurons was 
obtained in the fewest sections. This method of embedding was initially 
carried out and refined by Alannah Mole. 
 
For mice carrying the P53fl gene in Chapter 3, spinal columns were trimmed 
at vertebrae T4 prior to the ejection of the spinal cord. T4 was located by 
counting ribs starting at the 12th rib. Spinal cords were immersed in 30% 
sucrose for 48 hours prior to embedding in 50% OCT; 30% sucrose in PBS 
mixture. This method was also used for P18 mice used in Chapter 4. For the 
mice aged 3 months or older that were used in Chapter 5, spinal columns 
were trimmed at vertebrae T8 prior to the ejection of the spinal cord. Again, 
T8 was located by counting ribs starting at the 12th rib. T8 was the vertebrae 
chosen in this case as it was below the lordosis curvature of the upper spinal 
column that makes ejection of the spinal cord difficult. As before, these spinal 
were immersed in 30% sucrose for 48 hours prior to embedding in 50% OCT; 
30% sucrose in PBS mixture. The thoracic spinal cord was used for analysis, 
as this is the region where motor neurons that supply the thoracic and 
abdominal musculature and are vulnerable to degeneration lie.  
 
Regardless of the preparation method that was used, all embedded tissue 
was snap frozen on dry ice and stored at -80oC.  Frozen sections were cut at 
10𝜇m on a cryostat (Leica). 
 
For characterisation work carried out in Chapter 3, longitudinal sections were 
collected on alternating glass slides to give two sets of slides, an A set and B 
set. All sections were collected.  
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For work relating to the investigation of P53 in SMA in Chapter 3 and for all 
mice used in Chapter 4 and 5, spinal cords were sectioned transversely. 
Every 10th section was collected on one slide. This was carried out in 
triplicate to provide three sets of slides. Approximately 2mm of the spinal 
cord was sectioned. 
 
All slides were stored at -20oC until they were processed for 
immunofluorescent staining. 
 
Staining of spinal cord sections 
	  
Staining of slides was done in the Sequenza Immunostaining Centre (Fisher) 
and all reagents were applied at a volume of 300µl per slide. Two staining 
protocols were used; one for ChAT and anti-active caspase 3 and the other 
for pH2AX. 
 
For ChAT and anti-active caspase 3 
 
Sections were washed in PBS, permeabilised in 0.3% Triton X-100 in PBS 
for 30 minutes and blocked in 0.1% Power Block (100x, Biogenex 
Laboratories, HK085-5K) in PBS for 10 minutes. Following two 2-minute PBS 
washes, sections were incubated in ChAT or anti-active caspase 3 primary 
antibody (detailed in Table 2.7) in 0.3% Triton X-100; 1% Bovine Serum 
Albumin (BSA) in PBS at 4oC, for 72 hours. Following this, slides were 
washed twice with 0.2% Triton X-100 for 5 minutes. Secondary antibody 
(detailed in Table 2.7) was applied for 2 hours at a dilution of 1:250 at room 
temperature. Sections were then stained with DAPI (Life Technologies) at 
1:1000 for 10 minutes, washed with 0.2% Triton X-100 three times for 5 
minutes and stained with the fluorescent Nissl stain NeuroTrace (Either 
500/525 (Green) or 530/615 (Red), both Life Technologies, depending upon 
the fluorophore of the secondary antibody that had been used) at 1:100 for 
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30 minutes. Sections were subsequently washed twice with 0.2% Triton X-




Sections were washed in PBS, permeabilised in 0.3% Triton X-100 in PBS 
for 30 minutes and blocked in 0.3% Triton X-100; 4% BSA in PBS for 30 
minutes. Sections were incubated in anti-pH2AX primary antibody (detailed 
in Table 2.7) in blocking solution (0.3% Triton X-100; 4% BSA) that had been 
diluted 1:250 in PBS. Slides were left for 24 hours at 4oC. Following this, 
slides were washed three times with PBS for 5 minutes. Secondary antibody 
(detailed in Table 2.7) was diluted in 0.3% Triton X-100 at 1:250 and applied 
for 2 hours at room temperature. Sections were then stained with DAPI (Life 
Technologies) and NeuroTrace as above before washing with PBS and 
mounted in Mowiol (Sigma).  
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Table 2.7: Antibodies, and their associated information, used in the 
immunofluorescent staining of spinal cord sections  
Primary 
Antibody 
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2.7 Quantification and Statistics 
	  
2.7.1 NMJ Analysis 
Occupancy 
	  
The occupancy of post-synaptic endplates was assessed and graded using 
specific criteria (Table 2.8; Figure 2.8). At least three fields of view were 
analysed with >50 NMJs quantified per muscle. All analysis was done on a 
standard fluorescent microscope (Leica DM8) at 40x magnification. 
Representative images were taken on a confocal microscope (Nikon A1R 
FLIM) at 40x magnification. All data was collated and analysed using 
Microsoft excel (Mac 2011) and GraphPad Prism (Version 6 for Mac OS X). 
The percentage of NMJs displaying each stage of occupancy was calculated 
and a Mann Whitney-U test compared these between experimental mice and 
their relevant controls.  
 
 













Pre-synaptic terminal partially covers the post-synaptic 





No axonal input to the post-synaptic endplate 
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Pre-synaptic Swelling 
	  
The level of pre-synaptic swelling at NMJs was graded (Table 2.9; Figure 
2.8). As above, at least three fields of view were analysed with >50 NMJs 
quantified per muscle. All analysis was done on a standard fluorescent 
microscope and representative images were taken on a confocal 
microscope, both at 40x magnification.  All data was collated and analysed 
using Microsoft excel (Mac 2011) and GraphPad Prism (Version 6 for Mac 
OS X). The percentage of NMJs with each grade of swelling was calculated 
and a Mann Whitney-U test compared each grade of pre-synaptic swelling 
between experimental mice and their relevant controls. 
 
 
Table 2.9: The criteria used to determine the level of pre-synaptic 












Evidence of some axonal swelling and/or pre-synaptic 




Evidence of clear axonal swelling and significant pre-synaptic 




Significant and obvious swelling along the length of the axon 
and severe swelling around the pre-synaptic terminal, which 
obscures the endplate 
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Endplate Size 
	  
Images of endplates within each muscle were captured on a standard 
fluorescent microscope (Leica DM8). The number of images depended upon 
the number of endplates within each image. Enough images were captured 
in order to measure >50 endplates. In Fiji Image Processing Software, the 
periphery of each endplate was traced and the area within measured. 
Microsoft Excel was used to collate the measurement information and this 
was subsequently analysed in GraphPad Prism. The average endplate area 
for a muscle was calculated and an unpaired t-test compared the average 




A criterion was established to stage the maturity of individual endplates 
(Table 2.10; Figure 2.8). As above, at least three fields of view were 
analysed with >50 NMJs quantified per muscle. All analysis was done on a 
standard fluorescent microscope. All data was collated and analysed using 
Microsoft excel (Mac 2011) and GraphPad Prism (Version 6 for Mac OS X). 
The percentage of NMJs displaying each stage of maturation was calculated 
and a Mann Whitney-U test compared each stage of maturity between 
experimental mice and their relevant controls.  
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Table 2.10: The criteria used to determine the stage of endplate 












Endplate is developing from a plaque-like structure and 




Endplate is developing into a pretzel-like structure, ‘highlights’ 
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Figure 2.8: Features of NMJ morphology can be categories for analytical 
purposes. (A) Images show examples of fully occupied (full), partially occupied 
(partial) or vacant post-synaptic endplates. White arrowheads point out the NMJs 
that display the category of occupancy noted above their image. The criteria used to 
describe each of the stages can be seen in Table 2.8 (B) Images show examples of 
NMJs with none, mild, moderate and severe pre-synaptic swelling. The criteria used 
to describe each of the stages can be seen in Table 2.9 (C) Images show examples 
of stage 1-4 endplate maturity. The criteria used to describe each of the stages can 
be seen in Table 2.10. All scale bars = 10um 
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2.7.2 Whole Motor Unit Analysis  
 
Images of the motor unit were taken at x20 magnification on a standard 
fluorescent microscope (Leica DM8, Leica Application Suite X). These were 
assembled in Adobe Photoshop to allow the whole motor unit to be traced. 
Areas of ambiguity were checked on the fluorescent microscope to confirm 
the layout of the motor unit. Once traced the morphology at the NMJs of the 
motor unit were assessed on the fluorescent microscope. Various features 
were quantified; Pre-synaptic swelling, occupancy, endplate maturation and 
evidence of sprouting. Endplate size was determined by imaging the 
endplates of interest and measuring the area of these in Fiji Image Analysis 
Software. NMJs that were not quantifiable due to being misaligned or, in 
terms of endplate size, out of focus in the images were excluded. The 
branching pattern of the traced motor unit was simplified into a tree diagram 
on Adobe Photoshop. A tree diagram was made for each parameter 
measured for each motor unit traced. Data was collated in Microsoft Excel 
(Mac 2011) and GraphPad Prism (Version 6 for Mac OS X) was used to 
generate graphs. 
 
2.7.3 Motor Neuron Cell Body Analysis 
	  
Motor Neuron Number 
	  
	  
For characterisation work carried out in Chapter 3, longitudinal sections were 
collected on alternating glass slides to give two sets of slides, an A set and B 
set. One set was stained with ChAT to labels motor neurons. This allow the 
counting of motor neuron cell bodies (MNCBs) within the ventral horn of the 
spinal cord. Using a standard fluorescent microscope (Leica DM8), the 
number of MNCBs within each field of view was counted. MNCBs were 
distinguished from other neuronal material by their large size, irregular shape 
and were double stained with Nissl and ChAT. Only MNCBs that conformed 
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to this criterion and had a visible nucleus and nucleoli were counted. The 
numbers were collated in Microsoft excel and analysed in GraphPad Prism. 
A paired t-test compared the absolute number of MNCBs in Smn2B/- mice 
compared to Smn2B/+ controls. 
 
For work relating to the investigation of P53 in SMA in Chapter 3 and for all 
mice used in Chapter 4 and 5, where spinal cords were sectioned 
transversely, one slide (which contained every 10th section) was stained with 
ChAT. Again, only MNCBs that conformed to the criterion above were 
counted. The numbers were collated in Microsoft excel and analysed in 
GraphPad Prism. Using the number of MNCBs counted an approximate 
number was calculated for the whole area in which every 10th section was 
collected. This was then compared by unpaired t-test between experimental 
mice and their relevant controls.  
 
Motor Neuron Size 
	  
To assess the size of MNCBs and their nuclei images of MNCBs (see the 
criterion above) were captured on a standard fluorescent microscope (Leica 
DM8). Images were opened in Fiji Image Processing Software and the 
periphery of each MNCB was traced. The area within was measured. In 
addition, the area of the nuclei was measured using the same method. 
Microsoft Excel was used to collate the measurement information and this 
was subsequently analysed in GraphPad Prism. The average area of MNCB 
or their nuclei, for each mouse, was calculated and a Mann Whitney-U test 
compared experimental mice and their relevant controls.  
 
Activated Caspase 3 Quantification 
	  
The second set of slides collected from Smn2B/+ and Smn2B/- mice in Chapter 
3 were stained with anti-active caspase 3. Cells that stained positive for 
active caspase 3 and that fell within a motor neuron rich area were counted. 
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This number was used along with the total number of motor neurons counted 
on the ChAT stained slides to calculate the percentage of positive cells within 
the ventral horn of the spinal cord. Again, this data was collated in Microsoft 
Excel and analysed in GraphPad Prism. A Mann Whitney-U test compared 





In Chapter 4, spinal cord sections from Smn2B/-;YFP-H mice were stained for 
pH2AX. Images of MNCBs in these spinal cord sections were taken on a 
confocal microscope (Nikon A1R FLIM). The intensity of pH2AX staining was 
measured in Fiji imaging software, using mean grey value, in MNCBs that 
were YFP positive and YFP negative. Approximately 40 motor neurons per 
group were measured in three different Smn2B/-;YFP-H mice. The data was 
collated in Microsoft Excel and was analysed in GraphPad Prism. An 
unpaired t-test compared the intensity of pH2AX staining in YFP positive and 
YFP negative MNCBs.  
2.8 qPCR 
 
Spinal cords were removed from recently sacrificed mice (see above for 
method), snap frozen on dry ice and were stored at -80oC. RNA was 
extracted using a mini RNeasy kit (Qiagen), according to the manufacture’s 
instructions. Briefly, tissue was homogenised in a mixture of 2-
mercaptoethanol and the RLT buffer that was supplied within the kit. This 
was centrifuged and the supernatant was removed and mixed with 70% 
ethanol (prepared with RNase-free water). This mixture was added to the 
spin columns provided within the RNeasy kit prior to centrifugation. The spin 
columns are designed to collect RNA on their membrane while flow-through 
can be discard from the collection tube. The application of wash buffers and 
subsequent centrifugation ensured the RNA was clean. In addition, an 
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RNase-free DNase kit (Qiagen) was used during the RNA extraction process 
to remove any genomic DNA. Prior to their storage at -80oC, the 
concentration of RNA samples was tested using a nanodrop (NanoDrop 
2000, Thermo Scientific).  
 
RNA was subsequently converted to cDNA using the QuantiTect Reverse 
Transcription kit (Qiagen), as per the manufacturer’s instructions. Two sets of 
each sample were made, one that had reverse transcriptase added and one 
that did not. This means that one would have RNA converted to cDNA and 
one would not, thus controlling for genomic DNA contamination.  
 
Kapa SYBR Fast Universal (Kapa Biosystems) and the CFX Connect Real-
time PCR detection system (Biorad) was used to preform SYBR green-based 
qPCR. Primers obtained from Sigma had been previously optimised for use 
(Table 2.11). Primers from Qiagen were pre-optimised (Table 2.11). All cDNA 
samples were run in technical triplicate and the ‘no reverse transcriptase’ 
samples were run to check for genomic DNA contamination. The relative 
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Table 2.11: Summary of primers used for transcriptional analysis by 
qPCR  










CDKN1A Qiagen Pre-optimised primer against mouse CDKN1A 
FAS Qiagen Pre-optimised primer against mouse FAS 
PMAIP1 Qiagen Pre-optimised primer against mouse PMAIP1 
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Chapter 3 
 
Investigating the timing and mechanism of motor neuron pathology 




In this chapter, the time course of motor neuron pathology in the Smn2B/- 
mouse model of SMA is investigated in order to determine the relationship 
between pathological hallmarks of motor neurons in SMA. Both NMJ 
pathology (including pre-synaptic terminal swelling and post-synaptic 
endplate occupancy and area) and MNCB pathology (including number and 
area) are quantified and transcriptional analysis of the spinal cord is 
performed. Furthermore, by genetically modifying the Smn2B/- mouse model 
of SMA, P53 is ubiquitously reduced in this mouse model to determine the 
effects of P53 on motor neuron pathology.  
 
The results that are detailed in the following chapter show that: 
 
1. The onset of NMJ pathology occurs between P5 and P7 in the Smn2B/- 
mouse model of SMA 
2. There is a decrease in the number and area of MNCBs between P10 
and P15 in the Smn2B/- mouse model of SMA   
3. The onset of NMJ pathology coincides with the up-regulation of 
transcripts involved in the P53 signaling pathway in the spinal cords of 
Smn2B/- mice 
4. A reduction in P53 in the Smn2B/- mouse model of SMA does not 
improve the overall phenotype of the mouse model or reduce motor 
neuron loss but does result in a decrease in denervation 
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3.1 Introduction 
 
In SMA, motor neurons are selectively vulnerable to degeneration. This 
degeneration causes denervation of muscles resulting in muscle atrophy, 
weakness and subsequent paralysis. It is thought that motor neurons 
degenerate in a ‘die-back’ manner, as the pre-synaptic terminal appears to 
withdraw from the post-synaptic endplate, leaving partially occupied 
endplates (Murray et al. 2008). In support of this, a study found that there 
was a 78% loss of axons in the ventral roots while there was only a 30% loss 
of MNCB in the ventral horn of the lumbar spinal cord suggesting distal to 
proximal degeneration of the motor neuron (Cifuentes-Diaz 2002). Further to 
this, NMJ defects occur prior to symptom onset in mouse models of SMA and 
therefore, it is reported that the NMJ is an ‘early pathological target’ in SMA 
(Murray et al. 2008; Murray et al. 2015). 
 
However, the temporal relationship between NMJ degeneration and the loss 
of MNCBs remains unknown. Reports of MNCB loss tend to be from mid- to 
late- symptomatic stage studies where motor neuron degeneration is already 
clearly evident. For example, Le et al reported a 20% loss of MNCB in the 
lumbar spinal cord of SmnΔ7 mouse model at P9, with the average life span 
of these mice being 14 days (Le et al. 2005). They also report significant 
denervation in the gastrocnemius muscle at P14 however, as these time 
points are different, conclusions regarding the relationship between these 
two pathologies cannot be drawn. In the Smn2B/- mouse model of SMA, 
Bowerman et. al. report both a loss of MNCB, of approximately 50%, in the 
lumbar spinal cord and significant denervation in the TVA muscle at P21 
compared to controls (Bowerman et al. 2012a). However, this is again a 
symptomatic time point, with both ends of the motor neuron displaying 
significant pathology compared to controls. 
 
What also remains unknown is the relationship of motor neuron degeneration 
to the onset of cell death pathways. Recently, it has been shown that there is 
an up-regulation of transcripts involved in the P53 signaling pathway in motor 
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neurons in SMA prior to the onset of NMJ pathology (Murray et al. 2015; 
Simon et al. 2017; Nichterwitz et al. 2018). The P53 signaling pathways is 
known to be involved in cell cycle control, DNA repair and apoptosis (Elmore 
2007; Li & Yuan 2008; Williams & Schumacher 2016). Furthermore, in post-
mortem analysis of SMA patients, there was shown to be an increase in P53 
within their spinal cords (Simic et al. 2000). Therefore, it has been suggested 
that the activation of P53 may be causing the initiation of motor neuron 
degeneration (Murray et al. 2015; Simon et al. 2017; Nichterwitz et al. 2018).  
 
P53 has previously been shown to co-localise with SMN (Young et al. 2002). 
In this study, the authors found that under normal circumstances, where P53 
was not active in control cells, P53 was at low levels and was dispersed 
evenly throughout the nucleus. However, upon activation of P53 in these 
control cells, P53 co-localised with SMN in both cajal bodies of the nucleus 
and in the nucleolus (Young et al. 2002). In fibroblasts derived from SMA 
patients, P53 was found to accumulate only in the nucleolus and not in cajal 
bodies. Furthermore, it was reported that while functional full-length SMN can 
interact with P53, mutated SMN and SMNΔ7 had a reduction in their ability to 
interact with P53 (Young et al. 2002). The mutated forms of SMN tested were 
from three different patients with three unique mutations and the binding 
affinity of these three different mutated SMNs for P53 correlated with the 
disease severity of the patients they were obtained from (Young et al. 2002). 
This therefore suggests that SMN plays a role in regulating P53.  
 
It is widely accepted that during development, apoptosis is responsible for 
the death of cells, including motor neurons, however, whether apoptosis is 
responsible for the death of motor neurons in SMA pathogenesis remains 
disputed (Oppenheim 1991; Pérez-García et al. 2017). During the search for 
the genetic cause of SMA, initial findings pointed towards a role of the 
Neuronal Apoptosis Inhibitory Protein in pathogenesis (Pérez-García et al. 
2017). Approximately 45% of SMA type I cases also have a homozygous 
deletion of the NAIP gene and this lead many to believe that SMA motor 
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neuron loss was as a result of uncontrolled apoptosis (Roy et al. 1995; Biros 
& Forrest 1999). Tsai et. al. report increased apoptosis in SMA mouse model 
spinal cord through an increase in positive TUNEL staining, which labels 
DNA fragmentation (Tsai et al. 2006a). TUNEL staining has also been 
performed in post-mortem patient samples of spinal cord and this showed an 
increase in DNA fragmentation of cells in the ventral horns (Simic et al. 
2000). However, it has been previously reported that TUNEL is not able to 
distinguish between different types of cell death including apoptosis and 
necrosis (Grasl-Kraupp et al. 1995). 
 
Sareen et. al., 2012, observed apoptotic morphology, specifically nuclear 
condensation and increased caspase-3 activation, in iPSCs derived from 
SMA patients compared to iPSCs derived from controls (Sareen et al. 2012). 
The loss of motor neurons, observed in cultured SMA iPSCs, was decreased 
by blocking apoptosis through the Fas receptor (Sareen et al. 2012). Despite 
this, post-mortem analysis of patient motor neurons in the spinal cord 
revealed that motor neurons in the spinal cords of SMA patients appeared to 
be swollen and present features more consistent with necrotic cell death 
rather than apoptotic cell death (Kato & Hirano 1990; Korinthenberg et al. 
1997; Simic et al. 2000; Ito et al. 2011; Harding et al. 2015; Pérez-García et 
al. 2017). Therefore, the mechanism of motor neuron death in SMA remains 
unclear. 
 
From the literature presented within this introduction, it is clear that there are 
gaps in our knowledge regarding motor neuron pathology, including the 
relationship of NMJ and MNCB pathology, in SMA. In order to address this, I 
aimed to carry out a time course analysis of pathology of both the NMJ and 
the MNCBs within the Smn2B/- mouse model of SMA. This mouse model is 
described as an intermediate mouse model of SMA due to its extended pre-
symptomatic period compared to other mouse models in the field. As a 
result, any subtle pre-symptomatic changes that may be occurring and may 
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be missed in other mouse models that have a more rapid decline can be 
observed.  
 
Further to this, I genetically modified the Smn2B/- mouse model of SMA in 
order to induce a reduction of ubiquitously expressed P53. In doing so, I 
aimed to determine what effect P53 has on motor neuron pathology. If 
indeed the activation of the P53 signaling pathway is responsible for the 
degeneration of the motor neuron, then I would hypothesise that a reduction 
in P53 would have a positive impact on motor neuron pathology. To address 
this, analysis of NMJs and MNCBs was performed at a symptomatic time 
point following the pre-symptomatic knockout of P53. 
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3.2 Results 
 
3.2.1 Phenotypic Analysis of Smn2B/- mice  
 
The phenotype of the Smn2B/- mouse model has previously been described in 
the literature however, many factors can affect the severity and phenotypic 
features of mouse models (Bowerman et al. 2012a). For example, genetic 
background has a huge bearing on phenotype (Eshraghi et al. 2016) as well 
as the type of caging in which animals are housed (Logge et al. 2014). 
Therefore, a basic assessment of the phenotype of the Smn2B/- mouse model 
of SMA that was used within this study was performed. 
 
Firstly, the body weight of Smn2B/- and control Smn2B/+ mice was measured. 
This showed that the body weight of Smn2B/- mice is significantly lower than 
that of control Smn2B/+ littermates from P10 (Figure 3.1B). The Smn2B/- mice 
fail to gain weight at the same rate as Smn2B/+ mice and in the later stages of 
the disease Smn2B/- mice begin to lose weight. 
 
Secondly, motor performance was assessed, using the time to right (TtR) 
test, on Smn2B/- and Smn2B/+ mice between P8 and P12. This was the critical 
time window in which the onset of an SMA like phenotype was occurring. It 
was found that, although the performance of both Smn2B/- and Smn2B/+ mice 
improves over time, Smn2B/- mice do not perform as well as Smn2B/+ mice. 
The time to right for Smn2B/- and Smn2B/+ mice was significantly different at 
P9 (Figure 3.1C). 
 
It was also noted that Smn2B/- mice develop distinguishing features as the 
disease progresses. By P15, Smn2B/- mice have a short dark tail and small 
ears (Figure 3.1A). 
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Furthermore, the life span of the Smn2B/- mouse model is commonly reported 
as 28 days (Bowerman et al. 2012a). This mouse model is on a mixed 
genetic background but recently published data shows that on a pure genetic 
background, life span of the Smn2B/- mouse model is shorter, with death 
occurring from P19 (Eshraghi et al. 2016). This is consistent with the findings 
in this study as Smn2B/- were presenting with a severe phenotype at P18-
P19. To ensure there were no fatalities, in keeping with Home Office 
regulations, Smn2B/- mice were not kept alive longer than 19 days.  
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Figure 3.1: Phenotypic analysis of the Smn2B/- mouse model of SMA shows 
that it becomes significantly different from control littermates around P9 to 
P10. (A) Representative images showing a Smn2B/- mouse and a control Smn2B/+ 
littermate at P10 and P15. Note that the yellow arrowhead highlights the short dark 
tail and the green arrowhead highlights the small ears. (B) The graph (Mean±SEM) 
shows that the weights of Smn2B/- mice are significantly different from their Smn2B/+ 
littermate controls at P10 with an increase in the level of significance thereafter 
(n=4, unpaired t-test, *p<0.05, **p<0.01, ***p<0.005, ****p<0.001). (C) The graph 
(Mean ± SEM) shows the time it took for Smn2B/- and Smn2B/+ mice to right 
themselves between P8 and P12. There was a significant difference in the time to 
right of Smn2B/- mice compared to Smn2B/+ mice at P9 (n=4, unpaired t-test, 
*p<0.05). 
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3.2.2 Investigating the onset of pathology in motor neurons of the 
Smn2B/- mouse model of SMA 
 
In order to try and determine whether pathology in motor neurons begins first 
at the NMJ or at the MNCB, a comprehensive morphological assessment of 
both the NMJ and the MNCB in the Smn2B/- mouse model of SMA was 
carried out at various time points that ranged from pre-symptomatic to late 
symptomatic. Below, NMJ pathology (at both the pre- and post-synapse), 
MNCB number and size as well as molecular alterations in the spinal cord of 
Smn2B/- mice were assessed and compared to Smn2B/+ mice. 
 
3.2.2.1 Analysis of NMJs in Smn2B/- mice shows that the onset of pathology 
at the NMJ occurs between P5 and P7 
 
I aimed to comprehensively assess the level of NMJ pathology over the 
disease progression in the Smn2B/- mouse model of SMA. For this analysis, 
the transverse abdominis (TVA) muscle was used. This is a thin, flat muscle 
that is ideal for NMJ analysis as, when using immunofluorescence 
techniques, NMJs are clearly visible in the whole mounted muscle. This 
eliminates the need for the muscle to be sectioned, even when it is larger in 
older mice. In addition, the TVA is a known vulnerable muscle in the Smn2B/-
mouse model of SMA (Murray et al. 2012). There are several pathological 
hallmarks of SMA that can be quantified in order to assess alterations in NMJ 
morphology. These include occupancy of the post-synaptic endplate, pre-
synaptic swelling and endplate size. These features were quantified at P1, 
P5, P10 and P15 in Smn2B/- and Smn2B/+ mice to determine when NMJ 
morphology begins to differ in the Smn2B/- mouse model of SMA (Figure 3.2).  
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Figure 3.2: Representative images of NMJs in the TVA muscle of Smn2B/- and 
Smn2B/+ mice displaying features of NMJ pathology. Representative images of 
NMJs in the TVA muscle of Smn2B/+ and Smn2B/- mice at P1, P5, P10 and P15. Note 
that white arrowheads show no pre-synaptic swelling, yellow arrowheads show mild 
pre-synaptic swelling, blue arrowheads show moderate pre-synaptic swelling and the 
purple arrowhead shows severe pre-synaptic swelling. Vacant endplates (red 
arrowhead) are seen at P15 in the Smn2B/- mouse model of SMA (Scale bars = 20µm). 
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Occupancy measures the innervation of the post-synaptic endplate and 
determines the level of denervation within a muscle. The complete criteria for 
assessing occupancy can be found in Chapter 2. Briefly, endplates are fully 
occupied if they are completely covered by the pre-synaptic terminal, partially 
occupied if the pre-synaptic terminal only partially covers the endplate and 
vacant if they have no innervation from the pre-synaptic terminal (Figure 3.2). 
At P1 and P5 all endplates, in both Smn2B/- and Smn2B/+ mice, were fully 
occupied by the pre-synaptic terminal (Figure 3.3A). By P10, there was a 
significant decrease in the percentage of fully occupied endplates in Smn2B/- 
mice; some pre-synaptic terminals had begun to withdraw leaving a small but 
significant percentage of endplates only partially occupied. This withdrawal of 
the pre-synaptic terminal continued through the disease progression and by 
P15, there is a significant percentage of partially occupied and vacant 
endplates, compared to Smn2B/+ controls (Figure 3.3A). 
 
Another hallmark of pathology in SMA mouse models is pre-synaptic 
swelling. The level of pre-synaptic swelling was staged using the criteria 
detailed in Chapter 2: Methods; pre-synaptic swelling ranged from none to 
severe (Figure 3.2). This staging of pre-synaptic swelling was carried out in 
Smn2B/- and Smn2B/+ control mice over the disease progression of the Smn2B/- 
mouse model at the same time points used for occupancy: P1, P5, P10 and 
P15 (Figure 3.3B). At P1 and P5, there was no significant difference in the 
level of pre-synaptic swelling in Smn2B/- mice compared to Smn2B/+ mice. 
However, at P10 there was a significant decrease in the percentage of NMJs 
with no pre-synaptic swelling and a significant increase in the percentage of 
NMJs with mild and moderate pre-synaptic swelling in Smn2B/- mice 
compared to controls. At P15, there is again a significant increase in mild and 
moderate pre-synaptic swelling in Smn2B/- mice compared to controls but at 
this time point there is also significant percentage of NMJs displaying severe 
pre-synaptic swelling in Smn2B/- mice.  
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Additionally, the area of post-synaptic endplates in the TVA muscle was 
measured in P1, P5, P10 and P15 Smn2B/- and Smn2B/+ mice. At P1 and P10, 
there was no significant difference between control and Smn2B/- mice. 
However, at P5 there was a significant increase and at P15, there was a 
significant decrease in the area of endplates in Smn2B/- mice compared to 
controls (Figure 3.3C). This increase in the area of endplates in Smn2B/- mice 
compared to controls could potentially be caused by a developmental delay. 
Under normal circumstances, the post-synaptic endplate experiences a 
temporary decrease in area during postnatal synapse elimination (Marques 
et al. 2000). It is possible that there is a delay in this process in the Smn2B/- 
mice and as a result they appear to have larger endplates than controls.  
 
Ultimately, when taking all of this NMJ analysis into consideration, it is clear 
that pathological alterations at the NMJ occur at the pre-synaptic terminal 
Figure 3.3: There is significant pathology in the TVA muscle in Smn2B/- mice 
from P10. (A) Bar chart (Mean ± SEM) compares the percentage of full, partial and 
vacant endplates in Smn2B/- mice compared to Smn2B/+ controls. At P1 and P5, all of 
the endplates quantified in Smn2B/- and Smn2B/+ mice were fully occupied by the pre-
synaptic terminal. At P10, there is significant increase in the percentage of partially 
occupied endplates and at P15, there is a significant increase in the percentage of 
both vacant and partially occupied endplates in Smn2B/- compared to Smn2B/+ mice 
(Mann Whitney-U test, ns>0.05, *p<0.05, **p<0.01; n=4 mice per genotype). P15 
data acquired in collaboration with Alannah Mole during a placement project. (B) 
Bar chart (Mean ± SEM) compares the stages of pre-synaptic swelling in Smn2B/- 
and Smn2B/+ mice. There is no significant difference in the level of swelling in Smn2B/- 
mice compared to controls at P1 and P5. At P10, there is a significant increase in 
the percentage of NMJs with mild and moderate swelling in Smn2B/-mice. At P15, 
there is a significant increase in the percentage of pre-synaptic terminals with mild, 
moderate and severe swelling in Smn2B/- mice compared to Smn2B/+ controls (Mann 
Whitney-U test, ns>0.05, *p<0.05; n=4 mice per genotype). P15 data acquired in 
collaboration with Alannah Mole during a placement project. (C) Bar chart (Mean ± 
SEM) compares the average size of endplates in the TVA of Smn2B/- mice compared 
to controls. At P1 and P10 there is no significant difference in the area of post 
synaptic endplates in Smn2B/- mice compared to controls. At P5, there is a small but 
significant increase in endplate area in Smn2B/- mice. At P15 there is a significant 
decrease in the size of endplates in Smn2B/- mice compared to controls (unpaired t-
test, ns>0.05, *p<0.05, **p<0.01; n=4-6 muscles per genotype).  
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somewhere between P5 and P10. In order to narrow the time window in 
which pathological changes at the NMJ are occuring, occupancy and pre-
synaptic swelling analysis was carried out at P7. This showed that although 
there was no evidence of denervation (all endplates were fully occupied), 
there was a significant decrease in the percentage of NMJs displaying no 
swelling and an increase in the percentage of pre-synaptic terminals with 
mild swelling (Figure 3.4). This not only identifies this as an earlier time point 
for the onset of pathology but also shows that pre-synaptic swelling precedes 
the onset of pre-synaptic withdrawal. 
 
The rectus abdominis (RA) is a muscle that appears to be more affected in 
end-stage Smn2B/- mice (Murray et al. 2015). The RA muscle is significantly 
thicker than the TVA and, although easily quantifiable as a whole mount 
muscle in young pups, it becomes progressively more difficult to reliably 
quantify NMJ pathology as these pups mature. Therefore, it was felt that this 
was not an appropriate muscle of choice when wishing to carry out NMJ 
analysis over time. However, to confirm that there was indeed no NMJ 
pathology present at P5 in Smn2B/- mice, pre-synaptic swelling and 
occupancy was quantified in the RA muscle (Figure 3.5). No significant 
difference in pre-synaptic swelling or occupancy was observed in Smn2B/- 
mice compared to Smn2B/+ controls. This therefore agrees with the finding 












Figure 3.4: At P7, there is significantly more pre-synaptic swelling at the NMJs 
in the TVA muscle of Smn2B/- mice compared to Smn2B/+ mice. (A) Representative 
micrographs of the NMJs in the TVA of P7 Smn2B/- and Smn2B/+ mice. White 
arrowheads show NMJs with no swelling and yellow arrowheads show NMJs with 
mild pre-synaptic swelling (Scale bars = 20µm). (B) Bar chart (Mean ± SEM) shows 
that at P7, 100% of endplates in the TVA of Smn2B/- and Smn2B/+ mice were fully 
occupied by the pre-synaptic terminal of an axon (by Mann Whitney-U test, ns>0.05; 
n=4 mice per genotype) (C) Bar chart (Mean ± SEM) compares the stages of pre-
synaptic swelling in Smn2B/- mice compared to Smn2B/+ controls. There is a significant 
decrease in the percentage of pre-synaptic terminals with no swelling and increase in 
mild swelling in the TVA of Smn2B/- mice compared to Smn2B/+ controls at P7 (by 
Mann Whitney-U test, **p<0.01; n=4 mice per genotype).  
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Figure 3.5: Analysis of NMJs in the Rectus Abdominis (RA) muscle of Smn2B/- 
mice confirms that there is no pre-synaptic pathology observed at P5 (A) 
Representative micrographs of the NMJs in the RA of Smn2B/- and control mice 
showing no significant difference in appearance (Scale bars = 40µm). (B) Bar chart 
(Mean ± SEM) shows that at P5, 100% of endplates in the RA of Smn2B/- and Smn2B/+ 
mice were fully occupied by the pre-synaptic terminal (by Mann Whitney-U test, 
ns>0.05; n=4 mice per genotype) (C) Bar chart (Mean ± SEM) compares the stages 
of pre-synaptic swelling in Smn2B/- mice compared to Smn2B/+. There is no significant 
difference in the level of pre-synaptic swelling in the RA of Smn2B/- mice compared to 
Smn2B/+ controls at P5 (by Mann Whitney-U test, ns>0.05; n=4 mice per genotype).  
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3.2.2.2 Smn2B/- mice begin to lose MNCBs between P10 and P15 
 
A temporal analysis of the number of MNCBs in the ventral horn of Smn2B/- 
and Smn2B/+ thoracic spinal cords was carried out. Spinal cord sections were 
stained with ChAT, Nissl and DAPI. Motor neurons were identifiable by their 
large size, irregular shape and were doubled stained with ChAT and Nissl. 
Only those with a visible nucleus and nucleolus were counted to avoid 
double counting the same motor neuron on different sections. 
 
No significant change in the number of MNCBs in the ventral horn of Smn2B/- 
and Smn2B/+ spinal cords was observed at P1 and P10 (Figure 3.6). 
However, at P5 there was a significant increase of 22% in the number of 
MNCBs in the ventral horn of Smn2B/- spinal cords compared to Smn2B/+ 
controls and at P15 there was a significant decrease of 51% in the number of 
MNCBs in Smn2B/- mice compared to littermate Smn2B/+ controls.  
 
The increase in the number of MNCBs in Smn2B/- mice compared to controls 
that was observed at P5 is potentially a very interesting finding and will be 
addressed within the discussion section of this chapter. However, ultimately, 
the phenotype of SMA is associated with a loss of motor neurons and these 
findings show that the loss of MNCBs in Smn2B/- mice occurs between P10 
and P15. This is after the onset of pathology at the NMJ. 
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Figure 3.6: There is a loss of MNCBs in Smn2B/- mice between P10 and P15.  
(A) Representative images showing the ventral horn of the spinal cord of P1 Smn2B/+ 
and Smn2B/- mice. Note the large and irregular shape of the ChAT and Nissl stained 
MNCBs, which also have a prominent, spherical nucleolus in the centre of the 
nucleus. (Scale bar = 40µm) (B) Graph plotting the absolute number of MNCBs 
counted in the ventral horn of the thoracic spinal cord of Smn2B/- and control mice. 
Note that only points that are linked by a grey line can be compared, as these spinal 
cords are size matched.  At P1 and P10 there is no significant difference between 
Smn2B/- and Smn2B/+ pairs. At P5 there is a significant increase in the number of 
MNCBs in Smn2B/- mice and at P15 there is a significant decrease in the number of 
MNCBs in Smn2B/- mice compared to Smn2B/+ controls (Paired T-test, **p<0.01, n=3 
per genotype per time point) (C) Bar chart (Mean±SEM) displaying the number of 
MNCBs in the ventral horn of the spinal cord of Smn2B/- mice as a percentage of 
controls. Smn2B/- absolute numbers are normalised to their paired control. Note that 
time points cannot be compared. 
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3.2.2.3 The area of MNCBs in Smn2B/- mice becomes significantly smaller 
compared to controls between P10 and P15 
 
The area of MNCBs at P1, P5, P10 and P15 was also assessed in Smn2B/- 
and Smn2B/+ control mice (Figure 3.7B). This analysis revealed that there is 
no significant difference in MNCB area at P1, P5 and P10. However, at P15 
there is a significant decrease in MNCB area in Smn2B/- mice compared to 
controls. While the area of MNCBs in Smn2B/+ mice increases over time, with 
a significant difference in area between P1 and P15, MNCB area in Smn2B/- 
mice does not change across the time course assessed (Figure 3.7). 
 
The same method for measuring MNCB area was used to measure the 
nuclear area of MNCBs. This showed that there is no significant difference in 
the nuclear area of MNCBs of Smn2B/- and Smn2B/+ mice at P1, P5, P10 and 
P15 (Figure 3.7C). This quantification also validates the counting method 
used for determining MNCB number. Since only MNCBs with a visible 
nucleus were counted, it is unlikely that motor neurons would have been 
excluded due to a reduction in their nuclear area. 
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3.2.2.4 There is an increase in the percentage of activated caspase-3 
positive cells in the ventral horn of spinal cords of P15 Smn2B/- mice 
 
Caspase-3 is a protein involved in the execution of apoptosis (Vila & 
Przedborski 2003). Therefore, I wished to consider the activation of caspase-
3 in MNCBs of Smn2B/- mice. Spinal cord sections from P1, P5, P10 and P15 
Smn2B/- and Smn2B/+ mice were stained for activated caspase-3. Positive 
cells in the ventral horn of the spinal cord were counted. During analysis, it 
was found that cells positive for activated caspase-3 could have different 
appearances (Figure 3.8A). For this analysis, all cell-like structures that lay 
within the ventral horn and still displayed a DAPI stained nucleus were 
counted.  
 
When spinal cord sections were cut, they were alternated between two sets 
of slides; one was used for ChAT staining (and MNCB counting) while the 
other was used for activated caspase-3 staining. Therefore, the number of 
MNCBs counted in the ventral horn of spinal cords was used to normalise the 
number of activated caspase-3 positive cells to the number of motor neurons 
present. 
 
Figure 3.7: There is a significant difference in the area of MNCBs in Smn2B/- 
mice compared to controls at P15 (A) Representative images showing MNCBs 
from Smn2B/- and Smn2B/+ control mice at P1, P5, P10 and P15. Note the relative 
decrease in area in Smn2B/- compared to Smn2B/+ mice at P15 (Scale bar = 20µm). 
(B) The graph (Mean ± SEM) shows that at P1, P5 and P10 there is no significant 
difference in the average area of MNCBs in the ventral horn of the spinal cord of 
Smn2B/- and Smn2B/+ mice. However, there is a significant decrease in the average 
area of MNCBs in Smn2B/- mice compared to Smn2B/+ mice at P15 (by unpaired t-
test, ns>0.05, *p<0.05, n= 4 mice per genotype). Statistical analysis has also shown 
that there is a significant increase in the area of MNCBs in Smn2B/+ controls between 
P1 and P15 (by one-way ANOVA, p<0.05) but no significant difference over time in 
Smn2B/+ mice (by one-way ANOVA, p>0.05). (C) The graph (Mean ± SEM) shows 
that there is no significant difference in the area of MNCB nuclei in Smn2B/-
compared to Smn2B/+ controls at any of the time points measured (by unpaired t-test, 
ns>0.05; n=4 mice per genotype). 
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It was found that at P1 there was significantly less activated caspase-3 
positive cells in the ventral horns of Smn2B/- spinal cords (Figure 3.8B). This 
suggests that there is a decrease in apoptosis in Smn2B/- mice at P1. At P5 
and P10, there was no significant difference in the percentage of activated 
caspase-3 positive cells. At P15, there was an increase in the percentage of 
activated caspase-3 positive cells in the ventral horn of Smn2B/- mice 
compared to Smn2B/+ controls (Figure 3.8B). Furthermore, over time there is 
a statistically significant decrease in the percentage of activated caspase-3 
positive cells in Smn2B/+ mice that is not observed in Smn2B/- mice (Figure 
3.8).  
 
Whether these cells are exclusively motor neurons or not cannot be 
confirmed, as they were not stained using a motor neuron specific marker. 
Preliminary work to double staining for both activated caspase-3 and ChAT 
was unsuccessful however, it is likely that the use of ChAT as a motor 
neuron specific marker when looking for dying motor neurons may not be 
appropriate as loss of function in motor neurons results in reduced 
expression of ChAT (Wu & Hersh 1994; Pérez-García et al. 2017). 
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3.2.2.5 Transcripts involved in the P53 signalling pathway are upregulated in 
the spinal cords of Smn2B/- mice between P5 and P7 
 
Previous work by Murray et. al. showed that transcripts involved in the P53 
signalling pathway were pre-symptomatically up-regulated in motor neurons 
of two different mouse models of SMA (Murray et al. 2015). Therefore, I 
aimed to determine the relationship between the onset of NMJ pathology and 
the up-regulation of transcripts involved in the P53 signalling pathway in the 
Smn2B/- mouse model of SMA. As motor neurons that supply the vulnerable 
abdominal musculature (notably the TVA muscle), which was used for NMJ 
analysis above, lie within the thoracic portion of the spinal cord, cDNA from 
the thoracic spinal cord of Smn2B/- and Smn2B/+ mice was used to perform 
qPCR. Transcripts of interest were Cdkn1A, Fas and Pmaip1, all of which are 
involved in the P53 signalling pathway. 
 
 qPCR analysis was performed first at P5. As shown above, at this time point 
there is no sign of pathological features at the NMJ or MNCBs. At P5, qPCR 
analysis showed that there is no significant change in the regulation of these 
transcripts in the spinal cords of Smn2B/- compared to Smn2B/+mice (Figure 
3.9A). 
Figure 3.8: There is an increase in the percentage of activated caspase-3 
positive cells in the ventral horn of the thoracic spinal cord of Smn2B/- mice at 
P15 (A) Representative images showing the different appearances that positive 
active caspase-3 cells can take. All cells with these appearances were counted in 
this analysis (Scale bar = 20µm). (B) The graph (Mean ± SEM) shows that at P1 
there is a significant increase in the percentage of activated caspase-3 positive cells 
in control, Smn2B/+ mice. At P5 and P10 there is no significant difference in the 
percentage of active caspase-3 positive cells between Smn2B/- and Smn2B/+ mice. At 
P15 there is a significant increase in the percentage of activated caspase-3 positive 
cells in the ventral horn of Smn2B/- spinal cords compared to controls (by Mann 
Whitney-U test; ns>0.05, *p<0.05; n= 3 mice per genotype). Statistical analysis has 
also shown that there is a significant decrease in the percentage of active caspase-
3 positive cells in Smn2B/+ controls between P1 and P15 (by one-way ANOVA, 
p<0.05) that is not observed Smn2B/- mice (by one-way ANOVA, p>0.05). 
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Therefore, the regulation of these transcripts of interest was assessed at P7. 
This revealed an up-regulation of Fas and Pmaip1 in Smn2B/- compared to 
Smn2B/+ mice. There was no significant difference in the regulation of Cdkn1A 
(Figure 3.9B).  
 
In conclusion, the up-regulation of these transcripts of interest in the spinal 
cord of Smn2B/- mice is occurring between P5 and P7, the same time window 
in which the onset of NMJ pathology was observed. These two events 
appear to be coinciding with each other and warrant further investigation to 
determine whether NMJ pathology is a consequence of the activation of the 
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Figure 3.9: There is a significant increase in the expression of transcripts 
involved in the P53 signalling pathway in the spinal cords of Smn2B/- mice 
compared to controls at P7 (A) The bar chart (Mean ± SEM) shows that there is 
no significant difference in the expression of transcripts involved in the P53 
signalling pathway in the thoracic spinal cord of Smn2B/- mice compared to Smn2B/+ 
mice at P5 (by Mann Whitney-U test; ns>0.05;n=4 per genotype) (B) The bar chart 
(Mean ± SEM) shows that there is a significant increase in the expression of 
transcripts involved in the P53 signalling pathway in the thoracic spinal cord of 
Smn2B/- mice compared to Smn2B/+ mice at P5 (by Mann Whitney-U test; 
ns>0.05;n=4 per genotype). Specifically, there is an increase in Fas and Pmaip1. 
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3.2.3 Investigating the relationship of the activation of the P53 
signalling pathway and NMJ pathology 
 
To investigate whether NMJ pathology is a consequence of the activation of 
the P53 signalling pathway or the cause of the activation of the P53 
signalling pathway a mouse model in which the levels of P53 could be 
decreased was created. It was hypothesised that NMJ pathology was caused 
by the activation of the P53 signalling pathway and by reducing P53 the level 
of pathology at the NMJ observed at P15 would be decreased. 
 
3.2.3.1 Reduction of P53 was confirmed using qPCR following derivation of 
the Smn2B/-;P53fl/fl ;Cre+ mouse model  
 
The Smn2B/-;P53fl/fl ;Cre+ mouse model is a conditional knockout Smn2B/- 
mouse model of SMA in which P53 levels can be reduced using the Cre-
LoxP system (Figure 3.10). This mouse model carries a P53-floxed gene 
(referred to as P53fl hereafter) that when in the presence of Cre-
recombinase (Cre) will recombine and will essentially be ‘knocked out’. In this 
case, mice carry the CAG-CreER allele. This is a tamoxifen inducible allele 
that leads to ubiquitous expression of Cre when tamoxifen is administered 
(Hayashi & McMahon 2002). Mice were bred to carry only one copy of Cre to 
exclude the need for Cre copy number genotyping and to ensure comparable 
recombination across mice.   
 
In addition, mice were derived to be homozygous for P53fl, maximising the 
knockdown of P53 in this mouse model. To determine P53fl copy number, 
qPCR was performed using primers targeted against P53fl (see section 2.2.3 
in Chapter 2). These primers were optimised for quantitative use and were 
shown to have an efficiency of 100% and 100.5% for P53fl primers and the 
control primer set, respectively (Figure 3.11A). 
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Here SYBR qPCR is used. SYBR green is a dye that binds to synthesised 
double stranded DNA and when it does so it begins to fluoresce. Therefore, 
when this dye is incorporated into the double stranded DNA synthesised 
during PCR, a fluorescent output can determine the quantity of DNA product 
within a sample (and therefore this is termed quantitative-PCR (qPCR)). 
Samples from homozygous mice will produce a greater fluorescent output, 
due to the increased starting quantity (two copies), than samples from 
heterozygous mice (one copy). The greater the starting quantity of DNA, the 
lower the number of cycles required for detection of the fluorescent output. 
 
Samples from mice that were known to be heterozygous for P53fl were 
compared with samples from mice with an unknown copy number of P53fl. 
DNA samples were exposed to primers for the P53fl allele and a standard 
control allele. By subtracting the mean Cq (number of cycles required to 
detect the fluorescence intensity) obtained from control primers and the 
mean Cq obtained from P53fl primers, for each sample, homozygous and 
heterozygous mice could be seperated. Those homozygous for P53fl had a 
difference of approximately 0.5 cycles whereas those heterozygous had a 
difference of 1.5 cycles (Figure 3.11B&C). This enabled us to select for 
P53fl/fl mice.  
 
Experimental litters contained mice of four genotypes; Smn2B/+ mice that are 
P53fl/fl and do not carry Cre (Smn2B/+;P53fl/fl ;Cre-), Smn2B/- mice that are 
P53fl/fl and do not carry Cre+ (Smn2B/-;P53fl/fl ;Cre-), Smn2B/+ mice that are 
P53fl/fl and carry Cre+ (Smn2B/+;P53fl/fl ;Cre+) and Smn2B/-  mice that are P53fl/fl 
and carry Cre+ (Smn2B/-;P53fl/fl ;Cre+) (Figure 3.11). All pups were treated 
with tamoxifen however only those that carried Cre would experience 
recombination of P53. This makes use of all pups within one litter and 
provides us with appropriate controls. For simplicity, hereafter, mice that 
were Cre-, and so did not experience P53 recombination, will be referred to 
as P53+/+ and mice that were Cre+, and did experience P53 recombination, 
will be referred to as P53-/-. 
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Figure 3.10: Derivation process to obtain experimental Smn2B/-;P53fl/fl;Cre+ 
mice and control littermates. Mice shown in red boxes are those that were within 
previously established colonies (Smn+/+ mice, Smn2B/2B mice and Smn+/- mice) or 
were donated to our lab (P53fl/fl mice and CreER mice). These mice were required to 
begin this colony. The arrows show the crosses that were carried out to obtain the 
next generation of desirable mice. Only desirable genotypes are shown, other 
genotypes were obtained from crossed in keeping with mendelian genetics. The 
mice in the green box represent an experimental litter. All mice in these litters were 
treated with tamoxifen and those that expressed CreER would have P53 knocked 
down (Please note that CreER will now be referred to as ‘Cre+’).  




Figure 3.11: Copy number genotyping separates P53fl/+ mice and the desired 
P53fl/fl mice. (A) The standard curve (created by plotting the fluorescence intensity 
(Cq) against the log of the relative starting quantity of DNA) shows that the efficiency 
of P53 primer set is 100%. An efficacy of 90-110% is desirable and so these primers 
are appropriated for quantitative use. (B) The graphs show amplification cycles for 
DNA samples from mice that have now been shown to be homozygous or 
heterozygous for the P53fl allele. Exponential amplification curves for control primers 
and P53 primers are shown in each of the three graphs. Note that in heterozygous 
samples these curves appear separated. This is due to a lower starting 
concentration of P53fl DNA (i.e one copy rather than two copies) meaning the 
amplification of this requires more cycles that if there were two copies of this allele. 
In addition, for reference, the Cq value is the number of cycles at which the 
amplification curve crosses the green horizontal threshold line that can be seen in 
these three graphs (C) The graph shows the difference between the mean Cq of 
control primers and P53fl primers, for each sample. Samples that were known to be 
heterozygous were used as reference. Those heterozygous consistently showed a 
difference of approximately 1.5 cycles and those homozygous for P53fl consistently 
showed a difference of approximately <0.5 cycles.  
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To confirm that P53-/- mice did express reduced P53, qPCR was performed 
using spinal cord cDNA and primers targeted against P53, which had been 
previously used by Simon et. al. (Simon et al. 2017). Optimisation of these 
primers showed an efficiency of 94%. This qPCR analysis revealed a 
reduction in P53 in Smn2B/-;P53-/- mice compared to Smn2B/-;P53+/+ mice at 
P15. This reduction was also seen in Smn2B/+;P53-/- when compared to 
Smn2B/+;P53+/+ mice (Figure 3.12). Although this was not a complete 
knockdown, a reduction of 40% of P53 mRNA was achieved in both Smn2B/- 
and Smn2B/+ mice. It should be noted that this is a reduction in P53 mRNA 
expression rather than in the levels of functional protein. In order to confirm 
that this reduction is also observed at the protein level, western blotting 
should be performed. Unfortunately, this was not possible due to time 
constraints. 
Figure 3.12: Reduction of P53 was confirmed using qPCR on spinal cord 
cDNA. Bar chart (Mean ± SEM) shows that there is a significant decrease in P53 at 
the transcript level in the spinal cord of Smn2B/+;P53-/- mice compared to 
Smn2B/+;P53+/+ mice and in Smn2B/-;P53-/- mice compared to Smn2B/-;P53+/+ mice (by 
Mann Whitney-U test, *p<0.05, **p<0.001; n=3 for Smn2B/-;P53+/+, n=4 for all other 
genotypes.) 
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3.2.3.2 Reducing P53 does not improve the phenotype of Smn2B/- mice 
 
In order to investigate whether a reduction in P53 expression affects the 
phenotype of Smn2B/- mice (and control Smn2B/+ mice) both weight and motor 
performance of Smn2B/-;P53-/-, Smn2B/-;P53+/+, Smn2B/+;P53-/- and 
Smn2B/+;P53+/+ mice were monitored, following tamoxifen treatment at P4 and 
P5. In both Smn2B/- and Smn2B/+ mice a separation in the body weights of 
P53+/+ and P53-/- mice was observed (Figure 3.13). Smn2B/-;P53-/- and 
Smn2B/+;P53-/- displayed a decrease in body weight compared to their 
respective P53+/+ controls. There was a significant difference in the body 
weights of Smn2B/+;P53-/- mice compared to Smn2B/+;P53+/+ mice at P5 and a 
significant difference in the body weights of Smn2B/-;P53-/- mice compared to 
Smn2B/-;P53+/+ mice at P6 (Figure 3.13B).  
 
In order to investigate the effect of reduced P53 levels on motor 
performance, an age appropriate motor test was applied (‘Time to Right’ 
(TtR) test or the ‘Turn Around’ (TA) Test, both of which are explained fully in 
Chapter 2). The TtR test, used on pups aged between P7 and P11, involves 
the pups being place on their back and recording the time it takes for them to 
right themselves, or turn onto all four paws. There was no significant 
difference between Smn2B/+;P53-/- and Smn2B/+;P53+/+ mice and also no 
significant difference between Smn2B/-;P53-/- and Smn2B/-;P53+/+ mice (Figure 
3.13C). Therefore, a reduction in P53 does not affect the ability of mice to 
right themselves.  
 
To assess motor ability in mice aged between P12 and P15, the TA test was 
performed. This involves placing the mouse in a downward facing position on 
a grid that is placed at a 45o angle and recording the time it takes for the 
mouse to turn 180o to face upwards on the grid. There was no significant 
difference between Smn2B/+;P53-/- and Smn2B/+;P53+/+ mice and between 
Smn2B/-;P53-/- and Smn2B/-;P53+/+ mice (Figure 3.13D). This would imply that 
reducing P53 levels does not improve motor performance.  Indeed, there is a 
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significant decrease in the ability of Smn2B/-;P53-/- mice to perform this test 
when compared to Smn2B/-;P53+/+ mice at P13. 
 
Overall this shows that knocking down P53 does not improve the phenotype 
of Smn2B/- mice and if anything, it has a negative impact on the phenotype of 
both Smn2B/- and Smn2B/+ mice.  
 
3.2.3.3 A reduction in P53 decreases denervation in the TVA of Smn2B/- mice 
but does not improve the overall health of the NMJ 
 
The hypothesis of this investigation was that by reducing P53 levels in 
Smn2B/- mice NMJ pathology at P15 would improve. Therefore, NMJ analysis, 
as previously performed in Smn2B/- mice, was performed at P15 in Smn2B/-
;P53-/- and Smn2B/-;P53+/+ mice. This involved assessing occupancy, pre-
synaptic swelling and endplate size in the TVA muscle. 
 
Firstly, the occupancy of post-synaptic endplates of Smn2B/-;P53-/- and 
Smn2B/-;P53+/+ mice was assessed. This showed a significant increase in the 
percentage of fully occupied endplates and a decrease in the percentage of 
vacant endplates seen in Smn2B/-;P53-/- mice compared to Smn2B/-;P53+/+. 
This indicates that there is a decrease in denervation when P53 is reduced 
(Figure 3.14B). 
 
Pre-synaptic swelling at the NMJs of Smn2B/-;P53-/- and Smn2B/-;P53+/+ mice 
was also assessed. As before, the level of pre-synaptic swelling was staged 
from ‘none’ to ‘severe’. This showed that there was no significant difference 
in the level of swelling at pre-synaptic terminals in the TVA of Smn2B/-;P53-/- 
mice compared to Smn2B/-;P53+/+ mice (Figure 3.14C).  
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Maturation of the NMJ, including its post-synaptic endplate, is activity 
dependent and so maturity of the endplate is related to the activity and 
function of an NMJ (Darabid et al. 2014). Therefore, to gain an idea as to the 
functioning ability of NMJs in Smn2B/-;P53-/- the maturity of endplates in the 
TVA of Smn2B/-;P53-/- and Smn2B/-;P53+/+ mice was assessed. A staging 
system that categorised endplates into groups based on their maturity was 
devised. Stage 1 was most mature, displaying a pretzel-like structure 
whereas stage 4 was the least mature where the endplate has a plaque-like 
appearance (see Chapter 2 for the full criteria). This showed that there is no 
significant difference in the maturity of endplates in the TVA of Smn2B/-;P53-/- 
mice when compared to Smn2B/-;P53+/+ mice (Figure 3.14D). This suggests 
that although there is a decrease in denervation in Smn2B/-;P53-/- mice there 
is not necessarily an improvement in function. 
 
Figure 3.13: Reducing P53 does not improve the phenotype of Smn2B/- mice. 
(A) Representative images of mice with the various genotypes within 
experimental litters at P15. (B) Graph (Mean ± SEM) shows body weight in 
Smn2B/+;P53+/+ and Smn2B/+;P53-/- on the left and Smn2B/-;P53+/+ and Smn2B/-;P53-/- 
on the right. There is a significant difference in weight between those that are 
P53+/+ and P53-/- in Smn2B/+ from P5 and in Smn2B/- from P6 (C) Graph (Mean ± 
SEM) shows time to right for Smn2B/+;P53+/+ and Smn2B/+;P53-/- on the left and 
Smn2B/-;P53+/+ and Smn2B/-;P53-/- on the right. There is no significant difference 
between the time to right for Smn2B/+;P53+/+ and Smn2B/+;P53-/- and also for 
Smn2B/-;P53+/+ and Smn2B/-;P53-/- mice. Note that where no statistics are shown 
on the graph for particular time points is where there was not a sufficient n 
number to perform statistical analysis. (D) Graph (Mean ± SEM) shows 
performance in the time to turn around for Smn2B/+;P53+/+ and Smn2B/+;P53-/- on 
the left and Smn2B/-;P53+/+ and Smn2B/-;P53-/- on the right. There is no significant 
difference between the time to turn around for Smn2B/+;P53+/+ and Smn2B/+;P53-/-. 
There is a significant difference between the time to turn around for Smn2B/-
;P53+/+ and Smn2B/-;P53-/- mice at P13 but not at any other time point, on which 
statistical analysis was performed. There may be a trend to Smn2B/-;P53-/- mice 
performing poorly compared to Smn2B/-;P53+/+ mice. (For all graphs, where 
statistical analysis was possible, it was by unpaired t-test; ns>0.05, *p<0.05, 
**p<0.01, ***p<0.005; n=3-5 (n=2 where no statistics are shown)). 
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The area of endplates in the TVA of Smn2B/-;P53-/- and Smn2B/-;P53+/+ mice 
was also measured. This showed that reducing P53 decreases the area of 
endplates of Smn2B/-;P53-/- mice compared to Smn2B/-;P53+/+ mice (Figure 
3.14E). It is possible that this decrease in area may be caused by the 
decrease in size of the mouse and/or muscle. Further investigation into 
muscle fibre size would be required to confirm this. 
 
Additionally, to confirm that a reduction in P53 did not cause alterations in 
NMJ morphology in control Smn2B/+ mice, occupancy, pre-synaptic swelling 
and endplate maturation and size were assessed in Smn2B/+;P53-/- and 
Smn2B/+;P53+/+ mice. This showed that there was no significant difference in 
any of these features between Smn2B/+;P53-/- and Smn2B/+;P53+/+ mice 
(Figure 3.15).  
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Figure 3.14: A reduction in P53 reduces denervation in the TVA of Smn2B/- 
mice (A) Representative confocal images showing NMJs from the TVA of Smn2B/-
;P53+/+ and Smn2B/-;P53-/- mice. Note that the white arrowheads point out vacant 
endplates (Scale bar = 40µm). (B) The graph (Mean ± SEM) shows that there is a 
significant increase in the percentage of fully occupied endplates and a significant 
decrease in vacant endplates in Smn2B/-;P53-/- compared to Smn2B/-;P53+/+ (by 
Mann Whitney-U test; *p<0.05, **p<0.01). (C) The graph (Mean ± SEM) shows 
that there is no significant difference in the level of pre-synaptic swelling in the 
TVA of Smn2B/-;P53+/+ and Smn2B/-;P53-/- mice (by Mann Whitney-U test; ns>0.05). 
(D) The graph (Mean ± SEM) shows that there is no significant difference in the 
maturity of endplates in the TVA of Smn2B/-;P53+/+ and Smn2B/-;P53-/- mice (by 
Mann Whitney-U test; ns>0.05). (E) The graph (Mean ± SEM) shows that there is 
a small but significant decrease in the area of endplates in the TVA of Smn2B/-
;P53+/+ and Smn2B/-;P53-/- mice (by Unpaired T-test; *p<0.05; n=6 muscles per 
genotype for all analysis). 
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3.2.3.4 A reduction in P53 does not alter the number or size of MNCBs in 
Smn2B/- mice at P15 
 
To determine whether reducing P53 in Smn2B/+ and Smn2B/- mice had any 
effect on the number of MNCBs in the ventral horn of the spinal cord, MNCBs 
were counted in the thoracic segments T4-T8. Spinal cord sections from 
P53+/+ and P53-/-, Smn2B/+ and Smn2B/- mice were stained for ChAT and Nissl 
and counterstained with DAPI. MNCBs were counted if they conformed to the 
criteria set out in Chapter 2; they would have a large, irregular shape and 
would be double stained with ChAT and Nissl. They would lie within the 
ventral horn of the spinal cord and have a visible nucleus and nucleoli 
(Figure 3.16). By following this criteria, it was found that there was no 
significant difference in the number of MNCBs in Smn2B/+;P53-/- compared to 
Smn2B/+;P53+/+ mice or in Smn2B/-;P53-/- compared to Smn2B/-;P53+/+ mice 
(Figure 3.17A). However, there was a significant difference between Smn2B/+ 
and Smn2B/- mice (Figure 3.17A) which is consistent with what had been 
previously seen earlier in this chapter (Figure 3.6). 
 
Figure 3.15: A reduction in P53 in control Smn2B/+ mice does not alter NMJ 
morphology. (A) Representative confocal images showing NMJs from the TVA of 
Smn2B/+;P53+/+ and Smn2B/+;P53-/- mice (Scale bar = 20µm). (B) The graph (Mean 
± SEM) shows that when P53 is knocked down there is no significant difference in 
the occupancy of endplates in the TVA of Smn2B/+;P53-/- compared to 
Smn2B/+;P53+/+ mice (ns>0.05 by Mann Whitney-U test). (C) The graph (Mean ± 
SEM) shows that there is no significant difference in the level of pre-synaptic 
swelling in the TVA of Smn2B/+;P53+/+ mice compared to Smn2B/+;P53-/- mice (by 
Mann Whitney-U test; ns>0.05). (D) The graph (Mean ± SEM) shows that there is 
no significant difference in the maturity of endplates in the TVA of Smn2B/+;P53+/+ 
mice compared to Smn2B/+;P53-/- mice (by Mann Whitney-U test; ns>0.05). (E) The 
graph (Mean ± SEM) shows that there is no significant difference in the area of 
endplates in the TVA of Smn2B/+;P53+/+ mice compared to Smn2B/+;P53-/- mice (by 
Unpaired T-test; ns>0.05; n=6 muscles per genotype for all analysis). 
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Imaging of these MNCB allowed their cytoplasmic and nuclear area to be 
measured. This showed no significant difference in both the cytoplasmic area 
and in the area of the nucleus of MNCB between Smn2B/+;P53-/- and 
Smn2B/+;P53+/+ mice as well as Smn2B/-;P53-/- and Smn2B/-;P53+/+ mice (Figure 
3.17 B&C). 
 
3.2.3.5 Reducing P53 does not decrease the levels of transcripts 
downstream of P53 in Smn2B/- mice at P15 
 
Transcripts involved in the P53 signalling pathway were of interest as Murray 
et. al. had shown that they were up-regulated pre-symptomatically in two 
different mouse models of SMA (Murray et al. 2015). As detailed above, it 
was also found that their up-regulation, in the Smn2B/- mouse model, 
coincided with the onset of NMJ pathology. I wished to determine the effect 
of reducing P53 on the regulation of these transcripts that are downstream of 
P53. The transcripts of interest were Cdkn1A, Pmaip1 and Fas. It was found 
that there was no significant difference in mRNA level of these transcripts in 
Smn2B/-;P53-/- compared to Smn2B/-;P53+/+ mice (Figure 3.18). The reasons 
for this remain unclear and provide an interesting discussion topic (refer to 
section 3.3.5). 
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Figure 3.16: Reducing P53 in Smn2B/- and Smn2B/+ mice does not alter the 
morphology of MNCBs in the ventral horn of their spinal cord (A) 
Representative images showing MNCBs in the ventral horn of the spinal cord of 
Smn2B/+;P53+/+ and Smn2B/+;P53-/- mice and Smn2B/-;P53+/+ and Smn2B/-;P53-/- mice. 
White arrowheads highlight MNCBs in the thoracic spinal cord of Smn2B/- and Smn2B/+ 
mice that have normal P53 levels (P53+/+) and have had P53 reduced (P53-/-) (Scale 
bar = 40µm). 
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Figure 3.17: Reducing P53 does not alter the number or size of MNCBs in the 
ventral horn of the thoracic spinal cord. (A) The graph (Mean ± SEM) shows that 
when P53 is reduced there is no significant difference in the number of MNCBs in 
the ventral horn of both Smn2B/+ and Smn2B/- spinal cords. There is a significant 
difference in the loss of MNCBs in Smn2B/- mice compared to Smn2B/+ mice (by One-
way ANOVA; ns>0.05, ****p<0.001; n=3 mice per genotype). (B) The graph (Mean 
± SEM) shows that when P53 is reduced there is no significant difference in the 
area of MNCBs in the ventral horn of both Smn2B/+ and Smn2B/- spinal cords (by One-
way ANOVA; ns>0.05; n=3 mice per genotype). (C) The graph (Mean ± SEM) 
shows that when P53 is reduced there is no significant difference in the area of the 
nuclei of MNCBs in the ventral horn of both Smn2B/+ and Smn2B/- spinal cords (by 
One-way ANOVA; ns>0.05; n=3 mice per genotype). 
  
 
Figure 3.18: Reducing P53 does not alter the overall regulation of transcripts 
that are downstream of P53 in the P53 signalling pathway (A) The bar chart 
(Mean ± SEM) shows the relative normalised expression of Fas, Pmaip1 and 
Cdkn1A in the spinal cords of Smn2B/+;P53-/-, Smn2B/+;P53+/+, Smn2B/-;P53+/+ and 
Smn2B/-;P53-/-  mice. It compares Smn2B/+;P53-/- and Smn2B/+;P53+/+ mice as well as 
Smn2B/-;P53-/- and Smn2B/-;P53-/- mice. There is a significant increase in the 
expression of Pmaip1 in Smn2B/+;P53-/- mice compared to Smn2B/+;P53+/+ mice but 
there is no significant difference in all other comparisons (by Mann Whitney-U test; 
ns>0.05, *p<0.05; n=3 for Smn2B/-;P53+/+, n=4 for all other genotypes). 
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3.3 Discussion  
 
 
3.3.1 Overview of Results 
 
In this chapter, I first investigated the time course of motor neuron pathology 
in the Smn2B/- mouse model of SMA, in order to determine the relationship 
between the pathological hallmarks of motor neurons in SMA. It was found 
that, in the Smn2B/- mouse model of SMA, the onset of NMJ pathology 
coincides with the onset of phenotypic symptoms and precedes a decrease 
in the number and area of MNCBs. This therefore demonstrates that motor 
neurons degenerate in a distal to proximal manner. 
 
Furthermore, I have shown that the onset of NMJ pathology coincides with 
the up-regulation of transcripts involved in the P53 signalling pathway in the 
spinal cords of Smn2B/- mice. By reducing the expression of P53 in the 
Smn2B/- mouse model of SMA, it was found that, although this does not 
improve the overall phenotype of the mouse model or decrease the loss of 
MNCBs, it does result in a decrease in the level of denervation observed at 
the level of the NMJ. This implies that P53 plays a role in synaptic withdrawal 
in this mouse model of SMA.  
 
3.3.2 Understanding the temporal relationship of motor unit pathology 
in SMA 
 
It has commonly been assumed that motor neurons in SMA degenerate in a 
distal to proximal manner, based on the fact that the pre-synaptic terminal 
appears to withdraw from the post-synaptic endplate, leaving partially 
occupied endplates (Murray et al. 2008). However, there is no literature that 
explicitly explores the relationship of NMJ and MNCB pathology in SMA. 
Therefore, by performing a temporal analysis of motor units in the Smn2B/- 
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mouse model, I was able to determine that pre-synaptic pathology, including 
withdrawal of the pre-synaptic terminal, occurs prior to MNCB shrinkage and 
loss, with the earliest pathological feature to occur being an increase in 
abnormal pre-synaptic swelling. It was found that the onset of NMJ defects 
coincides with the onset of a symptomatic phenotype in the Smn2B/- mouse 
model of SMA, which is supported by findings in an ALS mouse model that 
show the onset of a symptomatic phenotype is caused by degeneration of 
the distal compartment of the motor neuron (Gould et al. 2006). As a result, 
these findings support the idea that degeneration of the motor neuron occurs 
in a distal to proximal manner. 
 
Interestingly, the quantification of pre-synaptic swelling indicated that, at 
early time points, there was mild swelling at the NMJs of Smn2B/+ mice as 
well as Smn2B/- mice. Over the time course, pre-synaptic swelling 
progressively decreased in Smn2B/+ control mice but increased in Smn2B/- 
mice. It is worth considering the possibility that poly-innervation of post-
synaptic endplates may contribute to the swollen appearance of axons and 
pre-synaptic terminals early in post-natal life. Poly-innervation of a post-
synaptic endplate is observed in early postnatal life (Sleigh et al. 2014). 
However, following axonal pruning post-synaptic terminals are left with only a 
single axonal input (Sleigh et al. 2014). In mice, the process of axonal 
pruning is complete within the first two weeks of post-natal life (Sleigh et al. 
2014). As swelling decreases in Smn2B/+ mice, with almost all of the pre-
synaptic terminals displaying no swelling by P15, it is possible that axonal 
pruning is responsible for eliminating the mild swollen appearance of the pre-
synaptic terminal.  
 
At a late symptomatic time point, after NMJ pathology had been observed, 
MNCB area in the Smn2B/- mouse model of SMA was decreased in 
comparison to Smn2B/+ controls. It could be suggested that MNCBs are 
undergoing cytoplasmic shrinkage, which is known to be a feature of 
apoptosis (Ernest et al. 2008; d’Errico et al. 2013). However, by looking at 
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the temporal analysis for both Smn2B/- and Smn2B/+ mice it was observed that 
while the area of MNCBs in Smn2B/+ mice shows an increasing trend over 
time, MNCB area in Smn2B/- mice does not change. In cultured neurons, cell 
body area was shown to increase with maturation and therefore, this 
morphological alteration that was observed in Smn2B/- mice compared to 
Smn2B/+ mice may be due to a lack of motor neuron growth and development. 
In support of this, the production of growth factors from astrocytes is thought 
to be reduced in SMA (McGivern et al. 2013).  
 
An increase in activated caspase-3 staining at P15 was observed in Smn2B/- 
mice compared to Smn2B/+ controls. The majority of the caspase-3 positive 
cells that were observed, exclusively within motor neuron rich regions, had 
an abnormal, shrunken appearance (Figure 3.8). As caspase-3 is 
responsible for degrading cellular components, which is thought to result in 
the altered structure of the cell, it is likely that these cells were undergoing 
apoptosis (Vila & Przedborski 2003; Fink & Cookson 2005). Whether these 
activated capase-3 positive cells are motor neurons or not cannot be 
confirmed, due to the lack of a motor neuron specific marker as double 
staining of spinal cord sections, for both ChAT and activated caspase-3, was 
unsuccessful. It is predicted that the use of ChAT as a motor neuron specific 
marker when looking for dying motor neurons may not be appropriate as loss 
of function in motor neurons results in reduced expression of ChAT (Wu & 
Hersh 1994; Pérez-García et al. 2017).  
 
It has been suggested that SMN has an anti-apoptotic role (Kerr et al. 2000; 
Vyas et al. 2002; Wang et al. 2005; Parker et al. 2008; Anderton et al. 2011). 
In a study by Kerr et. al., cells infected with an apoptotic-causing virus are 
given SMN resulting in an increase in cell survival. When alternatively spliced 
variants of SMN are given to these cells there is a decrease in cell survival 
(Kerr et al. 2000). It has also been shown that SMN interacts with Bcl-2, an 
anti-apoptotic factor, and by doing so it inhibits Bax and Fas mediated 
apoptosis (Iwahashi et al. 1997; Sato et al. 2000). Furthermore, SMN is also 
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thought to play an anti-apoptotic role by inhibiting cytochrome-C release from 
the mitochondria as well as inhibiting caspase-3 activation (Vyas et al. 2002; 
Wang et al. 2005; Parker et al. 2008; Anderton et al. 2011). SMA fibroblasts 
were more susceptible to cell death, than control fibroblasts, following 
treatment with camptothecin, which causes cell death through DNA damage, 
however they were no more susceptible to death than controls when treated 
with menadione, which causes cell death through oxidative stress (Wang et 
al. 2005). This therefore suggests that the pathway that results in cell death 
following DNA damage is compromised in SMA fibroblasts (Wang et al. 
2005).  
 
3.3.3 Early motor unit alterations may be consistent with a 
developmental delay 
 
During the temporal analysis of pathology within the motor unit an increase in 
MNCB number in the ventral horn of Smn2B/- spinal cords was observed at 
P5, when compared to Smn2B/+ controls. It is believed that this finding is 
suggestive of a developmental delay. As part of normal development, the 
nervous system undergoes programmed cell death (PCD) to compensate for 
an excess number of cells (Oppenheim 1991). If this process is delayed in 
Smn2B/- mice, this may be why an increase in the number of MNCBs in their 
spinal cords when compared to the number of MNCBs in Smn2B/+ mice was 
seen. While Smn2B/+ mice have already undergone this process, the delay in 
Smn2B/- mice would see a greater number of MNCB in their spinal cords. It 
has previously been suggested that the wave of PCD may be defective in 
SMA and that this process is somewhat uncontrolled, therefore highlighting 
that problems in this process are known to occur (Soler-Botija et al. 2002).  
 
Furthermore, at P1 a decrease in activated caspase-3 staining in Smn2B/- 
mice was observed and may represent the natural wave of PCD occurring in 
Smn2B/+ mice but not in Smn2B/- mice. It is believed that the developmental 
wave of PCD is caspase-3 dependent, which supports this idea (Raoul et al. 
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1999). In addition, it has been suggested that Bcl-2, which is thought to be 
involved in the regulation of developmental PCD, is down-regulated in post-
mortem tissue from SMA patients, supporting the idea that this process may 
be defective in SMA (Soler-Botija et al. 2002).  
 
In support of this theory, it was found that there was an increase in the area 
of post-synaptic endplates in the Smn2B/- mouse model of SMA compared to 
Smn2B/+ controls at P5. Under normal circumstances, the post-synaptic 
endplate experiences a temporary decrease in area during postnatal 
synapse elimination and therefore, there may be a delay in this process in 
Smn2B/- mice and as a result they appear to have larger endplates than 
controls (Marques et al. 2000).  
 
Since many believe that developmental delays may contribute to the 
pathogenesis of SMA, the observations from this study are potentially very 
interesting (Hausmanowa-Petrusewicz & Vrbová 2005). 
 
3.3.4 A role for P53 in synaptic withdrawal in SMA 
 
During the temporal analysis of pathology within the motor unit it was noted 
that the up-regulation of transcripts involved in the P53 signalling pathway 
coincides with the early onset of NMJ pathology in the Smn2B/- mouse model 
of SMA. Although this was in the whole spinal cord and not within motor 
neurons specifically, it is in keeping with results from other studies that show, 
using laser capture microdissection techniques, that these transcriptional 
changes occurred in motor neurons specifically at pre-symptomatic time 
points (Murray et al. 2015; Simon et al. 2017; Nichterwitz et al. 2018). This 
therefore led to the investigation into what role P53 plays on motor unit 
pathology and whether P53 was responsible for the degeneration of the 
NMJ. 
 
Chapter 3 111	  
When P53 was reduced in the Smn2B/- mouse model, no difference in MNCB 
number was observed. This is in contrast to recent reports from Simon et. al. 
showing a reduction in both denervation and MNCB loss when P53 
expression was reduced in the SmnΔ7 mouse model of SMA (Simon et al. 
2017). However, it is consistent with reports from Tsai et. al. who also found 
that there was no significant improvement in their tiawanese SMA mouse 
model when P53 was knocked out (Tsai et al. 2006b). These three studies all 
show varying results however, they are difficult to compare due to 
experimental differences that exist between them, notably, the mouse 
models and methods of P53 reduction that are used. For example, Simon et. 
al. used the SmnΔ7 mouse model, which has a shorter lifespan in 
comparison to the Smn2B/- mouse model. Therefore, if there are 
compensatory mechanisms of cell death that could be initiated when P53 is 
reduced, it could be speculated that, even with treating this mouse model at 
P1, there is not sufficient time for these to be initiated (Jacobs et al. 2006; 
Simon et al. 2017). In the study by Tsai et. al., P53 was knocked out from 
conception and therefore, it mat be possible that this allows suffiecient time 
for compensatory mechanisms to be recruited and as a result lead to the 
continued loss of motor neurons (Jacobs et al. 2006; Tsai et al. 2006b). In 
the case of the Smn2B/- mouse model, there is an extended life span giving 
the same effects as that seen by Tsai et. al. (Tsai et al. 2006b).  
 
However, our findings do show that reducing P53 in the Smn2B/- mouse 
model of SMA decreases denervation. This implies that P53 plays an 
important role in moderating the withdrawal of the pre-synaptic terminal in 
motor neuron degeneration. It is speculated that there may be a 
compartment specific requirement for P53 in motor neuron degeneration. 
The 40% reduction in P53 mRNA levels obtained in the Smn2B/- mouse 
model may not prevent the loss of MNCBs but could be sufficient to 
ameliorate the loss of synaptic connections of those motor neurons that 
remain. Furthermore, P53 is located within the synapse and is involved in the 
regulation of genes associated with synaptic function (Gilman et al. 2003; 
Chapter 3 112	  
Merlo et al. 2014). Moreover, it has been reported that P53 plays a major role 
in pre-synaptic degeneration following activation of apoptosis (Gilman et al. 
2003). It has also been shown that the apoptotic cascade can be involved in 
localised axon degeneration, for example axonal pruning that is important 
during development, which does not lead to overall neuronal death (Cusack 
et al. 2013; Geden & Deshmukh 2016). It is reported that axon pruning 
involves the expression of Bax and the release of cytochrome c from the 
mitochondria, two events that are well known for their role in apoptosis 
(Geden & Deshmukh 2016). Perhaps surprisingly, due to its well-known role 
as an executor of apoptosis, caspase-3 is also activated during axonal 
pruning (Cusack et al. 2013; Geden & Deshmukh 2016). It is believed that 
although caspase-3 is activated ubiquitously within the neuron, its role is 
regulated within the various compartments of the cell, ensuring selective 
degeneration of the axon, by the proteasome system (Cusack et al. 2013). 
 
3.3.5 Dissociation of P53 and its downstream regulators 
 
Upon investigating the reduction in P53 within the Smn2B/-;P53-/- mouse 
model it was found that, despite the reduction in P53 expression, 
downstream targets of P53 did not decrease. Based on this result it is 
perhaps possible that upon the reduction of P53, other transcriptional factors 
are able to compensate, initiating the expression of these downstream 
targets and ultimately causing motor neuron cell death. From work 
investigating development in P53-/- mice, it has been suggested that family 
members of P53, P63 and P73, could compensate for a lack of P53 during 
development (Jacobs et al. 2006). Interestingly, PMAIP1, also known as 
NOXA, is thought to lie downstream of and be activated by P73, as well as 
P53 (Roos & Kaina 2006; Ploner et al. 2008). PMAIP1 has also been shown 
to be up-regulated in P53-/- mice following γ-irradiation, demonstrating that its 
activation can indeed occur independently of P53 (Fei et al. 2002; Ploner et 
al. 2008). Furthermore, Cdkn1A, often referred to as p21, has been up-
regulated, by over expression of the cell cycle checkpoint and tumour 
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suppressor gene Chk2 kinase, in tumour cells that are P53-deficient. 
Suggesting that Cdkn1A can also be regulated by other transcriptional 
factors, and not solely by P53 (Aliouat-Denis et al. 2005). 
 
However, it is thought that when DNA damage occurs, that these 
compensatory pathways are less sensitive to DNA damage than P53 (Merritt 
et al. 1997). When low levels of DNA damage were induced, via radiation, 
these pathways were not initiated (Merritt et al. 1997). Furthermore, some 
studies have shown that loss of P53 only has a temporary effect and that 
there is a delayed, P53-independent mechanism of cell death that can be 
initiated (Merritt et al. 1997). This is consistent with the finding that inhibition 
of PCD delays but does not prevent neurodegeneration (Kostic et al. 1997; Li 
et al. 2000; Gould et al. 2006). Therefore, it is perhaps possible that the 
effects that were observed in the Smn2B/-;P53-/- mouse model of SMA is a 
delayed onset of motor neuron death and/or synaptic withdrawal as 
compensatory mechanisms are employed. One possible way to investigate 
this would be to determine whether, when P53 is reduced, there is an 
increase in phosphorylated, and therefore activated, P73 and P63.  
 
This P53-independent mechanism of cell death is also thought to be tissue 
specific as while some tissues in P53-/- mice are resistant to radiation 
induced cell death, other are not (Merritt et al. 1997). Fei et. al. have shown 
that P53-independent, up-regulation of PMAIP1 is tissue specific (Fei et al. 
2002). They report that while PMAIP1 was up-regulated in the thymus, 
following γ-irradiation, it was not up-regulated in the spleen. Interestingly, our 
lab has recently begun investigating P53 in non-neuronal tissues of the 
Smn2B/- mouse model of SMA. In contrast to the spinal cord, where a, 
perhaps unexpected, sustained increase in transcripts involved in the P53 
signalling pathway was observed, it was found that in the liver of Smn2B/-
;P53-/- mice, these transcripts of interest returned to a level that was not 
significantly different from Smn2B/+ controls  (Murray Laboratory, Unpublished 
data). This finding shows that there may be differences in the control of cell 
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death in different tissues, which could potentially contribute to the selective 
vulnerability of neurons compared to other non-neuronal tissues in SMA.  
 
It is perhaps due to this sustained increase in these transcripts that an overall 
improvement in the MNCB loss and phenotype of this mouse model was not 
seen. Inhibiting other members of the P53 family, specifically P73, may be 




The temporal analysis of motor unit pathology that was performed has 
clarified an important issue in the field and the idea that motor neuron 
degeneration in SMA occurs in a distal to proximal manner can now be 
confirmed. Furthermore, the role that P53 plays in motor neuron 
degeneration has been addressed. Although the reduction in P53 was only 
confirmed at the mRNA level and not at the level of the functional protein, 
this reduction was still able to prevent, or delay, the withdrawal of the pre-
synaptic terminal. Due to the complex nature, the degree of overlap and the 
possibility of compensatory mechanisms that appears to occur in cellular 
death, it is acknowledged that untangling this pathway and its role in SMA 
may be difficult and require further work.  
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Chapter 4 
 
Investigating compensatory sprouting of motor neurons in 





In this chapter, I aimed to investigate whether compensatory sprouting could 
be responsible for the differential vulnerability of muscles in the Smn2B/- 
mouse model of SMA. NMJ morphology and sprouting in a muscle that 
displays vast denervation (Triangularis Sterni [TS]) is compared to a muscle 
that displays lower levels of denervation (Levator Auris Longus [LALr]), in the 
Smn2B/- mouse model of SMA. In terms of NMJ morphology, pre-synaptic 
terminal swelling and post-synaptic endplate occupancy and area are 
assessed and in terms of sprouting, both nodal and terminal sprouting are 
quantified. 
 
In addition, Schaefer et. al. previously reported that, in a mouse model of 
ALS, there were two populations of motor units (refer to Figure 1.1 for motor 
unit description); one that was small compared to controls and another that 
was significantly larger than controls (Schaefer et al. 2005). They suggest 
that these small motor units have been degenerating and the large motor 
units have been compensating for this by sprouting. Therefore, I also aimed 
to examine the synchronicity of pathology within motor units and investigate 
whether there were compensatory subpopulations of motor neurons in 
Smn2B/- mice. It is reasoned that if some, ‘healthy’, motor neurons were 
compensating for degenerating motor neurons by sprouting, then pathology 
would be synchronous within motor units; some would have severe 
pathology while others would appear normal and healthy. In order to assess 
individual motor units, the Thy1-YFP-H transgene is crossed onto the Smn2B/- 
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mouse model of SMA. Motor units within the LALr muscle were reconstructed 
and various features of pathology within each motor unit were assessed. 
 
This chapter begins with the assessment of the YFP expression pattern in 
different muscles of mice of different ages. Based on this analysis a 
description of the usefulness and limitations of this model for our purposes is 
provided. Reports that YFP is not biologically inert are also considered by 
assessing the effect that YFP has on motor units of the Smn2B/- mouse model 
of SMA.  
 
The results that are detailed in the following chapter show that: 
 
1. Thy1-YFP-H expression is age dependent and varies between 
muscles. 
2. Thy1-YFP-H expression does not have an adverse effect on NMJ 
pathology in the Smn2B/- mouse model of SMA. 
3. The TS muscle displays vast denervation and pre-synaptic swelling as 
well as smaller post synaptic endplates. 
4. The LALr muscle displays little denervation but does exhibit pre-
synaptic swelling and smaller post-synaptic endplates. 
5. Sprouting is ongoing in both the TS and LALr muscles but the level of 
sprouting in the LALr cannot account for the significant decrease in 
denervation observed within this muscle. 
6. Pathologically divergent subpopulations of motor units are not 
observed in the LALr of the Smn2B/- mouse model of SMA. 
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4.1 Introduction 
 
In SMA, the NMJ is targeted early in the disease progression (See Chapter 
3; Murray et al. 2008). Under normal, non-pathological conditions, when NMJ 
degeneration, and resulting muscle fiber denervation occurs, neighboring 
motor neurons sprout, sending out new axonal branches, in order to re-
innervate the muscle fiber (Slack et al. 1983). Sprouting has been shown to 
occur in mouse models and patients of SMA (Crawford & Pardo 1996; 
Murray et al. 2012). Sprouting was observed in the Smn2B/- mouse model of 
SMA and although it was shown that the rate of axon growth was unaffected 
by a reduction in Smn in this mouse model, the level of paralysis induced 
sprouting was decreased (Murray et al. 2012). In patients, EMG results from 
those with milder forms of SMA suggest that they have large motor units that 
are indicative of sprouting while those with severe SMA show EMG results 
that suggest ongoing denervation rather than sprouting (Crawford & Pardo 
1996). This could suggest that sprouting is a disease modifier in SMA.  
 
In 1950, Hoffman described two different types of sprouting; terminal and 
nodal (Hoffman 1950). Terminal sprouts extend from the pre-synaptic 
terminal of an innervated NMJ whereas nodal, or collateral, sprouts extend 
from the internodes of axons (Figure 4.1) (Hoffman 1950; Slack et al. 1979). 
It is unclear how these different types of sprouts are initiated as terminal 
sprouting can occur independently of nodal sprouting (Slack et al. 1979; 
English 2003). Inactivity of a muscle, which is induced by botulinum toxin, 
does not appear to induce nodal sprouting but does induce terminal 
sprouting (Slack et al. 1979). Therefore, it is thought that while terminal 
sprouting is induced by factors released from the muscle following inactivity, 
nodal sprouting is induced by the degeneration of the motor neuron (Slack et 
al. 1983).   
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These neurotrophic factors that induce sprouting do so by initiating the 
creation of Schwann cell bridges, from innervating motor neurons, that 
extend towards denervated endplates and eventually carry within them new 
axonal branches (Gordon et al. 2004). Neurotrophic factors include CNTF, 
GDNF and IGF, which are released from the Schwann cells, neuron and 
muscle respectively (English 2003). Although IGF is reported as being 
released from the muscle it is interesting that increased IGF2 expression in 
motor neurons correlates with neuroprotection (Allodi et al. 2016). This study 
found that in oculomotor neurons, which are resistant to degeneration in 
ALS, IGF2 levels were increased in both patients and the SOD1G39A mouse 
model (Allodi et al. 2016). Further to this, IGF2 was up-regulated in motor 
neurons that supply muscles with decreased susceptibility to denervation in 
the Smn2B/- mouse model of SMA (Murray et al. 2015). This finding 
suggested that sprouting could be a phenotypic modifier of differentially 
vulnerable muscles in SMA. It is possible that, in those muscles that appear 
to be less susceptible to degeneration of motor neurons, an increased level 
of compensatory sprouting means that on-going denervation is masked. In 
contrast, in those muscles that show vast denervation, the level of sprouting 
occurring is not sufficient to mask denervation.  
Figure 4.1: Motor neurons sprouting can take to form of either terminal or 
nodal sprouting. (A) The blue arrow in the schematic highlights a terminal sprout, 
which extends from the synaptic terminal of a motor neuron to re-innervate a vacant 
neighboring endplate. (B) The purple arrow in the schematic shows a nodal sprout, 
also known as a collateral sprout, which extends from the internode of a motor axon 
to re-innervate a vacant neighboring endplate. 
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In ALS, it has also been reported that while some motor neurons degenerate 
others compensate for this by sprouting and as a result enlarging (Schaefer 
et al. 2005). Schaefer et. al. presented different models for how motor units 
could be altered during the disease progression in their ALS mouse model 
(Figure 4.2). One suggestion is that there are compensatory subpopulations 
of motor neurons that sprout while others degenerate (Figure 4.2A). The 
other was that motor units contain both a mixture of degeneration and 
compensatory sprouting (Figure 4.2B). Based on their results, that showed 
that sprouting and degeneration did not occur within the same motor unit, 
they concluded that in their ALS mouse model there were compensatory 
subpopulations of motor neurons (ie Figure 4.2A) (Schaefer et al. 2005). It is 
unknown is whether this phenomenon is exclusive to ALS or whether it is 




Figure 4.2: There are different 
suggestions for how 
compensatory sprouting of 
motor neurons could occur 
following denervation in MNDs. 
(A) The schematic shows the 
method of compensatory 
sprouting that Schaefer et. al. 
believe occurs during motor 
neuron degeneration in ALS. One 
motor unit enlarges following 
sprouting to compensate for the 
degeneration of another motor 
unit. (B) The schematic shows an 
alternative model in which motor 
units all show signs of both 
denervation and sprouting. 
Adapted from Schaefer et. al., 
2005. 
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To investigate motor unit synchronicity, Schaefer et. al. utilised the Thy1-
YFP-H transgene (Feng et al. 2000; Schaefer et al. 2005). Expression of this 
transgene results in in a subset of motor neurons exhibiting cytoplasmic 
expression of yellow fluorescent protein (YFP), which is a variant of green 
fluorescent protein (GFP) that was originally isolated and cloned from the 
jellyfish, Aequorea victoria (Feng et al. 2000). In this case, YFP expression is 
under the control of the Thy1 gene (Feng et al. 2000). Thy1 is normally 
expressed in a variety of neuronal and non-neuronal cells, however by 
deleting a specific intron within this gene it was found that expression of this 
gene became almost exclusively neuronal (Vidal et al. 1990; Kelley et al. 
1994). Thy1 expression is also developmentally regulated and as a result 
YFP expression is known to increase postnatally (Feng et al. 2000). During 
the creation of this transgene, many mouse embryos were transfected with 
the Thy1-YFP vector and the insertion point of this vector within the genome 
was random in each embryo. The different insertion sites resulted in a 
different YFP expression pattern within 8 mouse lines (Feng et al. 2000). 
Specifically, the Thy1-YFP-H mouse line expresses YFP in only a few of their 
motor neurons allowing the visualisation of individual motor neurons within a 
muscle (Feng et al. 2000).  
 
Both YFP and GFP have been reported as being inert proteins that had no 
adverse effect when expressed in vivo (Okabe et al. 1997; Feng et al. 2000). 
However, others have disputed this belief (Huang et al. 2000; Comley et al. 
2011). Expression of GFP within the hearts of mice was shown to increase 
the likelihood of a cardiomyopathy (Huang et al. 2000). Comley et. al. 
reported that YFP expression was associated with increased expression of 
transcripts associated with cell stress in the spinal cords of Thy1-YFP-16 
mice (Comley et al. 2011). They also reported that there was abnormal 
neurofilament accumulation (NFA) present in YFP expressing motor axons of 
2-4 month old Thy1-YFP-H mice. 
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Therefore, to consider this uncertainty in the toxicity of YFP, it is worth 
assessing the effects of this transgene and its expression when using YFP 
as an experimental tool.  
 
The Thy1-YFP-H transgene, was utilised to examine motor unit pathology in 
the Smn2B/- mouse model. I aimed to examine motor units in the Smn2B/2B and 
Smn+/- mouse models, which have reduced Smn but are asymptomatic, in the 
subsequent chapter of this thesis (Bowerman et al. 2012a; Simon et al., 
2010). Therefore, this chapter begins with the assessment of YFP expression 
in various muscles of mice of different ages. Whether carrying the Thy1-YFP-
H transgene and expressing YFP in motor neurons has an adverse effect on 
the pathology of the NMJ, in terms of NFA, was also assessed in the Smn2B/- 
mouse model of SMA. In addition, the possibility that expressing YFP can 
cause increased stress in motor neurons of the Smn2B/- mouse model of SMA 
is addressed. 
 
Secondly, I question whether sprouting can account for the decreased 
amount of denervation in muscles that are less susceptible to degeneration 
of motor neurons. This is investigated by comparing NMJ morphology and 
sprouting in a muscle that displays vast denervation to a muscle that displays 
lower levels of denervation, in the Smn2B/- mouse model of SMA. 
 
Thirdly, I examine the synchronicity of pathology within motor units by tracing 
individual motor units in the LALr muscle of Smn2B/- mice and mapping NMJ 
pathology across the motor unit. I look to determine whether pathology is 
synchronous across motor units and whether there are divergent populations 
of motor neurons in the Smn2B/- mouse model of SMA, with some displaying 
severe pathology whilst others display no or mild pathology.  
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4.2 Results 
 
4.2.1 Characterisation of the Thy1-YFP-H gene  
4.2.1.1 Crossing of the Thy1-YFP-H gene onto the Smn2B/- mouse model of 
SMA 
 
In order to investigate whether compensatory motor units are present within 
the Smn2B/- mouse model of SMA, the Thy1-YFP-H transgene (referred to as 
YFP-H hereafter) was crossed onto this mouse model. This transgene results 
in the expression of Yellow Fluorescent Protein (YFP) in the cytoplasm of a 
random subset of motor neurons (Feng et al. 2000). Due to this expression 
pattern of YFP, individual motor units are visible and potentially traceable 
within muscles (Schaefer et al. 2005; Murray et al. 2008). 
 
The YFP-H transgene was crossed onto the Smn2B/- mouse model by initially 
breeding Smn2B/+ and Smn+/- mice with Smn+/+;YFP-H mice (strain: 003782, 
Jackson Laboratories) (Figure 4.3). Smn2B/2B;YFP-H and Smn+/-;YFP-H mice 
were selected to cross together and obtain Smn2B/-;YFP-H mice; an SMA 
mouse model that expresses YFP in an apparently random subset of motor 
neurons.  
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Figure 4.3: The YFP-H transgene was crossed onto mouse models that 
express various levels of Smn protein. The schematic shows the process of 
crossing the YFP-H transgene onto various mouse models of interest. Smn+/+;YFP-
H mice were originally obtained from Jackson Laboratories. These were crossed 
with Smn2B/+ mice, which had been established within our laboratory, to produce 
Smn2B/+;YFP-H (left side of the schematic). Subsequently, Smn2B/+;YFP-H mice 
were bred to obtain Smn2B/2B;YFP-H mice.  In addition, Smn+/+;YFP-H mice were 
also crossed with Smn+/- mice to produce Smn+/-;YFP-H mice (right side of the 
schematic). Finally, Smn2B/2B;YFP-H and Smn+/-;YFP-H mice were crossed to 
produce Smn2B/-;YFP-H mice. The red boxes highlight the mice with desirable 
genotypes, either in terms of subsequent breeding or for tissue analysis. 
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4.2.1.2 Characterisation of YFP-H  
 
YFP-H expression patterns vary in mice of different ages and between 
muscles 
 
Previous work has shown that the level of YFP-H expression can vary with 
age and between muscles (Feng et al. 2000). Therefore, as I aimed to 
examine individual motor units in various muscles from mice of various ages, 
I sought to determine the level of YFP-H expression in the different muscles 
that I had aimed to use for motor unit analysis, and the impact that age has 
on expression. 
 
I aimed to examine motor units from differentially vulnerable muscles, in the 
Smn2B/- mouse model at P18 as well as examining motor units in the 
Smn2B/2B and Smn+/- mouse models, which have reduced Smn but are 
asymptomatic, in the subsequent chapter of this thesis (Bowerman et al. 
2012a; Simon et al. 2010). These asymptomatic mouse models would be 
examined at aged time points, including 3 months, 6 months and 1 year, to 
determine whether compensatory sprouting had been employed to mask 
degeneration (please refer to Chapter 5 for background) (Simon et al. 2010). 
Therefore, to determine how aging affects YFP-H expression, the number of 
muscles that expressed YFP, within cranial musculature, in Smn+/+;YFP-H 
mice at 3 months, 6 months and 1 year of age was quantified. It was found 
that in all four cranial muscles YFP-H expression increased with age. An 
increase in the percentage of muscles that had YFP positive axons was 
observed at 6 months compared to 3 months and a subsequent increase at 1 
year of age. (Table 4.1). Of the four cranial muscles, the LALr had the 
greatest YFP expression. At 3 months, 50% of LALr muscles had positive 
YFP axons and this increased to 100% of LALr muscles examined 
expressing YFP. In contrast, no AS muscles at 3 months and 6 months 
expressed YFP and only 50% of the AS muscles examined at 1 year of age 
expressed YFP. 
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In addition, the number of YFP positive axons entering a muscle increased 
with age (Table 4.1). For example, in the LALr, there were an average of 3 
YFP positive axons entering the muscle at 3 months of age, while there was 
an average of 4.75 at 6 months and an average of 9 YFP positive axons 
entering the muscle at 1 year of age. 
 
To trace individual motor units, muscles should ideally express YFP in only 
one or two motor units. This allows the axon of the motor unit to be followed 
and all of its NMJs to be assessed. If the muscle contains two or more YFP 
expressing motor units, untangling the pattern of these to determine what 
branches and NMJs belong to each motor unit becomes more difficult (Figure 
4.4). Where two motor units are expressed, varying intensities of YFP 
expression can often allow the two motor units to be separated from each 
other (Murray et al. 2008). 
 
 
Table 4.1: YFP expression increases with age in Smn+/+;YFP-H 
Muscle Percentage of positive muscles (%) 
Number of axonal inputs in YFP 
positive muscles 
 3 months 6 months 1 year 3 months 6 months 1 year 
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Figure 4.4: A high number of YFP expressing axons entering a muscle means 
individual axonal inputs are untraceable. Images show an axonal bundle 
entering a muscle in the top right corner. Due to the high number of YFP-expressing 
axonal inputs entering the muscle it is no possible to trace and follow individual 
motor units and determine what motor unit individual NMJs belong to. Scale bar 
=150µm. 
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In the cranial musculature of P18 Smn2B/- mice, there were no YFP positive 
AS and AAL muscles from 13 Smn2B/- mice and only one YFP positive LALc 
(3.8%). The LALr showed increased YFP expression, with 11/28 muscles 
(39.3%) positive for YFP expressing motor neurons.  
 
Upon comparing the expression of YFP in the LALr of Smn2B/- to the level of 
YFP expression in the LALr of Smn2B/+ mice, it was found that there was a 
decrease in the percentage of LALr muscle that were positive for YFP in 
Smn2B/- mice compared to Smn2B/+. While 53.8% (14/26) of LALr muscle from 
Smn2B/+ mice were YFP positive, only 39.3% (11/28) of LALr muscles from 
Smn2B/- mice were positive for YFP. This may suggest that there is a 
decrease in expression when Smn is reduced. 
 
In the TVA of the abdominal musculature, there was no YFP expression 
throughout this investigation. As a vulnerable muscle that is thin and 
expresses YFP was desirable for whole motor unit analysis, the triangularis 
sterni (TS) muscle was also examined for YFP expression. This is a thoracic 
muscle that lies deep to the ribs but in close proximity to the TVA muscle. 
There was also no evidence of YFP expression in the TS muscle of Smn2B/- 
mice at P18.  
 
From this analysis, it can be concluded that YFP expression in Smn+/+;YFP-H 
mice does increase with age. Younger Smn+/+;YFP-H mice have fewer YFP 
positive motor axons, within a particular muscle, than older Smn+/+;YFP-H  
mice. This was true for all four of the cranial muscles that were assessed. 
YFP expression also differed between muscles with some muscles exhibiting 
many YFP positive motor axons while others had no YFP positive motor 
axons. It was found that individual motor units are traceable in the LALr 
muscle of the Smn2B/- mouse model but not in the TVA muscle or in the 
thoracic TS muscle. In older mice, motor units are untraceable due to either 
there being a lack of YFP expression at that age or an increase in the 
number of YFP positive axonal inputs entering the muscle. 
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YFP-H expression does not adversely affect motor unit pathology in Smn2B/- 
mice 
 
Comley et. al. previously reported that YFP expression could induce cell 
stress (Comley et al. 2011). They reported that genes involved in cell stress 
are up-regulated in spinal cords of YFP-16 mice and that YFP expression 
caused abnormal NFA. Therefore, I aimed to investigate whether the 
introduction of the YFP-H transgene had any impact on the motor neurons in 
Smn2B/- mice.  
	   
Firstly, I sought to determine whether carrying the YFP-H transgene affected 
NFA at the NMJ in the Smn2B/- mouse model of SMA. NFA in the TVA muscle 
of P18 Smn2B/- and Smn2B/-;YFP-H mice was quantified. This was an ideal 
muscle to use due to the absence of YFP expression. Therefore, whether 
simply carrying the YFP-H transgene affects NFA at the pre-synaptic terminal 
could be determined, excluding the possibility that expressing YFP within a 
motor unit affects NFA. TVA muscles from Smn2B/- and Smn2B/-;YFP-H mice 
were stained for neurofilament (NF) and the level of NFA was quantified from 
‘none’ to ‘severe’. It was found that there was no significant difference in the 
level of NFA in the TVA muscle of Smn2B/-;YFP-H mice compared to Smn2B/- 
mice (Figure 4.5). This suggests that carrying the YFP-H transgene does not 
alter NFA at the pre-synaptic terminals of Smn2B/- mice. 
 
Secondly, I aimed to address whether expressing YFP within a motor neuron 
could impact upon the NFA observed at its NMJ. To do so, cranial 
musculature was used due to the increased likelihood of YFP expression. 
Although these muscles are known to have relatively low levels of 
denervation, they still show pathology in their motor units (Figure 4.9; Murray 
et al. 2012). Cranial muscles that were positive for YFP expression were 
immunostained for NF. NFA at pre-synaptic terminals was staged from ‘none’ 
to ‘severe’, before determining whether the terminal belonged to a non-YFP 
expressing motor neuron or to a YFP-expressing motor neuron. 
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Quantification showed that there is a small but significant decrease in the 
level of moderate NFA at the pre-synaptic terminals of YFP-expressing motor 
neurons compared to motor neurons that do not express YFP (Figure 4.6B). 
Although all other severities showed no significant change, there is a trend 
for an increase in the percentage of YFP-expressing pre-synaptic terminals 
with no NFA. Overall, this data suggests that expressing YFP does not 
increase the severity of NFA, and there may be a slight reduction in NFA in 
YFP positive pre-synaptic terminals. This small but significant change in NFA 
in YFP-expressing motor neurons should still be considered when using 
YFP-H mice in further investigations. This is contrary to what may have been 
expected as YFP was thought to have an adverse effect on motor neurons 
(Comley et al. 2011). It may be possible that motor units that express YFP 
are those that are less affected by the neuromuscular pathology observed in 
SMA mouse models therefore appearing as if YFP expression have a 
positive effect on pathology. 
 
Endplate area of YFP positive and YFP negative NMJs was also quantified. 
Again, endplate area was measured before determining whether or not it was 
associated with a YFP positive or a YFP negative motor neurons. There was 
no significant difference in the area of post-synaptic endplates of YFP 
positive motor neurons compared to YFP negative motor neurons (Figure 
4.6C).  
  




Figure 4.5: Carrying the YFP-H transgene does not affect the severity of NFA 
in the Smn2B/- mouse model of SMA at P18. (A) Representative images of pre-
synaptic terminals in the TVA of Smn2B/- and Smn2B/-;YFP-H mice. Note the red 
arrowheads highlight moderate NFA and yellow arrowheads highlight mild NFA. 
Scale bar = 10µm. (B) Bar chart (Mean±SEM) compares the severity of NFA in 
Smn2B/- mice compared to Smn2B/-;YFP-H mice. There is no significant difference in 
the severity of NFA between the two mouse models (by Mann Whitney-U Test, 
ns>0.05, n=3 mice per genotype). Data acquired in collaboration with Shilpa 
Purushotham (MSc student). 
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Figure 4.6: Expressing YFP does not have an adverse effect on the NMJ in 
Smn2B/- mice at P18. (A) Representative image of NMJs in the LALr of Smn2B/-
;YFP-H mice. Note that the green arrows highlight the NMJ of a motor neuron that 
expresses YFP and the red arrow highlights the NMJ of a motor neuron that does 
not express YFP. Grey scale images are the separate channels of the image; top is 
NF, middle is YFP, bottom is BTX. Scale bar = 20µm. (B) Bar chart (Mean±SEM) 
compares the severity of NFA at pre-synaptic terminals in the LALr of Smn2B/-;YFP-
H mice. There is a small but significant decrease in the percentage of NMJs with 
moderate NFA in YFP positive motor neurons (by Mann Whitney-U Test, ns>0.05, 
*p<0.05; n=3 mice per genotype). (C) The graph (Mean±SEM) shows that there is 
no significant difference in the area of post-synaptic endplates that are supplied by 
motor neurons that express YFP and motor neurons that do not express YFP (by 
Unpaired T-test, ns>0.05; n= 4 mice per genotype). Data acquired in collaboration 
with Shilpa Purushotham (MSc student). 
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Thirdly, I wished to examine whether expressing YFP impacts on cellular 
stress of Smn2B/-;YFP-H motor neurons. This was done by quantifying and 
comparing the intensity of phosphorylated H2AX (pH2AX) in MNCBs that 
expressed YFP and MNCBs that did not. H2AX is a protein that is recruited 
to and phosphorylated at sites of DNA damage and so an increase in pH2AX 
may be attributed to an increase in cell stress (Fulda et al. 2010). Sections of 
spinal cord from P18 Smn2B/-; YFP-H mice were stained for pH2AX. Images 
of MNCBs that were YFP positive and YFP negative were taken and the 
intensity of pH2AX staining in each was subsequently measured. The 
intensity of pH2AX was compared (Figure 4.7) and showed no significant 
difference between MNCBs that expressed YFP and MNCBs that did not. 
Therefore, expressing the YFP-H transgene does not cause an increase in 
the levels of pH2AX, suggesting no increased stress on motor neurons 
expressing YFP. 
 
Overall, carrying the YFP-H transgene and expressing YFP in motor neurons 
does not have an adverse effect on the pathology of the NMJ in the Smn2B/- 
mouse model of SMA. In addition, expressing YFP does not cause increased 
stress, as evidenced by no change in the level of pH2AX, in motor neurons in 
the Smn2B/- mouse model of SMA. 
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Figure 4.7: Expressing YFP does increase the levels of pH2AX in motor 
neurons from Smn2B/- mice at P18. (A) Representative images of MNCBs in the 
ventral horn of the thoracic region of the spinal cord of an Smn2B/-;YFP-H mouse. 
The green arrow highlights a MNCB that expresses YFP and the red arrow 
highlights a MNCB that does not. Note that sections were stained with Nissl and 
although this was visible on the same channel as YFP, the intensity of YFP was 
substantially stronger. Scale bar = 20µm. (B) The graph (Mean±SEM) shows that 
there is no significant difference in the intensity of pH2AX staining in motor neurons 
that express YFP and motor neurons that do not express YFP (by Unpaired T-test, 
ns>0.05; n= 3 mice). (C) There is also no significant difference in the average 
intensity of pH2AX staining in motor neurons that express YFP and motor neurons 
that do not express YFP for each mouse (by Unpaired T-test, ns>0.05; n= 3 mice). 
Data acquired in collaboration with Shilpa Purushotham (MSc student). 
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4.2.2 Sprouting cannot account for a reduction in denervation in the 
LALr muscle of Smn2B/- mice 
 
Muscles of SMA mouse models fall on a spectrum of denervation; while 
some show high levels of denervation and pathology, others show 
considerably less (Thomson et al. 2012). I aimed to compare muscles of the 
Smn2B/- mouse model of SMA that show vast motor neuron degeneration to 
those that display considerably less, to address whether compensatory 
sprouting was responsible for this reduction in denervation. Both NMJ and 
motor unit morphology would be assessed in the LALr and TS muscles of the 
Smn2B/- mouse model to compare sprouting. 
 
Firstly, the level of denervation and pathology that occurs within the TS 
muscle of Smn2B/- mice had to be determined. This muscle was originally 
examined for YFP expression however its vulnerability status had never been 
determined in the Smn2B/- mouse model of SMA. Therefore endplate 
occupancy, pre-synaptic swelling and post-synaptic endplate area was 
quantified in Smn2B/- mice and Smn2B/+ controls at P18. It was found that 
there was a significant decrease in the percentage of fully occupied 
endplates, to an average of 31%, in the TS muscle of Smn2B/- mice when 
compared to controls (Figure 4.8). There was also a significant increase the 
severity of pre-synaptic swelling and a significant decrease in post-synaptic 
endplate area in the TS of Smn2B/- mice compared to controls (Figure 4.8). 
This muscle could therefore be classed as being vulnerable to degeneration.  
 
In addition, I wished to confirm the pathological status of the LALr muscle in 
Smn2B/- mice at P18 by endplate occupancy analysis as well as performing 
further NMJ morphological analysis, specifically, pre-synaptic swelling and 
endplate size analysis, within this muscle. As one of the cranial muscles, this 
muscle has been shown to be display lower levels of degeneration (Murray et 
al. 2015). This analysis showed that ~96% of endplates in the LALr muscle of 
Smn2B/- mice were fully occupied by a pre-synaptic terminal and so confirmed 
previous reports (Figure 4.9). In addition, despite this low level of 
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denervation, this muscle displays a significant increase in severity of the pre-
synaptic swelling observed in Smn2B/- mice compared to Smn2B/+ controls. 
There was also a significant decrease in endplate area in the LALr of Smn2B/- 
mice compared to Smn2B/+ controls (Figure 4.9). The pathology observed in 
the TS muscle was subsequently compared to pathology in the LALr muscle 
of P18 Smn2B/- mice (Figure 4.10). This showed that there was a significant 
decrease in the percentage of fully occupied endplates in the TS muscle 
compared to the LALr muscle of Smn2B/- mice and a significant increase in 
the severity of pre-synaptic swelling in the TS muscle compared to the LALr 
(Figure 4.10 A&B). There was no significant difference in the area of post-
synaptic endplates in the TS muscle compared to the LALr in Smn2B/- mice. 
There was also no significant difference in endplate occupancy, pre-synaptic 
swelling or endplates area in the TS muscle compared to the LALr of Smn2B/+ 
control mice (Figure 4.10). 
 
Following the investigation into degeneration in the TS and LALr muscles, I 
wished to investigate whether sprouting could account for the reduced levels 
of denervation that is observed in the LALr compared to the TS. Therefore, 
nodal and terminal sprouting in the TS and LALr muscles of Smn2B/- mice as 
well as Smn2B/+ control littermates was quantified. Nodal sprouts extend from 
an axon while terminal sprouts extended from a presynaptic terminal. Nodal 
sprouts were classified based on their thin axonal appearance that differed 
from other axonal branches (Refer to Figure 4.11, 4.19 and 5.3). There was 
no significant difference in the percentage of both nodal and terminal 
sprouting between the TS and LALr muscles in Smn2B/- mice (Figure 4.11). 
As sprouting was observed, albeit a small amount, in both the TS and LALr, 
there is evidence that sprouting is masking some denervation in the LALr 
muscle. However, as there was no significant difference in the level of 
sprouting between the TS and LALr, sprouting cannot account for the 
significant difference in denervation that is observed between the TS and the 
LALr muscle in Smn2B/- mice at P18.  
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Figure 4.8: The TS muscle of Smn2B/- mice exhibits significant denervation 
and pre-synaptic swelling when compared to Smn2B/+ controls. (A) 
Representative images of NMJs in the TS muscle of Smn2B/- and Smn2B/+ mice. 
White arrowhead = normal NMJ with no swelling; blue arrowhead = NMJ with mild 
pre-synaptic swelling; green arrowhead = NMJ with moderate pre-synaptic swelling; 
yellow arrowhead = partially occupied endplate; red arrowhead = vacant endplate. 
Scale bar = 10µm. (B) The bar chart (Mean ± SEM) shows that there is a significant 
decrease in the percentage of fully occupied endplates and a significant increase in 
the percentage of partially occupied and vacant endplates in the TS of Smn2B/- mice 
compared to Smn2B/+ mice (by Mann Whitney-U test; *p<0.01; n=6 muscles per 
genotype). (C) The bar chart (Mean ± SEM) shows that there is a significant 
decrease in the percentage of NMJs with no pre-synaptic swelling and an increase 
in the percentage displaying mild and moderate pre-synaptic swelling in the TS of 
Smn2B/- mice compared to Smn2B/+ mice (by Mann Whitney-U test; ns>0.05, 
**p<0.01; n= 6 muscles per genotype). (D) The graph (Mean ± SEM) shows that 
there is a significant difference in the average post-synaptic endplate area of the TS 
in Smn2B/- mice when compared to the average endplate area of the TS of Smn2B/+ 
mice (by Unpaired t-test, ***p<0.005; n= 5/6 muscles for Smn2B/+/ Smn2B/- 
respectively). Data acquired in collaboration with Roxanna Munir during a MSc 
project.  
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Figure 4.9: The LALr muscle of Smn2B/- mice exhibits increased pre-synaptic 
swelling but shows no significant denervation compared to controls. (A) 
Representative images display the increase in pre-synaptic swelling observed in the 
LALr of Smn2B/- mice compared to controls (White arrow = no swelling, yellow arrow 
= moderate swelling of the pre-synaptic terminal). Although there is some 
denervation (red arrowhead highlights a vacant endplate) in the LALr of Smn2B/- 
mice, this is not significantly different to controls. Scale bar = 10µm. (B) The bar 
chart (Mean ± SEM) shows that there is no significant difference in the occupancy 
of endplates in the LALr of Smn2B/- mice compared to the LALr of Smn2B/+ controls 
(by Mann Whitney-U test; ns>0.05; n= 4 for Smn2B/+, 6 for Smn2B/-). (C) The bar 
chart (Mean ± SEM) shows that there is a significant decrease in the percentage of 
NMJs with no pre-synaptic swelling and an increase in the percentage displaying 
mild pre-synaptic swelling in the LALr of Smn2B/- mice compared to Smn2B/+ mice (by 
Mann Whitney-U test; ns>0.05, *p<0.05; n= 4 for Smn2B/+, 6 for Smn2B/-). (D) The 
graph (Mean ± SEM) shows that there no significant difference in the average post-
synaptic endplate area of the LALr in Smn2B/- mice when compared to the average 
endplate area of the LALr of Smn2B/+ mice (by Unpaired t-test, *p<0.05; n= 4 for 
Smn2B/+, 5 for Smn2B/-). 
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Figure 4.10: The TS muscle displays significantly more pathology than the 
LALr muscle in P18 Smn2B/- mice (A) The bar chart (Mean ± SEM) compares the 
occupancy of endplates in the LALr and the TS muscles for Smn2B/+ and Smn2B/- 
mice. In Smn2B/+ mice, there is no significant denervation in both the LALr and TS 
muscles. In Smn2B/- mice, there is a significant decrease in the percentage of fully 
occupied endplates and a significant increase in the percentage of partially 
occupied and vacant endplates in the TS muscle when compared to the LALr (by 
Mann Whitney-U test; ns>0.05, **p<0.01; n= 6 TS per genotype, 4 LALr for Smn2B/+, 
6 LALr for Smn2B/-). (B) The bar chart (Mean ± SEM) compares pre-synaptic 
swelling in the LALr and the TS muscles for Smn2B/+ and Smn2B/- mice. In Smn2B/+ 
mice, there is no significant swelling in both the LALr and TS muscles. In Smn2B/- 
mice, there is a significant decrease in the percentage of NMJs with no pre-synaptic 
swelling and a significant increase in the percentage of NMJs displaying mild and 
moderate pre-synaptic swelling in the TS muscle when compared to the LALr (by 
Mann Whitney-U test; ns>0.05, *p<0.05; n= 6 TS per genotype, 4 LALr for Smn2B/+, 
6 LALr for Smn2B/-).  (C) The graph (Mean ± SEM) compares post-synaptic endplate 
area in the LALr and the TS muscles for Smn2B/+ and Smn2B/- mice. In Smn2B/+ mice, 
there is no significant difference in the average endplate area of the LALr and TS 
muscles. In Smn2B/- mice, there is also no significant difference in endplate area 
between the LALr and TS muscles (by Unpaired t-test, ns>0.05, *p<0.05, 
***p<0.005; n= 5 TS for Smn2B/+, 6 TS for Smn2B/-, 4 LALr for Smn2B/+, 5 LALr for 
Smn2B/-). Data acquired in collaboration with Roxanna Munir during a MSc project. 
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Figure 4.11: There is no significant difference in sprouting between the TS 
and LALr muscles in P18 Smn2B/- mice (A) Images show NMJs from the LALr 
muscle and TS muscle and highlight examples of sprouting. The arrowheads show 
terminal sprouts extending from the pre-synaptic terminal of an NMJ. Grey scale 
images show the separate channels of the images. The small image at the bottom 
left of each large image is the axons labelled with NF/SV2 and the small image at 
the bottom right of each large image is the endplate labelled with BTX. Scale bar = 
20µm. (B) The bar chart (Mean ± SEM) compares the percentage of nodal and 
terminal sprouts in the LALr and the TS muscles for Smn2B/+ and Smn2B/- mice. In 
both Smn2B/+ and Smn2B/- mice there is no significant difference in the level of 
sprouting observed in the TS muscle when compared to the LALr (by Mann 
Whitney-U test; ns>0.05; n= 6 TS per genotype, 4 LALr for Smn2B/+, 6 LALr for 
Smn2B/-) (C) The graph shows the percentage of terminal and nodal sprouts in each 
muscle. These bars have been pulled out from the graph in (B) in order to show the 
low percentage in more detail. Data acquired in collaboration with Roxanna Munir 
during a MSc project. 
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4.2.3 Motor unit reconstructions show that pathology is asynchronous 
in motor units of the LALr muscle in Smn2B/- mice 
 
Schaefer et. al. proposed that in a mouse model of ALS, there are 
subpopulations of large motor neurons that have sprouted to compensate for 
the degeneration of other small motor neurons (Schaefer et al. 2005). In 
addition, they show that degenerating axons and axonal sprouts are rarely 
found in the same motor unit. Therefore, in this mouse model, it appears that 
‘healthy’ motor neurons are compensating for degenerating motor neurons 
by sprouting. If this is the case then it could be proposed that pathological 
features of NMJs, such as denervation, pre-synaptic swelling and endplate 
shrinkage will be restricted to subsets of motor neurons.  
 
In order to address whether there are compensatory subpopulations of motor 
neurons the Smn2B/-;YFP-H mouse model was utilised. Prior to the 
examination of YFP expression, I had aimed to trace and assess individual 
motor neurons within a variety of differentially vulnerable muscles within this 
mouse model. However, due to the YFP expression in this mouse model, 
only motor neurons within in the LALr muscle were traceable. Entire motor 
units in this muscle were individually imaged, reconstructed and traced 
(Figure 4.12). From the trace of the motor unit a tree diagram was created, to 
show the structure and branching pattern of the motor unit (Figure 4.12C). 
The morphology (including endplate occupancy, pre-synaptic swelling, 
endplate size and maturation and sprouting) of each individual NMJ in the 6 
motor units that were traceable was assessed. NMJs were only quantified if 
they were clearly visible and in the correct orientation to ensure consistency 
of measurements. 
 
In 3 of the 6 motor units that were assessed, there was evidence of 
denervation (Figure 4.13 & Figure 4.14). In one of these motor units, 2 out of 
19 (10.5%) NMJs had partially occupied endplates. In the other two motor 
units, there were retraction bulbs, as evidenced by branches that did not 
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supply an endplate and had a bulbous end, suggesting the withdrawal of this 
axon from the NMJ. It must be noted that quantifying vacant endplates was 
not possible within Smn2B/-;YFP-H mice (whose muscles have not been 
stained to label all axons) as YFP expression is within only a subset of motor 
neurons. Therefore, endplates that appear vacant in YFP-H mice are not 
necessarily vacant and may be supplied by another, non-YFP expressing 
motor neuron. It is therefore possible that there is an undercounting of 
denervation. However, the average percentage of fully occupied endplates 
for the 6 motor units combined is 95.15%, which is in keeping with whole 
muscle occupancy analysis of the LALr, which shows that ~96% of endplates 
are fully occupied in the LALr of Smn2B/- mice (Whole muscle average from 
Figure 4.7; also displayed in Figure 4.14).  
 
For future analysis of motor unit pathology, the 6 motor units were 
categorised based on their denervation status; those that contained signs of 
denervation and those that did not. All endplates in motor units 1-3 were fully 
occupied and so these motor units therefore fell into the ‘non-denervated’ 
category. Motor units 4 and 6 contained retraction bulbs while motor unit 5 
had partially occupied endplates. Therefore, these three motor units fell into 
the ‘denervated’ category. By doing this, motor unit pathology between non-
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Figure 4.12: YFP allows individual motor neurons to be traced. (A) A montage 
of a motor unit was created by stitching together images taken, on a fluorescent 
microscope, at x20 magnification in Adobe Photoshop. Scale bar =300µm. (B) The 
montage was traced in Adobe Photoshop to show the layout of the motor unit as a 
single line drawing. (C) Tree diagrams were created from the line drawing of the 
motor unit, showing the branching pattern and assigning a number to individual 
NMJs within the motor unit. This allowed various features of these NMJs to be 
assessed. 





   
Figure 4.13: Features of denervation were visible using YFP expression in 
motor neurons (A) Representative image of a NMJ that has a partially occupied 
post-synaptic endplate (on the left). (B) Image shows an NMJ that had a partially 
occupied endplate. Note the unusual appearance of this pre-synaptic terminal. (C) 
Representative image of a retraction bulb visualised using YFP. Note the bulbus 
end of the axon as it withdraws away from a post-synaptic endplate. Scale bar (for 
all) = 10µm. 
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Figure 4.14: Denervation was visible in 50% of LALr motor units analysed in 
Smn2B/-;YFP-H mice. (A) Example of a tree diagram showing the occupancy 
endplates in motor unit 5. One of these tree diagrams was created for all 6 motor 
units analysed. By colour coding full and partial occupancy pathology across the 
entire motor unit can be visualised. (B) Bar chart stacks the percentage of fully and 
partially occupied endplates as well as the percentage of retraction bulbs in each of 
the 6 motor units assessed. In 2 of the 6 motor units there were retraction bulbs and 
in 1 of the 6 motor units there was partial occupancy of endplates. The percentage 
of occupancy for the entire muscle is shown on the left of the bar chart (Mean ± 
SEM, n= 6 muscles). 
Chapter 4 147	  
I wished to determine whether pre-synaptic swelling was synchronous 
throughout motor units within the LALr of Smn2B/-;YFP-H mice. Therefore, 
pre-synaptic swelling was quantified in each of the motor units (Figure 4.15 & 
Figure 4.16). It was observed that the overall percentage of NMJs with no, 
mild, moderate and severe swelling varied between motor units and within 
each of the motor units there was evidence of NMJs with and without 
swelling. In addition, the NMJs that had evidence of swelling were scattered 
throughout the motor unit rather than being confined to one area (Figure 
4.16). As a result, it appears that with regards to pre-synaptic swelling there 
are not bimodal populations of motor neurons in the LALr of Smn2B/-;YFP-H 
mice.  
 
Previously in this thesis, it was found that the percentage of NMJs with no 
pre-synaptic swelling for the muscle as a whole is approximately 69.3% 
(Figure 4.9). When the average percentage of NMJs displaying no pre-
synaptic swelling for the six motor units assessed is combined, 52.4% of 
NMJs displayed no pre-synaptic swelling. Due to the use of different pre-
synaptic terminal markers, this data should not be directly compared. 
However, the difference in pre-synaptic swelling between NF/SV2 stained 
and YFP expressing motor units may suggest that the latter display more 
severe pre-synaptic swelling than the whole muscle average. 
 
Additionally, the percentage of NMJs with no, mild, moderate and severe pre-
synaptic swelling was compared between non-denervated and denervated 
motor units (Figure 4.16C). This showed that there was no significant 
difference in the percentage of each of these categories between non-
denervated and denervated motor units.  
 
Subsequently, the area of endplates within each motor unit was measured 
(Figure 4.15). To observe the spread of endplate area across a motor unit 
tree endplate size was categorised into groups; 1-100𝜇m, 101-200𝜇m, 201-
300𝜇m and 301-400𝜇m. Collating this data into a bar shows that motor units 
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contain endplates of a variety of different sizes, with the most common 
categories being 101-200𝜇m and 201-300𝜇m (Figure 4.17 A&B). The area of 
the individual endplate measured within each motor unit was also plotted, 
alongside the area of endplates measured within the whole of the LALr 
(Figure 4.17C). From this, it appears that the endplate area within these 
motor units is relatively consistent with the spread of endplate areas 
observed within the muscle as a whole. There does not appear to be 
divergent subpopulations of motor neurons, when considering endplate area.  
 
Furthermore, the area of endplates for non-denervated and denervated 
motor units was collated. This shows that the spread of endplate area 
between denervated and non-denervated endplates was comparable and not 
significantly different (Figure 4.17D). In addition, the average endplate area 
for non-denervated and denervated motor units was also not statistically 
different (Figure 4.17E). This therefore shows that post-synaptic endplate 
area is not based upon the denervation status of the motor unit.  
 
The maturity of endplates within the motor units was also staged to 
determine whether this was synchronous across motor units in the LALr of 
Smn2B/-;YFP-H mice. Stage 1 denotes the most mature endplates and stage 
4 denotes the least mature. It was found that most endplates expressed 
stage 2 or 3 maturity (Figure 4.18). Two of the six motor units contained 
stage 4 endplates and one of these motor units also contained stage 1, 
immature endplates. This therefore shows that the maturity of endplates 
within motor units can vary. Motor units were again categorised into 
denervated or non-denervated and this showed that although there was no 
statistical difference in the maturity of endplates within these groups of motor 
units, there was greater variability in the maturity of endplates in denervated 
motor units (Figure 4.16C). 
 
I wished to determine whether there are subpopulations of motor units that 
sprout to compensate for the degeneration of other motor units. Therefore, 
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sprouting was assessed within the motor units of the LALr of Smn2B/-;YFP-H 
mice. Micro-sprouts, nodal sprouts and terminal sprouts were quantified. 
Micro-sprouting was a feature only observed in YFP expressing motor 
neurons, it had not previously seen in motor neurons stained using 
immunofluorescent techniques, and appeared as a ‘speckling’ of YFP that 
extended from the pre-synaptic terminal (Figure 4.19). While some motor 
units expressed a large degree of sprouting, others showed no evidence of 
sprouting (Figure 4.20B). Although not all motor units containing denervation 
expressed high levels of sprouting, motor unit 5 was of particular interest due 
to its high degree of pathology (although it still expressed variability in 
pathology throughout) and high degree of sprouting activity. This is contrary 
to the original hypothesis, which stated that denervation and sprouting occurs 
in different motor units. Micro-sprouting was still observed in one of the motor 
units that did not contain any denervation but no terminal or nodal sprouting 
was found in non-denervated motor units (Figure 4.20B). 
 
The level of sprouting in these motor units was compared with the average 
level of sprouting observed in the LALr as a whole (Figure 4.20B). The 
average percentage of nodal and terminal sprouts in the whole muscle was 
~6% whilst the average for the six motor units was ~9%, suggesting that 
these motor units are comparable to the muscle as a whole.  
 
Moreover, by collating the data for motor units 1-3 (non-denervated) and 
motor units 4-6 (denervated), sprouting between non-denervated and 
denervated motor units was compared. Although there is no statistical 
significance in sprouting between these two groups, there does appear to be 
a trend towards an increase in sprouting within denervated motor units 
(Figure 4.20C).   
 
Overall, it appears that pathology is asynchronous within a motor unit and it 
does not appear that there are pathologically divergent populations of motor 
neurons. It does not appear that apparently ‘healthier’ motor units are 
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sprouting to mask the degeneration of other motor units and in fact, motor 
units with greater pathology may exhibit greater levels of sprouting. In 
addition, it should be considered that sprouting is a motor neuron dependent 
activity since the muscle environment of these motor neurons is consistent 
yet the sprouting observed is not consistent across all motor units. 
 
Figure 4.15: Pre-synaptic swelling can be observed in motor neurons 
expressing YFP. Representative image of non, mild, moderate and severe pre-
synaptic swelling in motor neurons expressing YFP. (A) No pre-synaptic swelling: 
Pre-synaptic terminal and axon have a uniform expression of YFP. (B) Mild pre-
synaptic swelling: YFP expression is increased at the terminal. (C) Moderate pre-
synaptic swelling: YFP expression is increased at the terminal and there is some 
axonal swelling. (D) Severe pre-synaptic swelling: Pre-synaptic swelling is 
increased and obscures the endplate. Scale bar (for all images) = 10µm. 
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Figure 4.16: Pre-synaptic swelling severity is not synchronous within motor 
units of Smn2B/-;YFP-H mice. (A) The tree diagram shows the severity of pre-
synaptic swelling at each NMJ of motor unit 2. One of these tree diagrams was 
created for each of the 6 motor units analysed. By colour coding each stage of pre-
synaptic swelling pathology across the entire motor unit can be visually inspected. 
It appears that pathology is asynchronous within the motor unit and is not clustered 
in one location. (B) Bar chart stacks the percentage of pre-synaptic terminals with 
no, mild, moderate and severe swelling in motor units 1-6. It appears that the level 
of swelling varies across each of the motor units assessed. The average pre-
synaptic swelling appearance for the muscle is shown at the left of the bar chart 
(mean ±SEM, n= 6 muscles). (C) When the percentage of no, mild moderate and 
severe swelling is collated for motor units displaying no denervation and 
denervation, there is no statistically significant difference between the two groups in 
terms of the severity of swelling. Note the trend towards an increase in severity in 
motor units displaying denervation. (ns>0.05 by Mann Whitney U test; n= 3 motor 
units) 
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Figure 4.17: The area of post-synaptic endplates varies throughout a motor 
units of Smn2B/-;YFP-H mice. (A) Example of a tree diagram showing the endplate 
area of NMJs in motor unit 2. One of these tree diagrams was created for each of 
the 6 motor units analysed. By categorising the area measured into groups and 
colour coding each group (1-100𝜇m (red), 101-200𝜇m (yellow), 201-300𝜇m 
(orange) and 301-400𝜇m (green)), the area of endplates across the entire motor 
unit could be visualised. It appears that endplate size varies throughout the motor 
unit and smaller endplates are not clustered in one location.  (B) Bar chart stacks 
the percentage of endplates with and area of 1-100𝜇m, 101-200𝜇m, 201-300𝜇m or 
301-400𝜇m in motor units 1-6. It appears that the area of endplates varies across 
each of the motor units assessed, but the most common size categories are 101-
200𝜇m and 201-300𝜇m. (C) The graph (Mean ± SEM) shows the area of each 
individual endplate within motor units 1-6. The average for the LALr is shown at the 
left of the graph. Note that the area of endplate across the six motor units appear 
consistent with the area of endplates across the whole LALr muscle in Smn2B/- mice 
(ns>0.05 by Unpaired t-test; n= 3 motor units; muscle average = n of 5 muscles) (D) 
The area of endplates for motor units displaying no denervation and denervation is 
comparable and not statistically significant between the two groups (by Unpaired t-
test, ns>0.05; n= 34/52 endplates for non-denervated/ denervated motor units) (E) 
The average endplate area of motor units displaying no denervation and 
denervation was also not significantly different (by Unpaired t-test, ns>0.05; n= 3 
motor units). 
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Figure 4.18: Endplate maturation varies within motor units of Smn2B/-;YFP-H 
mice. (A) The tree diagram shows the stage of maturation of each post-synaptic 
endplate of motor unit 2 (least mature (stage 1) to most mature (stage 4)). One of 
these tree diagrams was created for each of the 6 motor units analysed. By colour 
coding each stage of maturation the pathology across the entire motor unit can be 
visualised. It appears that pathology is asynchronous within the motor unit and is 
not clustered in one location. Most pre-synaptic endplates were stage 2 or 3 
maturity. (B) Bar chart stacks the percentage of endplates displaying stage 1 to 4 
endplate maturity in motor units 1-6. The level of maturation appears to vary across 
each of the motor units assessed. (C) When the percentage of stage 1-4 endplate 
maturation is collated for motor units displaying no denervation and denervation, 
there is no statistically significant difference between the two groups (ns>0.05 by 
Mann Whitney U test; n= 3 motor units). However, it is interesting that non-
denervated motor units consistently display stage 2 and 3 maturity while motor units 
that do have on going denervation have more variability with these motor units also 
showing endplates with stage 1 and stage 4 maturity. 





Figure 4.19: Sprouting can be observed in motor neurons expressing YFP. (A) 
Representative image of a nodal sprout extending from an axon (highlighted using 
yellow arrowheads placed along its length). (B) Representative image showing a 
terminal sprout extending from the pre-synaptic terminal of the NMJ. (C) 
Representative image showing micro-sprouting, a feature that has only been 
observed through YFP expression. Scale bar (for all images) = 10µm. 
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Figure 4.20: Sprouting appears to be motor neuron dependent in Smn2B/-;YFP-
H mice. (A) Example of a tree diagram showing sprouting at NMJs in motor unit 5. 
One of these tree diagrams was created for all 6 motor units analysed. By colour 
coding the different types of sprouts sprouting across the entire motor unit can be 
visualised. (B) Bar chart stacks the percentage NMJs that show either micro-, 
nodal or terminal sprouts in the 6 motor units assessed. There was sprouting 
apparent in 3 of the 6 motor units, however, this did not correlate with the 3 motor 
units that expressed denervation. At the left of the bar chart is the average 
percentage of nodal and terminal sprouting for the LALr in the Smn2B/- mouse 
model. Note that this displays only nodal and terminal sprouting and not micro-
sprouts. (C) When the percentage of micro-, nodal and terminal sprouts is collated 
for motor units displaying no denervation and denervation, there is no statistically 
significant difference between the two groups. However, there does appear to be a 
trend towards there being more sprouting in motor units displaying denervation. 
(ns>0.05 by Mann Whitney U test; n= 3 motor units) 
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4.3 Discussion 
 
4.3.1 Overview of Results 
 
In this chapter, the uses and limitations of YFP-H, for the purposes of this 
experiment, were defined. The original aim was to examine the morphology 
of individual motor units in differentially vulnerable muscles and various 
mouse models. These mouse models included the Smn2B/- mouse model of 
SMA, at the late symptomatic time point of P18, as well as mouse models 
that have reduced Smn but are asymptomatic, at a variety of time points 
ranging from 3 months to 1 year of age (Bowerman et al. 2012a; Simon et al. 
2010). Therefore, YFP expression in differentially vulnerable muscles of the 
Smn2B/-;YFP-H mouse model at P18 and the Smn+/+;YFP-H mice, at 3 
months, 6 months and 1 year of age was evaluated. This showed that YFP 
expression increases with age, with an increase in the percentage of YFP 
expressing muscle as well as an increase in the average number of YFP 
positive axons entering individual muscles. It was also found that YFP 
expression varied between different muscles as no YFP expression was 
observed within the TVA muscle at any age and there was variability in the 
expression pattern between the different cranial muscles. This increase in 
expression over time and variability between muscles is consistent with 
previous reports (Feng et al. 2000).  
 
Furthermore, previous reports that YFP is not biologically inert were 
considered. The effect of YFP on motor units of the Smn2B/- mouse model of 
SMA was examined. Quantifying pathology at the NMJ in motor neurons that 
were YFP negative in the Smn2B/-;YFP-H mouse model, and comparing this 
with pathology in Smn2B/- mice, showed that carrying the YFP-H transgene 
did not have an adverse effect on the motor unit. In addition, NMJ pathology 
in motor neurons that expressed YFP and in motor neurons that did not 
express YFP was compared. This showed that YFP expression within a 
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motor neuron had no adverse effect on the pathology that was observed. 
Moreover, motor neurons that are positive for YFP do not appear to be 
excessively stressed when compared to those that were negative for YFP 
expression in the spinal cord of Smn2B/-;YFP-H mice, as evidenced by the 
lack of a significant change in  pH2AX expression.   
 
In this chapter, I subsequently investigated whether compensatory sprouting 
masks denervation in apparently resistant muscles and contributes to the 
observed phenomenon of differentially vulnerable muscles in the Smn2B/- 
mouse model of SMA. By comparing NMJ morphology and sprouting in a 
muscle that displays vast denervation (TS) to a muscle that displays lower 
levels of denervation (LALr), in the Smn2B/- mouse model of SMA, it was 
shown that, despite evidence of sprouting in both muscles, the level of 
sprouting observed could not account for the significant difference in 
denervation. 
 
In addition, by tracing and analysing individual motor units in the LALr muscle 
of the Smn2B/-;YFP-H mouse model, it was found that varying levels of 
pathology can occur within a single motor unit. Pathologically divergent 
subpopulations of motor neurons were not observed and therefore, it does 
not appear that apparently ‘healthier’ motor units are sprouting to mask the 
degeneration of other motor units. 
 
4.3.2 Assessing YFP expression and its effects on the motor unit 
 
The expression of Thy1, and as a result the expression of YFP, is reportedly 
developmentally regulated and increases with age (Feng et al. 2000; Porrero 
et al. 2010). The findings that are presented above support this, as it is 
shown that as mice age there is an increased incidence of muscles 
expressing YFP. For example, while no YFP positive axons were observed in 
the AS muscle at 3 and 6 months of age in Smn+/+;YFP-H mice, 50% of AS 
muscles from 1 year old Smn+/+ mice were positive for YFP.  
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This finding may lead to the assumption that in order to increase the chance 
of obtaining muscles that are positive for YFP expression, for motor unit 
tracing, older mice should be used, wherever possible, for the collection of 
tissue. However, it was also found during this analysis that as age increases 
the average number of motor neurons expressing YFP in a single muscle 
also increases and determining what axons belong to which motor unit 
becomes increasingly difficult. Often, if there are two YFP positive motor 
neurons within the muscle, varying intensities of YFP expression within these 
motor neurons can allow them to be separated from each other (Murray et al. 
2008). However, in the case of the AS muscle from 1 year old Smn+/+ mice, in 
which there was an average of ~10 axons entering the muscle, it becomes 
impossible to trace a single motor neuron. I originally wished to examine 
motor units in older, asymptomatic mice however, the increase in the 
average number of YFP positive axons entering a muscle hindered the 
tracing of individual motor units at older time points.  
 
In addition, differential expression of YFP within muscles of mice carrying the 
YFP-H transgene was observed. Within the cranial musculature, while the 
only evidence of YFP expression in the AS was in Smn+/+;YFP-H mice at 1 
year of age, there was evidence of YFP expression in the LALr muscle at all 
of the ages examined, including in P18 Smn2B/-;YFP-H and Smn2B/+;YFP-H 
mice. YFP was not observed within the abdominal TVA muscle of YFP-H 
mice at any of the ages assessed. This is in-keeping with findings from 
Thomson et. al. who excluded the TVA muscle from their analysis due to 
poor YFP expression in ~22 week old YFP-H mice (Thomson et al. 2012). 
YFP is reportedly expressed in a random subset of motor neurons in YFP-H 
mice however, these findings appear to suggest otherwise (Feng et al. 2000). 
Ideally, motor units would have been examined in a variety of differentially 
vulnerable muscles but due to the lack of expression within these 
differentially vulnerable muscles this was not possible. Despite being limited 
to the LALr muscle due to YFP expression, the lesser degree of pathology 
and denervation of the LALr muscle actually makes it ideal to perform motor 
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unit analysis. Muscles with vast denervation would have fewer motor units 
available and therefore be less informative when looking to determine the 
pattern of pathology within individual motor units. 
 
As I wished to examine pathology within these YFP expressing motor units, 
the effects of the YFP-H transgene and its expression on the motor unit of 
the Smn2B/- mouse model of SMA were considered. The insertion site of the 
YFP transgene within the genome varies between the various YFP lines 
(Feng et al. 2000). This is due to the insertion site being completely random 
upon transfection of the embryo with the Thy1-YFP vector and this is thought 
to play a part in altering the expression pattern of the different YFP mouse 
lines (Feng et al. 2000). The insertion site of the transgene is often unknown 
however, it is known that sometimes this random insertion can disrupt other 
genes impacting on phenotype (Yong et al. 2015; Kolossovski 2017). As it 
had been reported that there was NFA in YFP-H and YFP-16 mice, NFA was 
investigated in the Smn2B/-;YFP-H mouse model. This investigation began by 
addressing whether simply carrying the YFP-H transgene affected NMJ 
pathology in the Smn2B/-;YFP-H mouse model. To do so, a muscle that did 
not exhibit any YFP expression (TVA muscle) was used to exclude the 
possibility that the visible expression of YFP within the motor neuron causes 
increased abnormal NFA. This analysis showed that Smn2B/-;YFP-H mice did 
not exhibit an increase in the severity of NFA compared to Smn2B/- mice. 
Therefore, it is believed that carrying the YFP transgene at its current 
insertion site does not adversely affect NFA at the pre-synaptic terminal in 
the Smn2B/- mouse model of SMA. 
 
Whether foreign fluorescent proteins are biologically inert is debated topic. 
GFP, a well-known spectral variant of YFP, has been simultaneously 
expressed in various tissues within mouse models and has shown no toxic 
effects (Okabe et al. 1997). However, GFP has also been reported to 
increase apoptosis of cultures cells as well as increase the risk of cardiac 
defect in mice that express GFP exclusively within the heart (Huang et al. 
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2000).  Similarly, YFP has been was thought to be biologically inert in Thy1-
YFP mouse lines, displaying no morphological changes in synaptic structure, 
yet Comley et. al. report that YFP expression within the motor neuron leads 
to an increase in abnormal NFA at their pre-synaptic terminals (Feng et al. 
2000; Comley et al. 2011). In this study, no increase in abnormal NFA was 
found in YFP expressing motor neurons of Smn2B/-;YFP-H mice. In fact, there 
was a trend towards pre-synaptic terminals of YFP positive motor neurons 
displaying less severe NFA. These results may suggest that there is a slight 
reduction in NFA in YFP positive pre-synaptic terminals.  
 
Comely et. al. also reported that YFP expression can increase cellular stress 
in motor neurons of these mouse models (Feng et al. 2000; Comley et al. 
2011). In our study, there was no increase in the intensity of pH2AX staining 
in the cell bodies of YFP positive motor neurons compared to YFP negative 
motor neurons, in Smn2B/-;YFP-H mice. As this protein is recruited to sites of 
DNA damage and DNA damage is a common feature of cellular stress, it 
does not appear that motor neurons expressing YFP in the Smn2B/-;YFP-H 
mouse model at P18 are experiencing excess cellular stress (Fulda et al. 
2010; Sharma et al. 2012). The lack of adverse effects from YFP expression 
in this analysis is likely due to a dose dependent effect of YFP (Comley et al. 
2011). The Smn2B/-;YFP-H mouse model has very low levels of YFP 
expression compared to that used by Comley et. al. and therefore, it is likely 
that YFP expression is below the threshold required for the onset of adverse 
effects.    
 
4.3.3 Sprouting cannot account for the reduction in denervation 
observed in the LALr muscle of Smn2B/- mouse model of SMA  
 
In this chapter, I aimed to investigate whether neuronal sprouting is a 
phenotypic modifier in SMA. In patients of SMA, sprouting is thought to occur 
in those with milder forms of the disease but not in those with very severe 
SMA (Crawford & Pardo 1996). In mouse models, there are reported 
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differences in the quantity of terminal and nodal sprouting that is observed in 
muscles that are differentially vulnerable to degeneration (Murray et al. 
2012). Therefore, the possibility that compensatory sprouting could be 
masking any ongoing denervation, resulting in these muscles displaying 
reduced levels of denervation, was addressed.  
 
The findings presented in this thesis suggest that sprouting does not account 
for the differences in denervation observed in various muscle of the Smn2B/- 
mouse model of SMA. A significant difference in the severity of pathology 
was observed between the TS and the LALr muscles, with the more 
vulnerable TS muscle displaying an increase in both denervation and pre-
synaptic swelling compared to the less vulnerable LALr muscle. However, 
despite rigorous quantification and analysis of sprouting in both of these 
muscles, there was no significant difference in the level of sprouting when 
they were compared. Therefore, it does not appear that increased sprouting 
is responsible for the reduction in denervation in the LALr.  
 
The level of sprouting that was observed in the LALr muscle is similar to what 
has previously been reported (Murray et al. 2012). Murray et. al. also 
quantified sprouting in the TVA muscle and had suggested that sprouting 
correlated with the vulnerability of the muscle. Muscles with increased 
denervation showed increased terminal sprouting and decreased nodal 
sprouting while those with less denervation showed decreased terminal 
sprouts and increased nodal sprouts (Murray et al. 2012). However, the 
findings presented in this thesis do not support this correlation between the 
differential vulnerability of muscle and the sprouting that is observed within 
them. Here, the TS and LALr show differential vulnerability yet have similar 
levels of both terminal and nodal sprouting. There are a many possible 
reasons for the variation in findings, including the difference in age at which 
this analysis was performed. 
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Furthermore, in the LALr of Smn2B/-;YFP-H mice, it did not appear that there 
were subpopulations of motor units compensating for the degeneration of 
others, as Schaefer et. al. had reported in their mouse model of ALS 
(Schaefer et al. 2005). Pathology was not restricted to only some motor 
neurons and rather it was variable within each motor unit. For example, 
motor neurons had NMJs that had no pre-synaptic swelling as well as NMJs 
that displayed very severe pre-synaptic swelling. Furthermore, sprouting did 
not appear to be regulated by the denervation status of the motor neuron. 
This may suggest that sprouting is a motor neuron dependent activity, as the 
muscle environment of these motor neurons is consistent yet the level of 
sprouting observed is not consistent across all motor units. It is known that 
following denervation muscles release proteins that are involved in initiating 
sprouting (English 2003). Perhaps upon denervation, motor neurons become 
more sensitised to these proteins and therefore sprouting is increased.  
 
Based on this data it is not believed that sprouting is responsible for the 
decreased denervation observed in the LALr muscle. Another possible 
reason for the decreased denervation that was observed could be that there 
is an increase in synaptic stability at the NMJs of this muscle. Many factors 
and pathways contribute to the stability of the synapse, including ubiquitin 
homeostasis and mitochondrial energy metabolism (Gillingwater & Wishart 
2013; Groen et al. 2018b). In motor neuron populations that are less 
vulnerable to degeneration, there is an increase in mitochondrial-related 
transcripts (Murray et al. 2015; Boyd & Gillingwater 2017). Increasing 
mitochondrial biogenesis in a zebrafish model of SMA had a beneficial effect 
on phenotype (Boyd & Gillingwater 2017). Furthermore, ubiquitination 
pathways are also implemented in SMA with a decrease in transcripts of 
ubiquitin-conjugating enzyme (Ube) observed in motor neuron populations 
that are vulnerable to degeneration (Murray et al. 2015). When the ubiquitin-
like modifier activating enzyme (Uba1) was systemically increased in a 
mouse model of SMA, it caused a marked improvement in the phenotype 
(Powis et al. 2016). The altered regulation of these pathways between 
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differentially vulnerable motor neuron populations provides evidence that 
increased NMJ stability may contribute to the reduced denervation observed 




In this chapter, I have shown that the expression of YFP in Smn+/+;YFP-H 
increases with age and shown that YFP expression varies between 
musculature. I subsequently discussed the limitations of this finding and how 
these impact on our uses for YFP-H. I found that carrying the YFP-H 
transgene and expressing YFP did not have an adverse effect on motor unit 
pathology in Smn2B/- mice. This is in contrast to previous reports addressing 
whether YFP is inert, and I conclude that this is due to the low dose of YFP 
within the Smn2B/-;YFP-H mouse model. 
 
Furthermore, by addressing motor neuron degeneration and sprouting in 
differentially vulnerable muscles I conclude that sprouting cannot account for 
the reduction in denervation in the LALr muscle of the Smn2B/- mouse model 
of SMA at P18, compared to the TS muscle. I also addressed how pathology 
occurs within individual motor units and provide some interesting data that 
may suggest that, in contrast to mouse model of ALS, there does not appear 
to be subpopulations of compensatory motor neurons in the Smn2B/- mouse 
model of SMA.  
Chapter 5 168	  
Chapter 5 
 
Investigating motor units of mouse model that have reduced 




In this chapter, I wished to investigate compensatory sprouting in 
asymptomatic mouse models that have reduced Smn expression. MNCB 
loss and compensatory sprouting have previously been reported in the 
Smn+/- mouse model, which has 50% of normal Smn. However, in Smn2B/2B 
mice, which have a further reduction in Smn, to approximately 30% of normal 
levels, there is no reported loss of MNCBs and there has been no 
investigation into sprouting. Therefore, to clarify this paradoxical data and to 
investigate compensatory sprouting in mouse models that have reduced Smn 
but are asymptomatic, analysis of both degenerative and regenerative 
processes, including NMJ morphological analysis and MNCB counts, was 
performed in Smn+/- and Smn2B/2B mouse models. 
 
 
The results that are detailed in the following chapter show that: 
 
1. In contrast to reports in the literature, there is no significant loss of 
MNCBs in the thoracic spinal cord of Smn+/- mice 
2. There is no significant degenerative or regenerative NMJ phenotype in 
Smn+/- mice 
3. In keeping with previous findings, there is no significant loss of 
MNCBs in the thoracic spinal cord of Smn2B/2B mice 
4. There is no significant degenerative or regenerative NMJ phenotype in 
Smn2B/2B mice 
 
Chapter 5 169	  
Although these results may appear to show no significant result, they in fact 
address the paradoxical data on MNCB loss in these asymptomatic mouse 
models with reduced Smn and suggest that there is no significant difference 
in the remodelling of the NMJ of these mouse models compared to controls.  
Chapter 5 170	  
5.1 Introduction 
 
The Smn+/- mouse model expresses approximately 50% of normal levels of 
Smn protein yet it does not develop any symptoms and remains 
phenotypically normal throughout its life span (Simon et al. 2010). It does not 
display any defects in splicing, which is common in symptomatic SMA mouse 
models, and shows no reduction in gems within the nucleus of motor neurons 
(Jablonka et al. 2000). However, it has been reported that Smn+/- mice do 
display a reduction in MNCBs, although, the extent of this loss appears to 
vary with the reported literature (Jablonka et al. 2000; Simon et al. 2010; 
Bowerman et al. 2014; Udina et al. 2017). While one study reports a 54% 
loss of MNCBs at 1 year old, another reports a 19% loss at the same age 
compared to controls (Jablonka et al. 2000; Udina et al. 2017). Additionally, it 
has been reported that there is in fact no significant loss of MNCBs from this 
mouse model compared to controls at 1 year (Bowerman et al. 2014). 
 
Simon et. al. reported that the lack of an abnormal motor phenotype in the 
Smn+/- mouse model despite the reduction in MNCB number, is due to 
increased axonal sprouting of motor neurons. They report that there is an 
increase in the average single motor unit action potential (SMUAP) as well as 
increased axonal branching within the gastrocnemius muscle in the Smn+/- 
mouse model when compared to Smn+/+ mice. They also investigate the role 
of ciliary neurotrophic factor (CNTF), a neurotrophic factor released from 
Schwann cells in response to denervation, in sprouting within Smn+/- mice 
(English 2003; Simon et al. 2010). Simon et. al. show that knocking out 
CNTF in the Smn+/- mouse model has an adverse effect on the level of 
sprouting in the gastrocnemius muscle and the grip strength of this mouse 
model and as a result attribute the increased sprouting to CNTF (Simon et al. 
2010). However, it has also been shown that knocking out CNTF in Smn+/+ 
mice has an adverse effect on MNCB number and grip strength (Masu et al. 
1993). 
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The Smn2B/2B mouse model has a further reduction in Smn protein 
expression when compared to Smn+/- mice. It has approximately 30% of 
normal Smn levels and, like Smn+/- mice, does not display any abnormal 
motor phenotype (Bowerman et al. 2012a). In contrast to Smn+/- mice, it has 
been reported that in the Smn2B/2B mouse model there is no reduction in 
MNCBs in the lumbar spinal cord, when compared to Smn+/+ controls 
(Bowerman et al. 2012a). This is perhaps surprising due to the further 
reduction in Smn protein within this mouse model when compared to the 
Smn+/- mouse model.  
 
However, the lack of MNCB loss in this mouse model does not necessarily 
mean that there cannot be ongoing remodeling, including withdrawal and 
sprouting, occurring at the level of the NMJ. It has been shown in this thesis, 
that these compartments of the motor neuron can be altered independently.  
This finding is corroborated by literature that reports that synapses can be 
regulated without cell body involvement (Bettini et al. 2007). 
 
Therefore, I wished to not only clarify this paradoxical data regarding MNCB 
loss in Smn+/- and Smn2B/2B mice, but also investigate ongoing degeneration 
and regeneration within motor units of these mouse models to determine 
whether a reduction of Smn causes increased motor unit remodeling.  
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5.2 Results 
 
5.2.1 There is no significant degenerative or regenerative phenotype in 
motor units of Smn+/- mice 
 
I wished to confirm previous findings that there is a loss of MNCBs from the 
spinal cord, in 1 year old Smn+/- mice, and that subsequent compensatory   
sprouting is responsible for masking a phenotype (Simon et al. 2010).  
Therefore, the number of MNCB in the ventral horn of the spinal cord of 1 
year old Smn+/- and Smn+/+ mice was counted. Sections of spinal cord 
segments T8-T12 were stained for Nissl and with DAPI and, in every 10th 
section, the number of MNCBs within the ventral horn was counted. This 
analysis showed that there was no significant difference in the number of 
MNCBs between Smn+/- and Smn+/+ mice at 1 year of age (Figure 5.1). 
 
Despite a lack of alterations at the level of the MNCB, it is still possible that 
there is ongoing degeneration and regeneration at the level of the NMJ. 
Therefore, NMJ morphology within the Smn+/- mouse model was also 
analysed. Endplate occupancy, NFA and endplate area as well as nodal and 
terminal sprouting was quantified in the LALr muscle of 1 year old Smn+/- and 
Smn+/+ control mice. 
 
Denervation within the Smn+/- mouse model has previously been observed by 
Simon et. al., however no quantification data was provided in support of this 
observation (Simon et al. 2010). Quantification of denervation here found that 
there was no significant difference in the occupancy of post-synaptic 
endplates, with all endplates remaining fully occupied by the pre-synaptic 
terminal, in the LALr muscle of Smn+/- mice and Smn+/+ controls at 1 year old 
(Figure 5.2 & 5.4A). This suggests that there is no denervation occurring 
within this mouse model with reduced SMN. 
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There was also no significant difference in the severity of pre-synaptic NFA 
or in the area of post-synaptic endplates in Smn+/- mice when compared to 
Smn+/+ controls (Figure 5.2 & Figure 5.4). On average, 37% and 38% of 
NMJs for Smn+/-;YFP-H and Smn+/+;YFP-H mice, respectively, displayed 
‘mild’ NFA and therefore NFA was not significantly different (Figure 5.4B). 
This data suggests that there is no evidence of NMJ pathology or 
denervation in the LALr muscle of Smn+/- mice compared to Smn+/+ controls 
at 1 year old. 	  
 
In order to investigate the possibility that spouting could be masking 
denervation, the occurrence of distinct types of sprouts was quantified. 
Terminal and nodal sprouting was quantified in the LALr of Smn+/- and 
Smn+/+ mice at 1 year of age. There was no evidence of terminal or nodal 
sprouting in the LALr of Smn+/- and Smn+/+ mice at 1 year old (Figure 5.4D). 
As previous results suggested that some types of sprouting were more 
readily visualised when labelled with YFP compared to NF, sprouting was 
also quantified using YFP positive motor neurons in the cranial musculature 
(including LAL, AS and AAL) of Smn+/-;YFP-H mice and Smn+/+;YFP-H mice 
(Figure 5.3 & Figure 5.4E). YFP expressing terminal, nodal and micro-
sprouts were quantified. As before, terminal sprouts extend from a pre-
synaptic terminal while nodal sprouts extend from an axon and appear thin, 
compared to other axonal branches (Figure 5.3). Micro-sprouts appear as a 
‘speckling’ of YFP that extends from the pre-synaptic terminal and are not 
visible when staining for NF (Figure 5.3). Micro-sprouts were observed in 
both Smn+/-;YFP-H mice and Smn+/+;YFP-H mice and terminal and nodal 
sprouts in Smn+/+;YFP-H mice. However, the occurrence was very low, with 
incidence ranging from 0 - 7% of NMJs displaying sprouts within the cranial 
musculature. Therefore, although evidence of sprouting was noted, the 
prevalence was not increased in Smn+/-;YFP-H mice (Figure 5.3 & Figure 
5.4E). 
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Overall, no significant pathology was observed in the LALr of 1 year old 
Smn+/- mice when compared to Smn+/+ controls. There was also no 
significant increase in sprouting in the LALr of Smn+/- mice compared to 
Smn+/+ mice. This is in contrast to reports by Simon et. al. that increased 
sprouting of motor neurons is responsible for a lack of an SMA phenotype 
(Simon et al. 2010). Rather, the results presented here suggest that there is 
no loss of MNCB and no significant difference in remodelling of the NMJ 
compared to controls. 
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Figure 5.1: There is no significant difference in the number of MNCBs in 
Smn+/- mice compared to Smn+/+ mice at 1 year old. (A) Representative images 
of MNCBs in the ventral horn of the spinal cord of 1 year old Smn+/- and Smn+/+ 
mice. Greyscale images to the right show the separated channels; first and third 
images from the top are Nissl stained MNCBs and the second and forth images 
from the top are nuclei stained with DAPI. (Scale bar=30µm). (B) The graph (Mean 
± SEM) shows that there is no significant difference in the average number of 
MNCBs per transverse section, in the ventral horns of the spinal cord of 1 year old 
Smn+/- and Smn+/+ mice. (by Unpaired t-test, ns>0.05; n=4 mice per genotype) 
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Figure 5.2: There is no significant degenerative or regenerative NMJ 
phenotype observed in Smn+/- mice at 1 year old. Images show NMJs from the 
LALr of 1 year old Smn+/- and Smn+/+ mice. Note that there is no discernable 
difference between the two muscles in terms of degenerative or regenerative 
features. The arrowheads show examples of NMJs with no NFA (green) and mild 
NFA (yellow). Greyscale images to the right show the separated channels; axons 
(first and third image from the top) that were stained with NF and post-synaptic 
endplates (second and forth image from the top) that were stained with a 
fluorescent-conjugated bungarotoxin. (Scale bars = 10µm). 
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Figure 5.3: YFP positive NMJs of Smn+/- mice were examined for 
morphological alterations. Images show examples of features that were quantified 
using YFP. Pre-synaptic swelling: the pre-synaptic terminal appears to be swollen 
and obscuring the endplate. Terminal sprout: axon branched from the pre-synaptic 
terminal of a NMJ. Nodal sprout: branch extending from another axon. Micro-
sprouts: A ‘speckling’ of YFP that extends from the pre-synaptic terminal. (Scale 
bars = 10µm). 
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5.2.2 There is no significant degenerative or regenerative phenotype in 
motor units of Smn2B/2B mice 
 
 
The Smn2B/2B mouse model has a 70% reduction in Smn but, as with the 
Smn+/- mouse model, is asymptomatic (Bowerman et al. 2012a). No sprouting 
analysis has, to our knowledge, been performed in this mouse model and 
therefore the impact of a further reduction in Smn on this process has not 
been determined. However, due to the paradoxical reports that, despite a 
further reduction in Smn, this mouse does not display MNCB loss I wished to 
confirm this finding and further investigate motor unit pathology within this 
mouse model. 
 
 Figure 5.4: There is no significant degenerative or regenerative phenotype in 
the LALr muscle of Smn+/- mice at 1 year old compared to age matched 
Smn+/+ controls. (A) The bar chart (Mean ± SEM) shows that there is no significant 
denervation present in in the LALr muscle of Smn+/- and Smn+/+ mice at 1 year old 
as 100% of post-synaptic endplates were fully occupied (by Mann Whitney-U test; 
ns>0.05; n= 6 muscles per group). (B) The bar chart (Mean ± SEM) shows that 
there is no significant difference in pre-synaptic swelling between the LALr muscle 
of Smn+/- and Smn+/+ mice at 1 year old. There is evidence of mild pre-synaptic 
swelling however this was consistent in Smn+/- and Smn+/+ mice (by Mann Whitney-
U test; ns>0.05; n= 6 muscles per group). (C) The bar chart (Mean ± SEM) shows 
that there is no significant difference in the area of endplates in Smn+/- mice 
compared to Smn+/+ mice at 1 year old (by Unpaired t-test, ns>0.05; n=3 mice per 
group). (D) The bar chart (Mean ± SEM) shows that there was no significant 
sprouting observed in the LALr muscle of Smn+/- when compared to Smn+/+ mice at 
1 year old. All NMJs in both Smn+/- and Smn+/+ mice showed no evidence of 
sprouts associated with them (by Mann Whitney-U test, ns>0.05; n=6 muscles per 
group). (E) The bar chart (Mean ± SEM) shows that in 1 year old Smn+/;YFP-H- and 
Smn+/+;YFP-H mice micro-sprouts, nodal sprouts and terminal sprouts were 
observed as well as pre-synaptic swelling in YFP positive motor neurons in the 
cranial musculature. However, there was no significant difference in swelling, 
nodal, terminal and micro- sprouts in Smn+/-;YFP-H when compared to Smn+/+;YFP-
H mice (by Mann Whitney-U test; ns>0.05; n=5 mice per genotype). Note the small 
scale on the graphs meaning that these features are present in very small 
quantities. 
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Pilot data suggested that there was a subtle change in the area of the post-
synaptic endplates of 3 month old Smn2B/2B mice compared to Smn+/+ control 
mice. As a result, analysis was carried out in Smn2B/2B mice at 3 months of 
age. 
 
The number of MNCBs within the ventral horn of the spinal cord was 
investigated. The number of MNCB in segments T8-T12 of 3 month old 
Smn2B/2B mice was counted and compared to age matched Smn+/+ mice. 
Spinal cord sections were stained for Nissl and with DAPI. In keeping with 
findings from Bowerman et. al., it was found that there was no significant 
difference in the number of MNCBs between Smn2B/2B and Smn+/+ mice at 3 
months of age (Bowerman et al. 2012a).  
 
Again, no loss of MNCBs may not necessarily mean that there is no ongoing 
remodelling at the NMJ. Therefore, morphology of NMJs within the Smn2B/2B 
mouse model was analysed. As before, endplate occupancy, pre-synaptic 
swelling and endplate area as well as nodal and terminal sprouting were 
quantified. To increase the scope of this study, the NMJs of both the LALr 
and the TS muscles of Smn2B/2B and Smn+/+ mice were analysed, as they 
both show varying levels of denervation in the Smn2B/- mouse model of SMA 
(Figure 5.5).  
 
In the LALr muscle, there was no significant difference in endplate 
occupancy between Smn2B/2B and Smn+/+ mice, with all endplates fully 
occupied (Figure 5.6 & 5.7A). Pre-synaptic swelling was observed in both 
Smn2B/2B and Smn+/+ with 23% and 25% of NMJs displaying mild pre-synaptic 
swelling respectively, however this was not significantly different (Figure 
5.7B). There was also no significant difference in post-synaptic endplate size 
in the LALr of Smn2B/2B mice when compared to Smn+/+ mice (Figure 5.7C). 
This data suggests that there is no evidence of NMJ pathology or 
denervation in the LALr muscle of Smn2B/2B mice compared to Smn+/+ 
controls at 3 months old. 
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In addition, no evidence of terminal or nodal sprouting was found in the LALr 
of Smn2B/2B mice at 3 months of age (Figure 5.7D). Sprouting was also 
examined in Smn2B/2B;YFP-H mice, using the same criteria detailed for 
analysis in the LALr of Smn+/-;YFP-H mice, to ensure some types of sprouts 
that are more readily visible when labelled with YFP compared to NF were 
not overseen. Terminal, nodal and micro- sprouting in the cranial 
musculature (including LAL, AS and AAL) of 3 month old Smn2B/2B;YFP-H 
and Smn+/+;YFP-H mice was quantified. No terminal or nodal sprouting was 
observed in either Smn2B/2B;YFP-H or Smn+/+;YFP-H mice. Micro-sprouting 
was observed in Smn2B/2B;YFP-H mice however, the occurrence of this was 
very low, with incidence ranging from 0 – 9% of NMJs exhibiting sprouts 
within the cranial musculature, which was not significantly different to 
controls (Figure 5.7E).  
 
In the TS muscle, there was also no significant difference in endplate 
occupancy in Smn2B/2B mice when compared to Smn+/+, with all endplates 
fully occupied (Figure 5.6 & 5.8A). Again, pre-synaptic swelling was noted in 
the TS muscle of both Smn2B/2B and Smn+/+ mice, with 23% and 24% 
displaying mild pre-synaptic swelling respectively, but this was not 
significantly different (Figure 5.8B). There was also no significant difference 
in post-synaptic endplate size in the TS of Smn2B/2B mice when compared to 
Smn+/+ mice (Figure 5.8C). This data suggests that there is no evidence of 
NMJ pathology or denervation in the TS muscle of Smn2B/2B mice compared 
to Smn+/+ controls at 3 months old.  
 
In terms of sprouting, there was no evidence of terminal or nodal sprouting in 
the TS muscle of Smn2B/2B and Smn+/+ mice, and as a result there was no 
significant difference between Smn2B/2B and Smn+/+ mice (Figure 5.8D). 
 
Despite the suggestion from preliminary data that there may be 
morphological alterations at the NMJ of Smn2B/2B mice at 3 months, the in-
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depth study of NMJ morphology, in two different muscles of Smn2B/2B mice, 
revealed no increase in degeneration or regeneration, when compared to 
Smn+/+ mice. There was also no difference in the number of MNCBs in 
Smn2B/2B mice compared to Smn+/+ controls. As with Smn+/- mice it is still 
possible that ongoing denervation is being masked by sprouting, however 
based on the lack of significant sprouting observed within both the LALr and 
TS of Smn2B/2B mice it is not believed that the asymptomatic phenotype of 
this mouse model is due to increased sprouting. 
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Figure 5.5: There is no significant difference in the number of MNCBs in 
Smn2B/2B mice compared to Smn+/+ mice at 3 months old. (A) Representative 
images of MNCBs in the ventral horn of the spinal cord of 3 month old Smn2B/2B and 
Smn+/+ mice. Greyscale images to the right show the separated channels; first and 
third images from the top are Nissl stained MNCBs and the second and forth images 
from the top are nuclei stained with DAPI. (Scale bar =30µm). (B) The graph (Mean 
± SEM) shows that there is no significant the average number of MNCBs per 
transverse section, in the ventral horns of the spinal cord of 3 month old Smn2B/2B 
and Smn+/+ mice by Unpaired t-test, ns>0.05; n=3 mice per genotype). Data acquired 
in collaboration with Roxanna Munir (MScR student).  
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Figure 5.6: There is no significant degenerative or regenerative NMJ 
phenotype observed in Smn2B/2B mice. Images show NMJs from the LALr and TS 
of 3 month old Smn2B/2B mice. Note that there is no difference between the two 
muscles in terms of degenerative or regenerative features. Greyscale images show 
the separated channels; bottom left of each image shows axons stained for NF/SV2 
and bottom right of each image shows post-synaptic endplates stained with BTX. 
(Scale bar = 10µm). 
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Figure 5.7: There is no significant degenerative or regenerative phenotype in 
the LALr muscle of Smn2B/2B mice at 3 months old compared to age matched 
Smn+/+ controls. (A) The bar chart (Mean ± SEM) shows that there is no significant 
denervation present in in the LALr muscle of Smn2B/2B and Smn+/+ mice at 3 months 
old as 100% of post-synaptic endplates were fully occupied (by Mann Whitney-U 
test; ns>0.05; n= 6 muscles per group). (B) The bar chart (Mean ± SEM) shows that 
there is no significant difference in pre-synaptic swelling between the LALr muscle 
of Smn2B/2B and Smn+/+ mice at 3 months old. There is evidence of mild pre-synaptic 
swelling however this was consistent in Smn2B/2B and Smn+/+ mice (by Mann 
Whitney-U test; ns>0.05; n= 6 muscles per group). (C) The graph (Mean ± SEM) 
shows that there is no significant difference in the area of endplates in Smn2B/2B 
mice compared to Smn+/+ mice at 3 months old (by Unpaired t-test, ns>0.05; n=6 
muscles per group). (D) The bar chart (Mean ± SEM) shows that the bar chart 
shows that there was no significant sprouting observed in the LALr muscle of 
Smn2B/2B when compared to Smn+/+ mice at 3 months old. All NMJs in both Smn2B/2B 
and Smn+/+ mice showed no evidence of sprouts associated with them (by Mann 
Whitney-U test, ns>0.05; n=6 muscles per group). (E) The bar chart (Mean ± SEM) 
shows that there was no significant difference in the percentage of nodal, terminal or 
micro- sprouts in 3 month old Smn2B/2B;YFP-H mice when compared to Smn+/+;YFP-
H mice. Micro-sprouting was observed in YFP positive motor neurons in the cranial 
musculature however, this was not significant when compared to Smn+/+;YFP-H 
mice  (by Mann Whitney-U test; ns>0.05; n=5 muscles per genotype). Note the 
small scale on the graphs meaning that these features are present in very small 
quantities. 
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Figure 5.8: There is no significant degenerative or regenerative phenotype in 
the TS muscle of Smn2B/2B mice at 3 months old compared to age matched 
Smn+/+ controls. (A) The bar chart (Mean ± SEM) shows that there is no significant 
denervation present in in the TS muscle of Smn2B/2B and Smn+/+ mice at 3 months 
old as 100% of post-synaptic endplates were fully occupied (by Mann Whitney-U 
test; ns>0.05; =3 (Smn2B/2B) or 4 (Smn+/+) mice per group). (B) The bar chart (Mean 
± SEM) shows that there is no significant difference in pre-synaptic swelling in the 
TS muscle of Smn2B/2B compared to Smn+/+ mice at 3 months old. There is evidence 
of mild pre-synaptic swelling however this was consistent in Smn2B/2B and Smn+/+ 
mice (by Mann Whitney-U test; ns>0.05; =3 (Smn2B/2B) or 4 (Smn+/+) mice per 
group). (C) The graph (Mean ± SEM) shows that there is no significant difference in 
the area of endplates in the TS of Smn2B/2B mice compared to the TS of Smn+/+ mice 
at 3 months old (by Unpaired t-test, ns>0.05; n=3 (Smn2B/2B) or 4 (Smn+/+) mice per 
group). (D) The bar chart (Mean ± SEM) shows that there was no significant 
sprouting observed in the TS muscle of Smn2B/2B when compared to Smn+/+ mice at 
3 months old. All NMJs in both Smn2B/2B and Smn+/+ mice showed no evidence of 
sprouts associated with them (by Mann Whitney-U test, ns>0.05; n=3 (Smn2B/2B) or 4 
(Smn+/+) mice per group). Data acquired in collaboration with Roxanna Munir (MScR 
student).  
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5.3 Discussion 
 
5.3.1 Overview of Results 
 
In this chapter, I investigated MNCB number and NMJ remodeling in 
asymptomatic mouse models that have reduced Smn levels. In contrast to 
previous reports there was no evidence of MNCB loss, denervation or 
sprouting in the Smn+/- mouse model, which has 50% of normal Smn 
(Jablonka et al. 2000; Simon et al. 2010; Udina et al. 2017). However, it is in 
keeping with another report that also found no significant loss of MNCBs in 
the Smn+/- mouse model (Bowerman et al. 2014). 
 
In Smn2B/2B mice, which have a further reduction in Smn levels to 
approximately 30% of normal, there is no reported loss of MNCBs and there 
has been no investigation into sprouting (Bowerman et al. 2012a). In keeping 
with these reports, I found that there was also no loss of MNCBs in the 
Smn2B/2B mouse model (Bowerman et al. 2012a). Degeneration and 
regeneration at the NMJ was also investigated in two different muscles, 
which show varying levels of degeneration in a symptomatic SMA mouse 
model, and found that neither of these muscles displayed evidence of 
degeneration or sprouting. 
 
5.3.2 Smn levels in asymptomatic mouse models are above the required 
threshold 
 
As there was no obvious degeneration or on going sprouting in both the 
Smn+/- and Smn2B/2B mouse model that have reduced Smn but are 
asymptomatic it is possible that the Smn levels in these mouse models are 
adequate to sustain motor neuron survival. This is in keeping with the theory 
that there is a tissue-dependent threshold requirement for Smn protein 
(Sleigh et al. 2011). This theory suggests that some tissues, specifically 
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motor neurons, may have a higher requirement for Smn than other tissues 
and as a result are more sensitive to changes in the expression of SMN. 
Other tissues, that have a lower requirement for Smn protein, are able to 
sustain survival when there is a reduction of this protein (Sleigh et al. 2011). 
This theory is supported by recent findings that show that different tissues 
have different levels of Smn (Groen et al. 2018a). Interestingly, the brain and 
spinal cord had the greatest levels of Smn in Smn2B/+ control mice at P15, 
therefore presenting a reason for the increased susceptibility of neuronal 
tissue when the expression of SMN is reduced (Groen et al. 2018a). 
 
Furthermore, this theory of a tissue-specific threshold requirement for SMN is 
supported by observations from SMA patients. While those with type I SMA, 
who have very low levels of SMN protein, have an increased susceptibility to 
heart defects, those with types II, II and IV SMA, who have increased SMN 
levels, are no more likely to develop heart defects than the general 
population (Shababi et al. 2014; Deguise et al. 2016). This suggests that only 
when SMN is very low, do cardiac tissue becomes more susceptible.  
 
It may also be possible that, due to the known differential vulnerability of 
motor neurons in symptomatic SMA mouse models, that some motor 
neurons require more Smn that others (Murray et al. 2008). Therefore, it 
cannot be ruled out that while the LALr muscle in 1 year old Smn+/- mice 
does not show degeneration and sprouting, that the muscles examined by 
others in the literature, do experience these morphological changes.  
 
However, in the Smn2B/2B mouse model, two different muscles, which show 
differential vulnerability in the symptomatic Smn2B/- mouse model (refer to 
Section 4.2.2), were assessed. Both of these muscles showed no significant 
alterations in NMJ morphology. It could be argued that morphological 
changes may occur in this mouse model at a later time point to that 
examined in this study. However, these results are consistent with findings 
from Bowerman et. al., who found no significant alterations in MNCB number 
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or NMJ morphology in this mouse model at 8 months and 1 year of age 
(Bowerman et al. 2012a). 
 
Furthermore, an adjacent study from our lab has assessed the level of 
proteins involved in sprouting, including CNTF and IGF2 in the RA muscle of 
Smn2B/2B and Smn+/- mice (Munir 2017). When compared to age-matched 
Smn+/+ controls, this quantification showed no significant change in the level 
of CNTF and IGF2 in the RA muscle of 3 month old Smn2B/2B as well as 6 
month and 1 year old Smn+/- mice (Munir 2017). Since elevated levels of 
CNTF and IGF2 are associated within increased sprouting, this finding 
suggests that sprouting is not increased in the RA muscle of Smn+/- 
compared to Smn+/+ mice (English 2003; Simon et al. 2010). 
 
Moreover, this also supports the findings that show no significant loss of 
MNCBs in the thoracic region of the spinal cord, and suggests that there is a 
lack of motor neuron degeneration in these mouse models with reduced 
Smn. Interestingly, it is noted that over time the percentage loss of MNCBs 
that has been published appears to decrease. While the first report saw a 
54% loss of MNCBs subsequent reports saw a 40% and a 19% loss of 
MNCB from the lumbosacral region of the spinal cord (Jablonka et al. 2000; 
Simon et al. 2010; Udina et al. 2017). This has been highlighted in order to 
advise those who wish to use this mouse model as a mild model of SMA to 
perform appropriate investigation into the defects that their mouse exhibits, 




These findings from Smn2B/2B and Smn+/- mice suggest that there is no on-
going motor neuron loss that is being masked by compensatory sprouting. 
Based on these results, I believe that these mouse models have an 
appropriate level of Smn to sustain motor neuron survival and remain 
asymptomatic.
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Chapter 6 
 
General Discussion and Conclusions 
 
6.1 Overview of results 
 
At the beginning of this thesis I detailed three main aims and subsequently 
presented the work that was carried out in order to address those aims. 
 
The first aim investigated the timing of motor neuron pathology in the Smn2B/- 
mouse model of SMA. I performed a temporal analysis of NMJ and MNCB 
pathology in the Smn2B/- mouse model, to determine the relationship between 
the pathological hallmarks of motor neurons in SMA. I found that, in the 
Smn2B/- mouse model of SMA, the onset of NMJ pathology coincides with the 
onset of phenotypic symptoms and precedes a decrease in the number and 
area of MNCBs. This analysis has clarified an important issue in the SMA 
research field by confirming that motor neuron degeneration in SMA occurs 
in a distal to proximal manner. 
 
Furthermore, I showed that the onset of NMJ pathology coincides with the 
up-regulation of transcripts involved in the P53 signalling pathway in the 
spinal cords of Smn2B/- mice. By reducing the expression of P53 in the 
Smn2B/- mouse model of SMA I found that although this does not improve the 
overall phenotype of the mouse model or decrease the loss of MNCBs, it 
does result in a decrease in the level of denervation observed at the level of 
the NMJ. This implies that P53 plays a role in synaptic withdrawal in this 
mouse model of SMA.  
 
The second aim in this thesis investigated whether there are compensatory 
subpopulations of motor neurons in the Smn2B/- mouse model that are 
responsible for masking degeneration in muscles that are less vulnerable to 
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degeneration and contributing to the observed phenomenon of differentially 
vulnerable muscles. By comparing NMJ morphology and sprouting in a 
muscle that displays vast denervation (TS) to a muscle that displays lower 
levels of denervation (LALr), in the Smn2B/- mouse model of SMA, I found 
that, despite evidence of sprouting in both muscles, the level of sprouting 
observed could not account for the significant difference in denervation. I 
also found that in the LALr there are not pathologically divergent 
subpopulations of motor neurons and therefore, it does not appear that 
apparently ‘healthier’ motor units are sprouting to mask the degeneration of 
other motor units in this mouse model. 
 
The third aim investigated MNCB number and NMJ remodeling in 
asymptomatic mouse models that have reduced Smn levels. I found no 
evidence of MNCB loss, denervation or sprouting in Smn+/- and Smn2B/2B 
mice, which express only 50% and 30% of normal SMN protein levels 
respectively. This suggests that there is no on-going motor neuron loss that 
is being masked by compensatory sprouting. Based on these results, I 
believe that these mouse models have an appropriate level of Smn to sustain 
motor neuron survival and remain asymptomatic.  
 
6.2 Importance of findings  
 
Therapeutics are currently at the forefront of SMA research. The approval of 
Spinraza as the first treatment for SMA was a huge milestone however, work 
is still required to improve its efficacy (Shorrock et al. 2018). It is believed, 
based on research in mouse models, that Spinraza must be administered 
early, preferably pre-symptomatically, to improve its effectiveness (Lutz et al. 
2011; Robbins et al. 2014). Clinical trials are currently underway to determine 
the effects of early intervention with Spinraza in patients (Hwu et al. 2017). 
However, it is also hypothesised that the efficacy of Spinraza may be 
increased through the use of combinational therapies that are SMN-
independent (Bowerman et al. 2017). A variety of targets that are known to 
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be phenotypic modifiers have now been identified. For example, targeting the 
RhoA-ROCK pathway, which can regulate actin dynamics, in the Smn2B/- 
mouse model of SMA was shown to improve muscle pathology and 
increased lifespan (Bowerman et al. 2010; Bowerman, et al. 2012b). 
Furthermore, systemically increasing Uba1, which is known to be decreased 
in SMA mouse models, using gene therapy techniques increased the survival 
and improved the NMJ phenotype of the Taiwanese mouse model (Powis & 
Gillingwater 2016). It is thought that targeting these pathways in combination 
with Spinraza may increase the therapeutic benefits to patients (Shorrock et 
al. 2018). 
 
In this thesis, the effects of P53 reduction on the motor unit were addressed. 
A natural question to ask would be whether P53 could be a potential target 
for combinational therapies. Since the long-term inhibition of P53 can lead to 
the formation of tumors it may be an unlikely target for combinational therapy 
in patients (Donehower 1996). However, as the results presented in this 
thesis implicate P53 in synaptic withdrawal, further investigation into how 
P53 controls synaptic withdrawal may determine whether there are neuron 
specific molecules that are involved in this pathway and may be possible 
therapeutic targets. It is perhaps possible that P53-inhibition could be used 
as a short-term therapy to try and promote the persistence of synaptic 
connections while a long-term SMN therapy is administered (Benkafadar et 
al. 2017).  
 
In this thesis, I also addressed compensatory sprouting of motor neurons in 
SMA. As the mechanism of motor neuron sprouting was not specifically 
addressed, the therapeutic benefit of increasing compensatory sprouting 
cannot be verified and therefore this may still be effective as a combinational 
therapy. Given that symptomatic administration of an SMN-dependent 
therapy will mean that there is already NMJ loss, then the increased growth 
of motor neurons through sprouting may help to restore those synapses that 
had been lost due to the low levels of SMN. Moreover, since the results that 
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have been presented here show that sprouting is not responsible for the 
differential vulnerability of muscles in the Smn2B/- mouse model of SMA, there 
are likely to be other targets that do regulate this differential vulnerability, 
which may also be viable combinational therapies (Murray et al. 2015).  
 
Furthermore, these results also support the findings that there is an SMN-
threshold and above this threshold motor neurons remain stable, as 
demonstrated in Smn+/- and Smn2B/2B mice. It is understood that in patients 
this threshold is variable. While some individuals that have 3 copies of SMN2 
and no functional SMN1 are symptomatic, others with the same SMN 
genetics remain asymptomatic (Oprea et al. 2008). A large-scale study to 
determine the average threshold of SMN to sustain normal functioning within 
the human population would be informative, giving a target to which we 
would be required to increase SMN to in SMA patients. Increasing the levels 
of SMN above this threshold will be key to ensuring the stability of motor 
neurons and the future success of SMN-dependent treatments in SMA.  
 
6.3 Concluding remarks 
 
I conclude this thesis by emphasising that despite recent advances in 
therapeutics for SMA we must remember that increasing our basic 
understanding of SMA pathogenesis remains incredibly important. All 
research to date has been paramount to the recent success in the SMA field. 
Therefore, by continuing to increase our knowledge we strengthen our 
chance of finding further ways to improve the lives of SMA patients. The work 
I have presented in this thesis has provided an insight into the pattern of 
motor neuron degeneration and remodeling in SMA and therefore I have 
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